

























































































Prohlašuji,  že  jsem  disertační  práci  zpracovala  samostatně  a  že  jsem  uvedla  všechny  použité 





















































































































Background  and  Aims:  Endocrine  activity  of  adipose  tissue  is  implicated  in  the  development  of 
insulin resistance (IR). The thesis aimed to extend the knowledge of mechanisms contributing to IR. 
Study  I  –  To  investigate  the  effect  of  acute  hyperinsulinaemia  and  acute  angiotensin  II  type  1 









Methodology:  Hyperinsulinaemic‐euglycaemic  clamp,  Intralipid  infusion  and  saline  infusion  were 
used  to  simulate  specific  metabolic  conditions  in  vivo  in  4  groups:  8  young  healthy  men,  11 




differ from those  in healthy subjects.  Insulin differentially regulates circulating resistin and  leptin  in 
diabetes  and  healthy  subjects, while  plasma  adiponectin  and  TNFα  are  not  acutely  regulated  by 
insulin.  Stimulatory  effect  of  insulin  on  SAT  expressions  was  demonstrated  only  for  TNFα  and 
adiponectin.  Suppressive  effect  of  losartan  on  plasma  resistin  and  leptin  but  no  changes  of  the 
adipokines’  expression  were  shown  in  diabetic  patients  following  acute  treatment.  Importantly, 
losartan‐induced increase in plasma adiponectin and its expressions suggests a potential mechanism 
for metabolic effects of  losartan. Changes  in plasma adipokines cannot be explained by changes  in 






Study  III – Prolonged hyperlipidaemia  stimulates an  increase  in plasma TNFα and  resistin, while  it 
results in decline in plasma leptin and A‐FABP and it does not affect expressions of adipokines in SAT. 
Study  IV – The selected adipokines  including A‐FABP display differential  regulations on  the  level of 
circulating  concentrations  and  SAT expressions during  the progression of  glucose  intolerance. The 




subjects  and  patients  with  IFG  differed  in  terms  of  baseline  plasma  concentrations  and  SAT 
expressions  of  selected  adipokines.  We  have  also  demonstrated  differential  group‐specific 
regulations  of  adipokines’  concentrations  and  expressions  in  response  to  hyperinsulinaemia  and 






Insulin  resistance  (IR) was originally defined  as  a  reduced  response of  target  tissues  to metabolic 








of  potential  mechanisms  of  IR.  IR  usually  relies  on  altered  post‐receptor  actions  but  generally, 
defects at any level of insulin signalling may be involved in development of IR.   
Figure 1 Signal transduction in insulin action (adopted from [4]). The insulin receptor is a tyrosine kinase that 
undergoes  autophosphorylation  after  binding  of  insulin  and  catalyses  phosphorylation  of  cellular  signal 
protein  IRS  1‐4  (insulin  receptor  substrate),  Shc  and  Cbl.  Upon  tyrosine  phosphorylation,  these  proteins 
interact  with  signalling molecules  through  their  SH2  domains  resulting  in  a  diverse  series  of  signalling 
pathways,  including  activation  of  PI3‐kinase  (phosphatidylinositol  3‐kinase)  and  downstream 
PtdIns(3,4,5)P3‐dependent protein kinases, Ras and the MAP kinase cascade and Cbl/CAP and the activation 
of TC10. These pathways act in a concerted fashion to coordinate the regulation of vesicle trafficking, protein 
synthesis, enzyme activation and  inactivation and gene expression.  In  IR state, the decreased activation of 
PI3‐kinase pathway leads to an inhibition of metabolic actions (mainly decline in insulin‐dependent glucose 
transport). Resistance to insulin action increases the demand on insulin secretion by beta cells. Consequently, 
the  resulting  hyperinsulinaemia  and  increased  insulin  binding  to  its  receptor  significantly  activates  the 








release  from  the adipose  tissue mass  (which  is  resistant  to antilipolytic effect of  insulin),  impaired 
tissue utilisation or combination of both processes. NEFAs  impair  the ability of  insulin  to  suppress 
hepatic  glucose output  and  to  stimulate  glucose uptake  into  skeletal muscle,  as well  as  to  inhibit 
insulin secretion from pancreatic beta cells [4]. NEFAs are also implicated in the central regulation of 





intramyocellular and  intrahepatic  lipid contents are consistently  found already  in early stages of  IR 
development, such as in lean, normal glucose tolerant off‐springs of type 2 diabetic parents [7, 8], as 
well  as  in manifest  type  2  diabetes  and  obesity.  Further  studies  have  documented  reduced  lipid 
oxidation  and  reduced  expression  of  key mitochondrial  genes  involved  in  regulation  of  oxidative 
metabolism  in  skeletal muscle  [7]  and  provided  thus  support  for  the  hypothesis  of  the  role  of 
mitochondrial dysfunction in the pathogenesis of IR.   
Despite  of  elevated  NEFAs  in  fasting  state,  a  greater  reliance  on  glucose  oxidation  and  reduced 
efficiency of fat oxidation has been shown  in type 2 diabetes and obesity, which  is accompanied by 









[7]. Other humoral  factors  involved  in  IR  include an  increase  in  insulin‐contraregulatory hormones, 
insulin antibodies or a variety of cytokines and factors produced by adipocytes, endothelial cells and 
immunocompentent  cells.  The  latter  ones  are  recently  subject  of  intensive  investigation  and  the 
current knowledge on them is summarized in chapter Endocrine activity of adipose tissue. 
Neural  factors  involved  in  IR  pathogenesis  are  represented  by  insulin‐stimulated  sympathetic 





system.    In this context, a great scientific debate  is dealing with the questions: Where does  insulin 
resistance start? Where and which is the primary defect and what changes are secondary? Although 
increasing  experimental  evidence  can  be  found  for  the  priority  of  all  tissues mentioned,  there  is 
probably  no  simple  answer.    The  development  of  IR  clearly  relies  on  interactions  and  cross‐talk 
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between  the  involved  tissues  and  represents  a  very  complex  multifactorial  process.  Another 
noteworthy consideration is that not all insulin‐dependent processes and tissues are equally resistant 
to insulin.  




normal  glucose  tolerant  (NGT) offspring of  type 2 diabetic parents were  investigated.  Similarly  to 
patients  with manifest  type  2  diabetes,  a  decreased  glucose  uptake  has  been  demonstrated  in 
offspring,  for which  reduced non‐oxidative  glucose metabolism,  e.g.  a defect  in  insulin‐stimulated 
glycogen  synthesis  accounted.  Additionally,  an  increase  in  intramyocellular  lipid  content  and 
mitochondrial dysfunction  in myocytes has been documented in this cohort [11], accompanied with 
elevated NEFAs and metabolic inflexibility during hyperinsulinaemia. These findings however indicate 
the presence of marked adipocyte  resistance  to  insulin action  [7] and do not disclose  the parallel 
involvement of other tissues. 
Even  if adipose  tissue plays a minor  role  in  insulin‐stimulated glucose uptake postprandially,  it has 
been shown to be a key player in the development of IR, particularly due to production of variety of 
factors  (such as NEFAs, adipokines,  cytokines etc.), known  to modulate  insulin  sensitivity not only 
within  adipose  tissue  but  especially  in  other  organs  including  skeletal  muscle.  The  detailed 
description can be found in chapter Endocrine activity of adipose tissue. 
Liver plays a central role in regulation of nutrient metabolism and it is also the primary site of insulin 
degradation. With  the  increasing  experimental  and  clinical  knowledge  on  non‐alcoholic  fatty  liver 
disease  (NAFLD),  which  is  characterized  by  triglyceride  accumulation  within  hepatocytes 
accompanied  by  features  of  both  central  (impaired  insulin‐mediated  inhibition  of  hepatic  glucose 
production)  and peripheral  IR  (reduced  insulin‐mediated  glucose uptake  in muscle  and  decreased 
inhibition of  lipolysis by  insulin), there  is more evidence available supporting the primacy of  liver  in 
the  IR  pathogenesis  [8].  Ectopic  fat  in  liver may  be more  important  than  visceral  fat,  since  the 
intrahepatic  fat  content  is more  strongly  related  to  peripheral  IR  than  visceral,  subcutaneous  or 
intramyocellular lipid contents in obesity and type 2 diabetes [12‐14]. Fatty liver might interfere with 
insulin degradation and resulting hyperinsulinaemia contributes to  impairment of peripheral  insulin 





glucose homeostasis  [17].  Insulin  receptors and components of  the  insulin  signalling pathways are 
widely distributed  in the brain.  Insulin crosses the blood‐brain barrier through a receptor‐mediated 
and saturable transport mechanism.  Insulin  in association with other nutrient and adiposity signals, 
such  as  NEFAs,  amino  acids  or  leptin  directly  regulate  neuropeptide  expression  in  hypothalamic 
nuclei  and  are  involved  in  the  feedback  loop  that  is  necessary  for  regulation  of  food  intake. 




not  only  by  increasing  hypothalamic  anorexigenic  stimuli  but  also  by  activation  of  hypothalamic 







Adipose  tissue  is  no  longer  considered  as  an  inert  tissue  devoted  to  storage  of  energy‐rich 






White  adipose  tissue  is  a  heterogeneous  organ  composed  of  adipocytes  and  stromal‐vascular 
fraction, in which pre‐adipocytes, macrophages, nerves, fibroblasts, endothelial and vascular cells are 
present. Pre‐adipocytes originate from pluripotent mesodermal stem‐cell with  life‐long potential to 
generate new  adipocytes  [22].  Several  adipokines  are  secreted exclusively by  adipocytes, while  in 
production of other factors cells of the stromal‐vascular fraction are substantially involved.   
In  obesity  and  IR, macrophages  are more  abundant  in  adipose  tissue  [23].  Interestingly,  resident 
macrophages share certain characteristics with adipocytes, such as  lipid accumulation or secretory 
activity and  thus play an  important  role  in  initiation and maintaining of adipocyte dysfunction and 
the status of  low‐grade  inflammation.  It has been documented that  inflammation and macrophage 
infiltration intensifies with increasing obesity and can be reversed by weight loss [24]. Moreover, the 
increased macrophage  content  in  adipose  tissue  seen  in  obesity  is  composed  predominantly  of 
classically  activated  pro‐inflammatory  M1  macrophages,  whereas  the  proportion  of  anti‐
inflammatory M2 macrophages is substantially smaller than in lean state [25]. Several mechanisms of 
the macrophage  recruitment  into  adipose  tissue were  postulated:  increased NEFA  concentrations 
activate cellular pro‐inflammatory pathways (NF‐κB) in adipocytes and residing macrophages, which 
lead  to  release  of  chemotactic  and  pro‐inflammatory  cytokines  (e.g. monocyte  chemoattractant 
protein  1  or  osteopontin)  from  both  cell  types.  A  local  paracrine  loop  between  adipocytes  and 
macrophages establishes a vicious  cycle  [23]. Adipocyte apoptosis  represents another  stimulus  for 
macrophage  accumulation  [26]. Recently,  a  role of T  lymphocytes  in  the  initiation of macrophage 
infiltration in adipose tissue has been recognized in animal models. Large numbers of CD8+ T cells are 
present  in  adipose  tissue  in  obesity  and  are  able  to  promote  recruitment  and  activation  of 
macrophages  [27]. On  the other hand, CD4+ helper and  regulatory T  cells  that are able  to down‐







a sign of  IR  in adipose tissue.    Increased fat mass has been suggested to partly compensate for the 
defect  in  insulin action  [31]. The expansion of adipose  tissue  can be attributed  to both adipocyte 
hypertrophy  and  hyperplasia  [32].  Adipocyte  can  store  0.8μg  lipid  per  cell  as  a maximum.  Large 
hypertrophic  adipocytes  (140‐180  μm  in  diameter)  characterized  by  reduced  glucose  and 
triglycerides  clearance and  increased  lipolytic activity,  can be  found not only  in obese and  type 2 
diabetes patients, but also  in  lean NGT offspring of type 2 diabetic parents [6]. On the other hand, 
adipocyte  differentiation  is  a  sign  of  insulin‐sensitive  adipose  tissue  and  is  exactly  regulated  by 
means  of  sequential  activation  of  transcription  factor  cascade  including  PPARγ  (peroxisome 
proliferator‐activated  receptor  γ)  and  SREBP1c  (sterol  response  element  binding  protein  1c)  [33]. 
Interventions reducing adipocyte size either by recruitment of new small adipocytes (e.g. treatment 
with  thiazolidinediones  and  potentially  also  with  angiotensin  receptor  blockers)  or  by  depleting 
triglyceride stores in existing adipocytes (e.g. exercise, diet) are able to reverse the features of IR [6].   
Adipose  tissue blood  flow  increases with prolonged  fasting and during exercise  in order  to ensure 
supply of released NEFAs in the circulation, as well as after feeding when there is a need to increase 
substrate delivery for triglyceride clearance [30]. The close relation of angiogenesis and adipogenesis 
during  adipose  tissue  expansion  known  from  experimental  models  cannot  be  ensured  as  the 
adipocyte hypertrophy endures  [6, 23]. Reduced adipose  tissue blood  flow documented  in obesity 
leads  to  local hypoxia  since  the diameter of enlarged  fat  cell  is greater  than  the diffusion  limit of 
oxygen,  thus  limiting  the  exchange  between  blood  and  adipocyte  cytoplasm.  Hypoxia  further 





both  sympathetic  and  parasympathetic  activation  [30].  Sympathetic  innervation  is  known  to 
stimulate  lipolysis and  lipid mobilisation and  to negatively  regulate proliferation of pre‐adipocytes 
[30].  It  also  influences  adipose  tissue metabolism  indirectly  through  regulation  of  blood‐flow:  an 
increase  in postprandial perfusion  is dependent on  sympathetic activation  induced by  insulin  [30]. 
Changes in adrenoreceptor numbers and sympathetic drive have been documented in obesity, which 
suggests  the modulation of  autonomic  signals  to  adipose  tissue  in  response  to  energy  stores  and 
adipocyte size. Autonomic  innervation appears to have a sensory afferent component that conveys 
adiposity  information from the periphery to the brain. Parasympathetic  innervation was historically 





specific  functions.  It  is  found  in  subcutaneous,  visceral,  epicardial,  extramyocellular,  perivascular, 
retroorbital, facial and lymphnodal regions, as well as in bone marrow and mammary gland. 
Visceral, epicardial, intermuscular and perivascular fat depots are physiologically more metabolically 
active  and  less  insulin  sensitive,  showing  higher  lipolytic  activity  and  thus  ensuring  direct  energy 
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supply  to  the  vital  organs  (i.e.  liver,  heart,  skeletal muscle,  vessels).  These  depots  share  similar 
adipokine, cytokine and NEFA release patterns or higher density of adrenoreceptors [6]. Omental fat 
appears  to be  important  for regulation of disposal of  ingested nutrients  in  the  liver and periphery, 
with  feedback  to  the brain via autonomic neurons.  It has been  suggested  that  relative  IR of  intra‐
abdominal,  intrathoracic and  intermuscular fat optimizes their ability to release energy to proximal 





metabolically active,  subcutaneous  fat  can  substantially  contribute  to NEFA  and adipokine  release 
and  imbalance,  since  subcutaneous  fat mass  is at  least 10‐fold  larger  than  the visceral one.  It has 
been postulated  that  impaired  storage  capability and defective expandability of  subcutaneous  fat, 
independent  of  body  weight  or  adiposity, might  be  the  primary  cause  of  IR  rather  than  solely 
enlargement of visceral fat depot [6]. The defect in SAT storage capacity is accompanied by increased 
NEFA fluxes, compensatory enlargement of non‐subcutaneous fat depots and ectopic deposition of 





insulin  sensitive  adipocytes  seems  to  be  more  benign  in  terms  of  progression  of  metabolic 
dysfunction, than hypertrophic obesity.  
Endocrine activity of adipose tissue 
Several  lines of evidence  suggest  that  the disturbed endocrine  function of adipose  tissue  found  in 
obesity  and/or  type  2  diabetes  represents  one  of  the mechanisms  implicated  in  development  of 
insulin resistance, low‐grade inflammation and related abnormalities [39]. 
Leptin 
Leptin, the first adipokine  indentified  in 1994 [40],  is a 16‐kDa cytokine‐like peptide encoded by ob 
gene  that  is  produced  exclusively  by  differentiated  adipocytes.  Leptin  exerts  both  central  and 
peripheral  actions.  At  the  level  of  central  nervous  system  (CNS),  leptin  serves  as  a  satiety‐signal 
regulating food  intake and  increasing energy expenditure [41].  It crosses the blood‐brain barrier by 
diffusion through capillary junctures in the median eminence and by saturable receptor transport in 
the  choroid  plexus  [42].  In  the  hypothalamic  feeding‐regulating  areas,  such  as  the  arcuate, 
dorsomedial  and  ventromedial  nuclei,  leptin  stimulates  release  of  anorexigenic  peptides  (i.e. 
proopiomelanocortin)  and  inhibits  the orexigenic peptides  (neuropeptide Y or  agouti  gene‐related 
protein). After binding  to  the  leptin  receptor, cellular  signal  transduction cascades of  Janus kinase 
(JAK), activators of  transcription  (STATs) and  IRS/PI‐3 kinase are activated and  lead  to  subsequent 
specific changes in gene expression [43]. 
Besides  its central signalling role,  leptin also regulates peripheral metabolism and  insulin sensitivity 
both  directly,  since  almost  all  tissues  express  leptin  receptor,  and  indirectly  via  stimulation  of  α‐




it  contributes  to prevention of ectopic  lipid accumulation and  reduction of  lipotoxicity  [45]. These 
effects  are  involved  in  the  insulin‐sensitizing  action  of  leptin  and  are  mediated  through  direct 
activation of AMP‐kinase (adenosin monophosphate‐activated protein kinase), activation of Jak/STAT 
pathway  or  inhibition  of  SREBP‐1c  expression  [44‐46].  Leptin  signalling  also  activates  protein  of 
insulin  signalling  cascade,  such  as PI‐3  kinase  [45, 47]. Based on  experimental models,  leptin was 
suggested as an important player in the adipo‐insular axis, as it decreases insulin secretion and gene 
expression and protects beta cells  from  lipid accumulation  [43]. Leptin production  is stimulated by 
insulin  or  in  satiety,  while  it  is  decreased  during  starvation,  by  catecholamines  or  TNFα  (tumor 
necrosis factor α). 
The first promising results in leptin‐deficient rodent models (ob/ob mice) showed a decline in IR and 
reduction  of  body  weight  after  leptin  substitution  [48].  In  humans,  the  positive  effect  of  leptin 
administration on  IR and obesity could only be reproduced  in states of  leptin deficiency, such as  in 
congenital  and  HIV‐associated  lipodystrophy  [49,  50]  or  extreme  rare  cases  of  obesity  based  on 
mutations  of  ob  gene  or  leptin  receptor  gene  [44]. On  the  contrary,  in  common  human  obesity 
characterised by high levels of circulating leptin without adequate end‐organ response, the attempts 
to treat “typical” obesity with leptin failed [51], suggesting development of leptin resistance [44, 45]. 
Linear  correlation  between  serum  leptin  levels  and  total  body  fat  mass  in  humans  led  to  the 
postulation of  leptin’s  role as a signal of adipose  tissue stores  [44]. Enlarged adipocytes  in obesity 
secrete up to seven times more  leptin than small fat cells  in  lean subjects [52]. Despite of elevated 
leptin, obese  subjects appear  to be  insensitive  to  its action. Several mechanisms underlying  leptin 
resistance have been described in experimental models: impaired leptin transport across the blood‐
brain barrier  as  a  response  to hyperleptinaemia with  resulting  ”hypothalamic  leptin  insufficiency” 
[43], down‐regulation of leptin receptor or postreceptor inhibition of leptin signalling via induction of 
suppressor  of  cytokine  signalling‐3  (SOCS‐3),  protein  tyrosine  phosphatase  1B  (PTP1B)  or 
endoplasmic reticulum stress [44, 45]. 
Additionally,  leptin  reveals  angiogenic  activity,  may  contribute  to  thrombus  formation  through 
platelet  leptin  receptor,  stimulates  production  of  reactive  oxygen  species  (ROS),  activates 
macrophages  and  affects  production  of  other  cytokines  [42,  53].  While  increased  leptin 




Adiponectin  is  a  30‐kDa  insulin‐sensitizing  glycoprotein  expressed  specifically  and  abundantly  in 
adipocytes  that  is  released  into circulation at high concentrations. Adiponectin  forms homotrimers 
that  further associate  in  larger multimer complexes  [54, 55].  In  the circulation adiponectin can be 




Two  adiponectin  receptors  AdipoR1  and  AdipoR2  have  been  identified.  AdipoR1  ubiquitously 
expressed  in many  tissues  including  skeletal muscle,  primarily  up‐regulates AMP‐kinase  pathways 
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leading  to  inhibition of gluconeogenesis and  increased  fatty acid oxidation. AdipoR2, which  is also 
expressed  in  most  tissues,  but  plays  a  dominant  role  in  liver,  is  more  tightly  linked  to  PPARα 
activation that increases fatty acid oxidation and inhibits oxidative stress and inflammation [54, 56]. 
Adiponectin  directly  increases  hepatic  insulin  sensitivity,  decreases  hepatic  gluconeogenesis  and 
stimulates muscle glucose uptake, promotes  fatty acid oxidation,  inhibits  lipogenesis and  improves 
lipid profile. In a paracrine manner within adipose tissue, it attenuates TNFα expression, production 
of  reactive  oxygen  species  and  inflammation.  Its  role  in  vascular  protection  has  been  also  well 
explored: adiponectin decreases expression of adhesion molecules,  inhibits proliferation of vascular 
smooth‐muscle  cells,  suppresses  transformation  of macrophages  to  foam  cells  [57].  Additionally, 
adiponectin has been shown to be involved also in regulation of food intake at the brain level [56]. Its 
function appears to be complementary to leptin: adiponectin concentrations and AdipoR1 expression 
increase  during  fasting,  leading  to  stimulation  of  AMP‐kinase  activity  in  hypothalamus  and 
subsequently to promotion of food intake [58]. 
Based on experimental and clinical studies, hypoadiponectinaemia  is consistently  related  to  insulin 
resistance, obesity,  type 2 diabetes,  coronary heart disease, hypertension and atherosclerosis  [54, 
57]. HMW adiponectin was even suggested as a predictor of IR and type 2 diabetes [56, 59]. Despite 




and  the  whole  adipose  tissue,  increased  oxidative  stress  or  pro‐inflammatory  state  [57].    In 
conjunction with  lower  circulating  adiponectin,  an  impaired  tissue  response  to  this  adipokine has 
been  demonstrated  in  obese  rodent  and  human  muscle  [45].  Decreased  expression  levels  of 
AdipoR1/R2 may contribute to reduced adiponectin sensitivity, at  least  in rodent models of obesity 
[56].  In  humans,  the  comparison  of  AdipoRs mRNA  and  protein  levels  in  lean  and  obese  and/or 
diabetic subjects is equivocal [44, 45]. 
Adiponectin  exhibits  sexual  dimorphism with  higher  concentrations  in  females,  as well  as  diurnal 
variation with a decline at night [55].These variations are  lost  in obesity and diabetes and restored 
upon weight  loss.  Its  secretion  acutely  stimulated  by  insulin,  chronic  hyperinsulinaemia  results  in 




the mechanisms of  insulin‐sensitizing effects of  thiazolidinediones  (TZDs). Similar positive effect on 
adiponectin concentrations was observed following administration of angiotensin II receptor blockers 
(ARBs) or angiotensin‐converting enzyme  inhibitors (ACEI) [54]. Beside the therapeutic strategies to 
increase  adiponectin  concentrations  (i.e.  PPARγ  agonists),  interventions  improving  adiponectin 
action via increase in AdipoRs are tested. Here, PPARα agonists up‐regulate expression of AdipoRs in 
adipose tissue [62]. 
Despite  the  well  characterized  insulin‐sensitizing  and  antiatherosclerotic  effect  of  adiponectin, 
several recent findings brought controversy in the ”puzzle” [61]. Adiponectin is increased in patients 
with  high  risk  of  cardiovascular  death  and myocardial  infarction,  in  chronic  heart  failure,  while 
simvastatin  treatment  reduced  adiponectin.  Moreover,  circulating  adiponectin  was  actually 
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Resistin  is a 12‐kDa peptide  that represented after  its discovery  in 2001 another candidate  for  link 
between IR and obesity [63].The causal role of resistin in insulin resistance was postulated based on 
rodent models  with  altered  circulating  levels  of  resistin  [64‐66].  Both  gain‐  and  loss‐of‐function 
studies  demonstrated  the  role  of  resistin  in  induction  hepatic  and  skeletal muscle  IR, mediated 
primarily  by  increased  hepatic  glucose  production,  but  also  by  decrease  in  fatty  acid  uptake  and 
oxidation  in  skeletal muscle,  inhibition  of  adipocyte  differentiation  and  stimulation  of  lipolysis  in 
adipocytes. In rodent models of obesity, circulating resistin was increased [65, 67]. At the molecular 
level,  resistin effects  are mediated by up‐regulation of  SOCS‐3 protein  that  interferes with  insulin 
signalling cascade [66].  
However,  the  role  of  resistin  in  humans  is  controversial  so  far  [68,  69].  The  results  from  rodent 
models could not be repeated in human studies that do not show a consistent association between 
resistin and either obesity or  IR. Human  resistin  is only 64% homologous with murine  resistin  [63] 
and also  the source differs between species: rodent resistin  is primarily secreted by differentiating 
adipocytes, whereas  in humans,  its major source  is  represented by mononuclear‐macrophage cells 
[64, 66, 70]. Expression of  resistin  in other  tissues,  including  adipose  tissue,  is  likely  the  result of 
macrophage infiltration. 
Although the results regarding the effect of resistin in human glucose metabolism are contradictory, 
there  are more  explicit  data  proving  its  role  in  inflammation.  Resistin  is  up‐regulated  by  several 
cytokines,  such  as  TNFα,  IL‐6,  IL‐1β,  its  secretion  from  macrophages  is  stimulated  by 
lipopolysaccharide endotoxin  [66]. Resistin concentrations are  increased  in coronary artery disease 
[71], but also  in  inflammatory bowel disease or rheumatoid arthritis [43, 66]. The NFκB pathway  is 
activated by resistin and may mediate  the role of resistin  in  inflammation  [72]. With regard  to  the 
development  of  atherosclerosis,  resistin was  demonstrated  to  promote  foam  cell  formation  and 
migration of endothelial and smooth muscle cells, as well as to stimulate production of different pro‐
inflammatory  factors  (plasminogen  activator  inhibitor‐1,  endothelin‐1, monocyte  chemoattractant 
protein‐1)  [66].  Even  if  several  molecular  mechanisms  of  resistin  function  have  been  recently 
defined, the resistin receptor has not been identified yet.   




TNFα  is  a multifunctional  regulatory  cytokine,  which  is  synthesised  as  a  26‐kDa  transmembrane 
protein and released into the circulation as a 17‐kDa soluble protein. It plays a role in inflammation, 




of TNFα and  its adipose  tissue expressions are elevated  in obesity and decrease after weight  loss, 
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TNFα  reduces  insulin‐stimulated  glucose  uptake  [57,  75].  Again,  initial  experimental  evidence 
demonstrated promising  results  regarding causal  role of TNFα  in  the pathophysiology of  IR: TNFα‐
neutralising antibodies  restored  insulin sensitivity, mice with  targeted gene deletion of TNFα or  its 
receptors  are protected  from  IR  [76].  The underlying molecular mechanisms  include  activation of 





expression of  those  involved  in  fatty  acid oxidation. Additionally,  TNFα  alters  expression of other 
cytokines  from  adipose  tissue  (reduces  adiponectin  and  stimulates  IL‐1  and  IL‐6)  and  thus,  it  is 
suggested as a crucial and proximal contributor to adipokine dysregulation in obesity [57]. 




respective  tissues, modulating  local  cytokine  and NEFA  release  [21,  33,  57].  Its  endocrine  effects 
appear to be less important in humans. 
Interleukin 6 (IL­6) 
IL‐6  is  a  pleiotropic  cytokine,  circulating  as  a  glycosylated  protein  at  high  concentrations.  It  is 




IL‐6  plasma  concentrations  and  adipose  tissue  expression  correlate  with  fat mass,  IR  and  NEFA 
concentrations, weight  loss  leads  to  reduction of  IL‐6  levels  [42, 44].  IL‐6 administration  results  in 
elevated  blood  glucose  and NEFAs  and  induces  hepatic  IR  in  experimental  and  clinical  studies.  In 
hepatocytes and adipocytes, IL‐6 has been shown to impair insulin signalling through up‐regulation of 
SOCS‐3 and consequent inhibition of IRS‐1 phosphorylation [44, 46]. IL‐6 has been also demonstrated 
to  stimulate  adipose  tissue  lipolysis  and  de  novo  lipogenesis  in  liver  and  to  suppress  activity  of 
lipoprotein lipase in adipose tissue, which are responsible for IL‐6 induced NEFA elevation [46].  
In contrast, several studies in rodent models and humans focused on IL‐6 function in skeletal muscle 
brought different  information, suggesting possible anti‐inflammatory  role of  IL‐6  in skeletal muscle 
[44, 57]. Acute  IL‐6  infusion  increased  skeletal muscle glucose uptake  [78] and exercise associated 














visfatin  immunoassays.  Furthermore,  methodological  concerns  appeared  about  experiments 
demonstrating insulin‐mimicking action and the initial paper was partly retracted [84]. 
Nevertheless, visfatin was identified as a rate‐limiting enzyme essential for glucose‐stimulated insulin 
secretion  from β‐cell  [85]. Based on  the beneficial visfatin effect on glucose homeostasis  that was 
shown  in  experimental  studies  [86],  visfatin  has  been  speculated  to  provide  a  compensatory 
mechanism in response to hyperglycaemia in conditions of IR. Visfatin also plays a role in regulation 












concentrations correlate with visceral  fat mass and  in accordance,  increased mRNA expression was 
found in visceral adipose tissue compared to subcutaneous one [61]. Significant weight loss achieved 
by  bariatric  surgery  or  lifestyle modification,  and  exercise  lead  to  decline  in  RBP4  concentrations 
along with improvement of insulin sensitivity [43, 61]. However, other larger studies did not confirm 
the  above‐mentioned  associations  [43,  94,  95].  RBP4  exhibits  sexual  dimorphism  with  higher 






MCP‐1  is an  inducible  chemokine  responsible  for  recruitment of monocytes and T  cells  to  sites of 
injury and  infection. It  is secreted by various cell types such as endothelial, skeletal muscle, smooth 
muscle cells, adipocytes and macrophages and its action is mediated by chemokine CC motif receptor 
(CCR)2  [98].   This potent  chemoattractant  is  required  for  recruitment of monocytes/macrophages 
into  adipose  tissue  and  its  expression  correlates with  the  degree of macrophage  accumulation  in 
adipose  tissue.  In  animal models, MCP‐1  plasma  concentrations  and  expressions  are  increased  in 
obesity  and  diabetes,  MCP‐1  overexpression  in  adipose  tissue  results  in  IR  and  macrophage 
infiltration, whereas MCP‐1‐ or CCR2‐deficient mice prevented diet‐induced obesity,  IR and adipose 
tissue  inflammation  [57,  98].  In  line with  these  observations, MCP‐1  decreased  insulin‐stimulated 
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glucose uptake and expression of adipogenic genes  in  cell  cultures  [57]. MCP‐1  is up‐regulated by 
insulin, TNFα, IL‐6 or growth hormone.  
These experimental  results have been only partly  confirmed  in humans.  Several  studies described 
increased plasma concentrations and expressions in obesity [98, 99] with higher expression levels in 
visceral depot, as well as ability of  insulin‐sensitizing treatments (weight  loss, thiazolidinediones) to 
decrease  MCP‐1  levels.  On  the  other  hand,  other  authors  reported  comparable  MCP‐1  serum 
concentrations  between  lean  and  obese  subjects  [100‐102],  comparable  [101]  or  increased  [102] 
adipose  tissue  expressions  in  obesity.  Additionally,  circulating  MCP‐1  and  its  expressions  are 
differentially  regulated  by  insulin  when  comparing  insulin‐resistant  and  insulin‐sensitive  subjects 
[101]. 
MCP‐1  might  represent  an  important  link  between  adipose  tissue  inflammation  in  obesity  and 
pathogenesis of insulin resistance however, its role in humans remains to be confirmed. 
Macrophage inflammatory protein 1α  (MIP­1α) 
MIP‐1α  is  another  adipocyte‐  and  macrophage‐secreted  chemokine  that  is  responsible  for 
chemotactic  attraction of mononuclear  cells  from  circulation  into  tissues.  Similarly  to MCP‐1,  it  is 
postulated to play a role in low‐grade inflammation seen in obesity or atherosclerosis. In humans its 
circulating  concentrations  are  low,  which  is  connected  with  detection  difficulties  leading  to 
conflicting results: its serum levels were under the detection limit [101] or comparable between type 
2  diabetic  subjects  and  controls  [103]  or  between  obese  and  lean  subjects  [102].  Regarding  its 
adipose tissue expression, this was found to be increased in obesity [102] and comparable between 
subcutaneous and visceral depots. Other study showed no difference in MIP‐1α expression between 




As  a  mononuclear  cells‐derived  pro‐inflammatory  cytokine,  IL‐1β  is  specifically  implicated  the 
progression of type 2 diabetes through promotion of pancreatic β‐cell apoptosis and destruction. Its 
concentrations are  increased  in populations with metabolic  risk,  such as NGT offspring of parents 
with type 2 diabetes [104, 105], they correlate with IR indices, HbA1c, lipid profile and high‐fat/high‐
carbohydrate  diet  in  obesity  [106,  107].  Furthermore,  decreased  IL‐1β  expression  in  peripheral 
mononuclear cells was documented after weight  loss [108], as well as enhanced  IL‐1β release from 




IL‐1ra  competitively  antagonizes  the  inflammatory  effects  of  IL‐1β  and  IL‐1α  by  binding  to 
interleukin‐1  receptor  without  inducing  a  cellular  response  [110].  Thus,  IL‐1ra  reflects  the 
inflammatory  response and due  to  its anti‐inflammatory properties,  it  represents a  compensatory 
mechanism  for  IL‐1  induced  disease  processes.  IL‐1ra  is  secreted  by  immune  cells,  epithelium, 




IL‐1ra  has  protective  effect  on  pancreatic  β‐cell  function  and  survival  [112],  its  concentrations 
decrease, when  type 2 diabetes develops  [113]. Moreover,  treatment with  IL‐1ra  led  to  improved 
glycaemia, β‐cell secretory function and reduced CRP and IL‐6 concentrations in patients with type 2 
diabetes [114]. 
In  contrast,  experimental  studies  in  rodents  with  altered  IL‐1ra  production  and  in  patients  with 
metabolic  syndrome  showed  an  opposite  role  of  IL‐1ra  in  obesity‐related  abnormalities  [110]. 
Increased  IL‐1ra concentrations are reported  in metabolic syndrome, obesity and prediabetes state 
in  offspring  of  type  2  diabetic  parents,  they  correlate  with  number  of  metabolic  syndrome 
components and insulin resistance [104, 115‐117]. Weight loss results in decline in IL‐1ra expression 
in peripheral blood mononuclear cells [108] and lower serum concentrations [110]. In mice with diet‐





RANTES belongs  to T‐lymphocyte‐produced chemokines  involved  in T‐cell  recruitment  in a positive 
feedback loop. T‐cells, RANTES and its major receptor CCR5 are increased in adipose tissue in human 
and murine obesity [119] contributing to inflammatory state in an auto‐ and paracrine manner [120]. 
Several  clinical  studies  reported  increased  RANTES  plasma  concentrations  and  adipose  tissue 
expressions in obese compared to lean subjects [102, 119], with higher RANTES expression in visceral 
fat  depot.  Additionally,  progression  to  type  2  diabetes  in  Finnish Diabetes  Prevention  Study was 
associated with higher RANTES concentrations [121]. KORA S4 Study [122] demonstrated  increased 















considered  to  be  the  major  extrahepatic  source  of  angiotensinogen  and  thus  substantially 
contributes  to  its  increased  levels  and  development  of  hypertension  in  obesity  [42,  57]. 
Differentiating  adipocytes, mainly  of  the  visceral  fat  depot,  appear  to  be  quantitatively  the most 
important  source of  angiotensinogen. Concentrations of  renin  and  angiotensin‐converting enzyme 
activity are also  increased  in obesity  [129].   Both  types of angiotensin  II  receptors  (AT1‐ and AT2‐
Švehlíková, Mechanisms of insulin resistance 
  ‐ 21 ‐ 
receptors)  can be  found on adipocytes. Signal  transduction of angiotensin  II  is mediated by  signal 
proteins  shared  with  insulin  signalling  cascade  (PI3‐kinase,  Akt  kinase),  and  thus  angiotensin  II 
inhibits insulin stimulated glucose uptake [130]. Angiotensin II also inhibits adipocyte differentiation 
[23,  131].  Moreover,  evidence  has  been  accumulated  that  RAS  inhibition  may  improve  insulin 





An  important molecular pathway, which  integrates metabolic and  inflammatory  response  involves 
the  fatty  acid‐binding  proteins  (FABPs)  commonly  present  in  adipocytes  and macrophages  in  two 
isoforms – adipocyte FABP (A‐FABP) and epidermal FABP (E‐FABP) coded by FABP4 and FABP5 genes, 
respectively  [136]. As  cytoplasmic  lipid  chaperons  FABPs  are  responsible  for  cellular  trafficking  of 
fatty  acids  (to  the mitochondria  and peroxisomes  for oxidation,  to  the  endoplasmic  reticulum  for 
reesterification, to the lipid droplet for storage, or to the nucleus for regulation of gene expression). 
Moreover,  experimental  evidence  based  on  comprehensive  research  on  knock‐out mice models, 
supports  the  role  of  A‐FABP  in  systemic  regulation  of  lipid  and  glucose  metabolism  as  well  as 
inflammation, since A‐FABP deficiency prevents  the development of obesity,  insulin  resistance and 
atherosclerosis [137‐139].  In human studies, A‐FABP was found to be also present  in plasma [140], 
although  its  physiological  function  or mechanisms  of  its  appearance  in  circulation  have  not  been 
elucidated until now. A‐FABP plasma  concentrations are  increased  in patients with obesity and/or 
metabolic syndrome [140‐142] and it  is suggested as a novel risk marker predicting development of 







adipocyte/macrophage  FABP  represents  a  biomarker  of  obesity,  metabolic  syndrome  and 
atherosclerosis  or whether  it  is  a  causative  factor  of metabolic  and  inflammatory  dysregulation, 
which can be effectively and safely inhibited, remains to be elucidated. 
Peroxisome proliferator activated receptor­γ (PPARγ) 
PPARγ  are  nuclear  receptors,  which  serve  as  ligand‐activated  transcription  factors  regulating 
expression  of  genes  involved  in  carbohydrate  and  lipid metabolism,  adipocyte  differentiation  and 
inflammation.  In  the nucleus  they  are  found  in  the  complex with  retinoid X  receptor  (RXR). Their 
natural  ligands  are  fatty  acids  and  lipid‐derived  substrates  [149,  150].  PPARγ  are  expressed 
predominantly in adipose tissue, but they are also present in other cell types such as vascular smooth 





which  are  synthetic  PPARγ  agonists.  PPARγ  activation  leads  to  improvement  in  insulin  sensitivity, 
decreased plasma levels of insulin, NEFAs and triglycerides. Adipose tissue clearly represents the site 
of TZD action  [150]. Among mechanisms of action, NEFAs  re‐partitioning  into white adipose  tissue 
must  be mentioned.  Stimulated  NEFA  trapping  and  storage  in  adipocytes  as  well  as  stimulated 
adipogenesis  ensure  the  increased  lipid  clearance.  Resulting  decrease  in  circulating  NEFAs  and 
triglycerides  lowers  lipotoxicity  in other tissues and prevents ectopic  lipid accumulation  [150, 152]. 
Treatment  with  PPARγ  agonists  leads  to  redistribution  of  adipose  tissue  with  preferential 
adipogenesis in subcutaneous depot and parallel lack of change or reduction of visceral depot [153]. 
Another potential mechanism of effect on insulin sensitivity is the alteration of adipokine production: 
TZDs  lower  the  expression  of  TNFα,  plasminogen  activator  inhibitor‐1  or  resistin  and  stimulate 
secretion of adiponectin, especially  its HMW form [154]. Increased adiponectin concentrations may 
mediate  the  effects  of  TZDs  on  decrease  in  hepatic  steatosis,  increase  in  fatty  acid  oxidation, 
attenuation of inflammation and anti‐atherosclerotic effects [150]. However, the full PPARγ agonism 









In  the  past  decade,  experimental,  epidemiological  and  clinical  evidence  have  clearly  shown  that 
chronic  inflammation,  characterized  by  abnormal  cytokine  production,  increased  acute‐phase 
reactants and activation of networks of  inflammatory  signalling pathways,  is causally  linked  to  the 
development of obesity,  IR and  type 2 diabetes  [155].  Immune  response and metabolic  regulation 
are  highly  integrated  processes  ensuring whole‐body  homeostasis. Due  to  its  secretory  functions, 
adipose  tissue  represents  a  critical  site  for  the  interaction  between metabolic  and  inflammatory 
response systems that play a significant role in the pathogenesis of metabolic diseases[40]. 
Several  aspects  of  the  role  of  inflammation  have  been  discussed  in  detail  above.  Here  a  brief 
summary concludes this topic. First, adipose tissue contributes to inflammatory status of obesity via 
production of cytokines, such as TNFα, MCP‐1, IL‐1, IL‐6, resistin etc. Second, infiltration of immune 
cells  (monocytes, macrophages and T‐cells)  in adipose  tissue  substantially  contributes  to  initiation 
and promotion of inflammation in a positive feedback loop. Additionally, adipocytes share a number 
of  commonalities  with  immune  cells  (e.g.  complement  activation,  production  of  inflammatory 
mediators,  lipid‐accumulating  and  phagocytic  properties).  Third,  lipids  and  particularly  fatty  acids 
influence  both metabolic  and  immune  processes  via  specific  transcription  factors.  In  this  regard, 
PPARγ  represents  one  of  the  crucial  modulators  that  inhibit  expression  of  genes  involved  in 
inflammatory  response, while  adipocyte/macrophage  FABP  seems  to  have  pro‐inflammatory  and 
dysmetabolic  functions.  Inflammatory signals have been demonstrated  to  impair  insulin action and 
contribute  to  pathophysiology  of  IR  through  multiple  molecular  mechanisms  inducing  serine 
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phosphorylation of  IRS‐1 which results  in  impaired  insulin signalling. Here,  the  induction of SOCS‐3 
protein  through  several cytokines or activation of  JNK,  IκB kinase  (IKK) and protein kinase C  (PKC) 




of  activation  of  inflammatory  pathways?  Recent  data  from  experimental  models  suggest  that 
endoplasmic  reticulum  (ER)  stress  is  the  critical  initial  impulse  integrating  inflammatory  and 
metabolic  pathways  in  obesity  and  IR  [32,  155].  Nutrient  oversupply,  excess  adipose  tissue  and 
increased lipid and glucose concentrations increase ER activity, but the excessive demands on ER can 
lead  to dysfunction of protein  folding,  lipid‐droplet creation and cholesterol sensing. The unfolded 














2  diabetes  [133,  157,  158].  Several  independent  meta‐analysis  of  interventional  randomized 
controlled trials published till 2006 [132, 133, 159, 160] confirmed the protective effect of treatment 
with  ACEIs  or  ARBs  on  the  progression  to  overt  diabetes  in  risk  populations  (patients  with 
hypertension, cardiovascular risk factor and/or disease or heart failure). RAS  inhibition reduced the 
relative risk of new‐onset diabetes by 22‐26 %. This effect was comparable  for different ACEIs and 
ARBs  tested and  it was present  regardless of comparator used  (placebo or pro‐diabetogenic beta‐
blockers  and  diuretics  or  metabolically  neutral  calcium‐channel  blockers).    The  most  important 
studies are summarized in Table 1. However, these results show several limitations: first, a number of 
trials  included  in  the analysis did not have diabetes as a pre‐specified outcome  leading  to possible 
substantial differences in diabetes diagnostics; second, the well‐known negative metabolic effects of 
beta‐blockers and diuretics may be responsible for the difference seen between therapies [158, 161].  
Further  placebo‐controlled,  randomized,  diabetes  incidence  outcome  studies  were  designed  to 
resolve  the  issue;  they  yielded  however  inconsistent  results  (see  Table  1).  In  the  DREAM  trial 
(Diabetes  Reduction  Assessment  with  Ramipril  and  Rosiglitazon  Medication),  ramipril  treatment 
failed  to  reduce  the  incidence  of  new‐onset  diabetes  and  cardiovascular  disease  compared  to 




to previous studies  (resulting  in  lower degree of baseline RAS activation) or placebo control  [163]. 
However, ramipril treatment  led to more frequent regression to fasting normoglycaemia and  lower 
glucose  levels 2 hours after OGTT. Similarly,  in 56‐months ONTARGET  (Ongoing Telmisartan Alone 
and  in  Combination  with  Ramipril  Global  Endpoint  Trial)  [164]  and  TRANSCEND  (Telmisartan 
Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) [165] trials in 
high‐risk  patients with  cardiovascular  disease,  the  differences  in  diabetes  incidence  between  the 
respective  groups  were  not  significant.  On  the  other  hand,  the  most  recent  NAVIGATOR  trial 
(Nateglinide and Valsartan in Impaired Glucose Tolerance Outcome Research) [166] have shown that 
5‐year treatment with valsartan  led  to 14% reduction  in diabetes  incidence but did not reduce the 
rate  of  cardiovascular  events  among  patients with  impaired  glucose  tolerance  and  cardiovascular 
disease or risk factors. 
Thus,  evidence  accumulated  to  date  indicates  that  RAS  inhibiting  treatments  are  associated with 
reduced risk of new‐onset diabetes or at least with beneficial metabolic effects compared with other 








postulated  to play  role  in  increased glucose uptake, but  these  results were not confirmed by  later 
experiments. On  the contrary,  several groups described even a dissociation of haemodynamic and 
metabolic effects of AII [171] with AII treatment leading to increase in glucose uptake. 
As mentioned above,  there  is a direct crosstalk between AII and  insulin  signalling pathways at  the 
level  of  IRS‐1  phosphorylation  and  PI‐3  kinase  activation  [157,  167].  RAS  blockade  prevents  the 




Vasodilatation  reached by ACEI and ARB  treatment  is not accompanied by  increase  in sympathetic 
activity,  on  the  contrary,  the  circulating  catecholamines  are  reduced  [172].  The  decreased 
sympathetic activation can contribute to improvement of insulin sensitivity [173].  
Next,  angiotensin  II  type  1  receptor  blockade  (ARB)  has  been  proved  to  exert  direct  effects  on 
adipocytes  [157,  167]:  it  stimulates  adipocyte  differentiation  and  promotes  recruitment  of  small 
insulin‐sensitive  adipocytes  [174‐176],  which  prevents  ectopic  lipid  accumulation  and  improves 
insulin sensitivity. In rodent models, ARBs also inhibit activation of inflammatory processes in adipose 



































































































































































Blood  Pressure  Lowering  Arm;  CAD,  coronary  artery  disease;  CAPP,  Captopril  Prevention  Project;  CBVD, 
cerebrovascular disease; CHARM, Candesartan  in Heart failure – Assessment of Reduction  in Morbidity and 
Mortality;  CVD,  cardiovascular  disease;  DREAM,  Diabetes  Reduction  Assessment  with  Ramipril  and 
Rosiglitazone  Medication;  HF,  heart  failure;  HOPE,  Heart  Outcomes  Protection  Study;  LIFE,  Losartan 
Intervention For End‐point  reduction  in hypertension; LVH,  left ventricular hypertrophy; ns, not significant; 
NAVIGATOR,  Nateglinide  and  Valsartan  in  Impaired  Glucose  Tolerance  Outcome  Research;  ONTARGET, 
Ongoing Telmisartan Alone and  in Combination with Ramipril Global Endpoint Trial;   PEACE, Prevention of 
Events with Angiotensin‐Converting Enzyme  Inhibition; PVD, peripheral  vascular disease;  SCOPE,  Study on 






[178]  depending  on  properties  of  particular  compounds.  Indeed, ACEIs  and ARBs  appear  to  have 
different metabolic potential. 
In  case  of  ACEIs,  the  positive  metabolic  effects  are  at  least  in  part  attributed  to  increased 
bioavailability  of  bradykinin  leading  to  stimulation  of  NO‐production  [161,  169].  NO  mediates 
vasodilatation and modulates glucose transport  in skeletal muscle through enhancement of GLUT‐4 





Thanks to  its physicochemical properties with high  lipophility, telmisartan was  identified to act as a 
partial  PPARγ  agonist  [179,  180],  even  already  at  concentrations  achieved  by  conventional  oral 
dosing [181]. Similar effect can be also reached with relatively high concentrations of  irbesartan or 




of  gene  expression  of  phosphoenolpyruvate  carboxykinase  (PEPCK),  a  key  enzyme  necessary  for 
glycerol synthesis and fatty acid reesterification and with consequence of reduction of NEFA levels.  
Compared  to  TZDs,  telmisartan  acts  only  as  a  partial  PPARγ  agonist  and  therefore  its  insulin‐
sensitizing action is not associated with increased risk of fluid retention and heart failure [178, 180]. 
Additionally,  further  experiments  indicated  that  telmisartan  also  exerts  anti‐inflammatory  actions 
(inhibition  of  chemokine‐induced  lymphocyte migration)  [185]  or  vascular  effects  (increase  in NO 
levels,  inhibition  of  vascular  smooth  cell  proliferation)  [186,  187],  both  of  them  being  PPARγ‐
mediated. Thanks  to  its pleiotropic effects,  telmisartan was postulated  to  influence not only blood 




vasoconstriction  through  interference  with  thromboxane  A2/prostaglandin  endoperoxide  H2 






independent  mechanism,  how  ACEIs  and  ARBs  affect  IR.  Besides  of  direct  effects  of  treatment 

























Similarly  to  adipose  tissue,  all  components  of  RAS  system  are  expressed  in  pancreas  and  thus 
modulate  local  blood  flow  and  hormone  release.    Exaggerated  islet  RAS  activation  (e.g. 
hyperglycaemia‐induced) is supposed to potentiate oxidative stress, inflammation and increase NEFA 
concentrations, contributing thus to β‐cell dysfunction [190]. Improved islet microcirculation induced 
by RAS blockade  attenuates oxidative  stress  and  β‐cell  apoptosis  and  improves  first phase  insulin 
secretion [157, 167]. Improved ionic balance of potassium and magnesium ensured by RAS blockade 
was also postulated to improved insulin secretion [167]. However based on recent experiments, the 




The  above‐described  mechanisms  of metabolic  effects  of  ARBs  have  been  postulated  based  on 
experimental studies in models of IR, diabetes and obesity. The promising experimental conclusions 
cannot  be  always  confirmed  in  studies  with  human  cell  cultures,  in  clinical  studies  in  vivo  and 
interventional  studies.  This  only mirrors  the  complexity  of metabolic  regulations  on  the  level  of 
whole organism. Unfortunately, due to differences in study design and conditions, the comparison of 
conclusions of available  clinical  studies has  important  limitations. The  confounding  factors  include 
dose, duration and type of ARB treatment, studied population  (ethnics, healthy vs.  insulin‐resistant 
subjects,  patients  with  impaired  glucose  homeostasis  or  diabetes,  presence  of  additional 




First  evidence  for  positive  effects  of  losartan  on  carbohydrate  metabolism  came  from  large 




atenolol was  used  as  a  comparator  in  this  trial.  The  promising  results  of  this  study  subsequently 
stimulated  further  clinical  research of  losartan aiming  to  confirm  the experimental data. However 
their results are not conclusive. Even the studies that used hyperinsulinaemic‐ euglycaemic clamp as 
a gold standard for estimation of IR, have equivocal conclusions: some were able to demonstrate an 
increase  in glucose disposal  [172, 193‐195] or glucose oxidation  [196], whereas others did not  find 
any effects on  insulin action  in hypertensive subjects [197‐199] or  in normotensive  insulin‐sensitive 
offspring  of  hypertensive  patients  [200].  Several  studies  proved  an  increase  in  circulating  HMW 
and/or  total adiponectin  following  losartan  treatment  [201‐204], although  the  changes  in  IR were 
only assessed as HOMA‐IR. On the contrary, a recent study that showed increase in glucose disposal 
with  losartan  treatment, did not detect any changes  in adipokines or  inflammatory markers  [205]. 






promising  the  possibility  of  metabolic  treatment  of  hypertension.  Indeed,  there  are  number  of 
studies documenting that long‐term administration of telmisartan improves of fasting blood glucose 
and HbA1c  in  patients with  type  2  diabetes  [207‐214],  reduces  serum  triglycerides  together with 
improvement of  cholesterol profile  [207, 208, 215, 216],  leads  to decrease visceral  fat mass  [217, 
218] or  increase  in  adiponectin  [211,  212,  215,  217,  219,  220].   All  the  studies demonstrate  also 
attenuation of  IR  associated with  telmisartan  treatment, which  is  interestingly documented  solely 
with reduced HOMA‐IR index and/or decreased fasting insulin concentrations. There are virtually no 




telmisartan do  really  translate  into clinical benefit and  if  so, what  is  the  target patient group. The 
















Hypothesis  I.  Acute  hyperinsulinaemia  leads  to  significant  changes  in  gene  expression  of  selected 
cytokines  in  SAT  that  are  accompanied  by  changes  in  their  circulating  concentrations  in  healthy 
subjects, while different reactions will be found in patients with type 2 diabetes. Significant relations 
between humoral activity of adipose tissue and insulin sensitivity or inflammation will be found.   




Hypothesis  II.  Telmisartan  but  not  placebo  treatment  leads  to  improvement  in  Insulin  sensitivity, 
energy metabolism and other metabolic parameters that are accompanied by significant changes  in 
gene  expression  and  circulating  concentrations  of  selected  cytokines  in  subjects  with  metabolic 
syndrome.  
Study III. To  investigate the effect of prolonged hypertriglyceridaemia on plasma concentrations 
and  SAT  expressions  of  selected  cytokines  and  adipokines  in  patients  with  type  2  diabetes  and 
healthy control subjects  
Hypothesis III. Acute hypertriglyceridaemia leads to significant changes in gene expression of selected 
cytokines  in  SAT  that  are  accompanied  by  changes  in  their  circulating  concentrations  in  healthy 
subjects, while different reactions will be found in patients with type 2 diabetes.  
Study  IV.  To  assess  the  plasma  concentrations  and  SAT  expressions  of  selected  cytokines  and 
adipokines and markers of  low‐grade  inflammation  in subjects with different categories of glucose 
intolerance  and  to  explore  their  potential  relationships  with  anthropometric  and  metabolic 
characteristics. 
Hypothesis IV. Gene expression of selected cytokines in SAT and their circulating concentrations differ 







study‐specific  design  and  protocols  can  be  found  in  the  particular  Results  sections  and  in  the 
publications. 
Subjects 
4 groups of subjects with different categories of glucose  intolerance were recruited  for  the clinical 
studies described in this thesis. The detailed study group characteristics can be found in the Appendix 
as  indicated below. Only male subjects participated  in  the studies  in order  to exclude variability  in 
insulin sensitivity in women according to menstrual cycle and childbearing potential and with respect 
to sexual dimorphism of a number of investigated adipokines. Informed consent was obtained from 





Next,  eleven  overweight/obese  patients  with  type  2  diabetes  (D)  and  12  age‐matched  healthy 
controls(C) were enrolled  for  Studies  I.,  III.  and  IV. Detailed  characteristics of both  groups  can be 
found in Appendix 2. The patients with type 2 diabetes were treated with oral agents except of TZDs, 






Healthy  control  subjects  had  normal  glucose  tolerance  confirmed  by  oral  glucose  tolerance  test, 
normal  blood  pressure  and  serum  lipids.  They were  not  taking  any  drugs  and  none  had  a  family 
history of diabetes. All control subjects were euthyroid and none had a concomitant disease.  
The  last group of 12 patients with  impaired  fasting glucose  (IFG)  fulfilling  the criteria of metabolic 
syndrome,  defined  according  to  NCEP‐ATPIII  criteria  revised  in  2005  [221],  was  investigated  in 
Studies  II  and  IV.  For  detailed  characteristics  please  refer  to Appendix  3.  Patients  enrolled  in  the 
study were treatment‐naive with regard to oral antidiabetic medication.  Antihypertensive treatment 
was adjusted during  the 4‐week  run‐in period as  follows: beta‐blockers, ACEIs and ARBs had been 
stopped  and  replaced  by  metabolic  neutral  calcium‐channel  blockers.  The  dose  of  concomitant 










All  subjects  were  examined  on  an  outpatient  basis,  after  overnight  fasting  with  only  tap  water 




The  HEC was  conducted  as  previously  described  [222].  Briefly,  a  Teflon  cannula  (Venflon;  Viggo, 
Helsingborg, Sweden) was inserted into an antecubital vein for the infusion of all test substances. A 
second  cannula was  inserted  retrogradely  into a wrist vein  for blood  sampling, and  the hand was 
placed in a heated (650 C) box in order to achieve venous blood arterialization. A primed‐continuous 
insulin infusion (1 mU.kg.‐1.min‐1 of Actrapid HM; NovoNordisk, Copenhagen, Denmark ‐ dissolved in 
0.9% NaCl) was  administered  to  acutely  raise  and maintain  the  plasma  concentrations  of  insulin. 
Plasma  glucose  concentrations  during  the  clamp  were  maintained  at  the  5  mmol.l‐1  level  by 
continuous  infusion  of  15%  glucose.  To  prevent  hypokalaemia  during  insulin  infusion,  potassium 














A 24‐hour  infusion of  lipid emulsion  (Intralipid 20%; Fresenius Kabi AB, Uppsala, Sweden) was 
administered  through Teflon cannula  in  the antecubital vein.  Intralipid 20% contained soya oil 
200 g, egg lecithin 12 g and glycerol 22 g per 1 liter. For the first 4 hours, the infusion rate 125 
ml.h‐1 was used and subsequently until the 24th hour a constant rate was calculated to reach a 
total dose of 3g of  fat.kg body weight‐1.d‐1. This  two‐step  infusion was chosen  to achieve both 
maximum  effect  and  to  stay within  the  clinically  allowed  boundaries.  A  second  cannula was 
inserted  retrogradely  into  a  wrist  vein  for  blood  collection.  To  assess  the  plasma  levels  of 
selected adipokines, arterialized venous blood  samples were  taken at 0 min, 30 min, 240 min 
and 24 hours of the infusion. During the interventions, subjects were only allowed to drink water 






Substrate  utilization  and  energy  expenditure  were  assessed  by  indirect  calorimetry  [223].    Gas 
exchange measurements were performed during a 45‐min basal period prior to starting the  insulin 
infusion and during  the  last 45‐min period of the clamp. A transparent plastic ventilated hood was 
placed over  the  subject’s head and made airtight around  the neck. A  slight negative pressure was 
maintained in the hood to avoid loss of expired air. A constant fraction of air flowing out of the hood 


















Plasma glucose  concentrations were measured on a Beckman analyzer  (Beckman  Instruments  Inc, 
Fullerton, CA, USA) using glucose oxidase method.  Immunoreactive  insulin  (IRI) was determined by 
radioimmunoassay method  using  an  IMMUNOTECH  Insulin  IRMA  kit  (IMMUNOTECH  as,  Prague, 
Czech  Republic)  with  analytical  sensitivity  0.5  μIU.ml‐1,  intra‐assay  and  inter‐assay  coefficient  of 
variation below or equal to 4.3% and 3.4%, respectively. Haemoglobin A1c (HbA1c) was measured by 
high‐performance  liquid chromatography using the Variant  II HbA1c Program  (Bio‐Rad Laboratories 
GmbH,  Munich,  Germany).  Plasma  concentrations  of  non‐esterified  fatty  acids  (NEFA)  were 
estimated  by  Half‐micro  test  Free  fatty  acids  (Roche  Diagnostics  GmbH,  Penzberg,  Germany). 
Triglyceride  (TG)  plasma  concentrations  were  assessed  by  enzymatic  assay  (BIO‐LA‐TEST;  PLIVA‐
Lachema, Brno, Czech Republic).  
 




Human Resistin ELISA kit  (BioVendor Lab. Med.  Inc., Brno, Czech Republic) with  the detection  limit 






Human Adiponectin ELISA kit  (BioVendor  Lab. Med.  Inc., Brno, Czech Republic) with  the detection 















IL‐1β  and  IL‐10.  The  results  were  evaluated  using  Luminex  analyzer  (a  dual  laser,  flow‐based 






RNeasy  Lipid  Tissue Mini  Kit  and QIAzol  Lysis  Reagent  (QIAGEN,  Valencia,  CA, USA).  The  starting 
amount of 100 mg  tissue was excised  from  the biopsy, and homogenized  in 1 ml of a QIAzol Lysis 
Reagent  (Guanidin Thiocyanate – Phenol  solution)  for 2 minutes.  From  the homogenate,  the RNA 
was  isolated  by  extraction  on  silica‐gel‐  based  column,  according  to  the  kit  handbook.  Possible 
contamination  of  RNA with  genomic DNA  remains was  taken  off  by DNase  digestion  (RNase‐free 
DNase Set; QIAGEN, Valencia, CA, USA). This step is supposed to prevent any later DNA amplification. 
Beyond  this,  the denaturating curves were measured during each  reaction and  there was  just one 
product present in all the measurements. 
2)  The  cDNA  was  synthesized  using  a  recombinant  Omniscript  Reverse  Transcriptase  (QIAGEN, 




Green PCR Kit; QIAGEN, Valencia, CA, USA) were used  for  the RT‐PCR procedure. To eliminate  the 
influence  of  primer  dimmers  negative  controls  were  used.  To  account  for  differences  in  cDNA 







Cyclophilin  5’‐CAA ATG CTG GAC CCA CA‐3‘ 5‘‐TGCCATCCAACCACTCAGTC‐3‘ 
Leptin  5´‐CCC TAA GCC TCC TTT TGC T‐3´  5´‐GCT AAG AGG GGA CAA GAC A‐3´ 
Adiponectin  5´‐GGT TCA ATG GCT TGT TTG C‐3´  5´‐TCA TCC CAA GCT GAT TCT G‐3´ 
AdipoR1  5´‐TCG GAC TTT TTC CAA ACT GG‐3´ 5´ ‐CCA CAA TGA TGG CAG AAA TG‐3´
AdipoR2  5´‐CTC CCT TTT TGC GGT GTG TA ‐3´ 5´ ‐AGA GCA AGC AAG CCT CTG AC‐3´
TNFα  5´‐CTA TCT GGG AGG GGT CTT C‐3´  5´‐TTG GGA AGG TTG GAT GTT C‐3´ 
Resistin  5´‐ATA AGC AGC ATT GGC CTG G‐3´  5´‐TGG CAG TGA CAT GTG GTC T‐3´ 
A‐FABP (FABP4)  5‘‐ATG GCC AAA CCT AAC ATG A‐3‘ 5‘‐ATT CCT GGC CCA GTA TG‐3‘ 
E‐FABP (FABP5)  5‘‐AAT GGC CAA GCC ACA TTG TA‐3‘ 5‘‐CAC TCC TGA TGC TGA‐3‘ 





Insulin  action was  estimated  as  the  glucose disposal  (M)  calculated during  the  last 30 min of  the 







Calculations  of  substrate  oxidation  during  indirect  calorimetry  were  performed  using  standard 
equations [223]. Urinary urea excretion during the clamp was corrected for changes in urea pool size 




The  data  are  expressed  as means  ±  SEM  or mean  (95%  Confidence  Interval)  as  appropriate.  The 
means of  two  groups  (Studies  I.  and  III.) were  compared using Mann‐Whitney  test,  the means of 
three  groups  (Study  IV.) using one‐way ANOVA model with  least  significant difference  (LSD) post‐
tests to elucidate differences between subgroups. In Study II., the telmisartan and placebo treatment 
were compared using Wilcoxon’s paired test.  




Subject  factor  (represents  the  inter‐individual  variability  of  subjects)  and  their  interactions 
(Intervention  ×  Time;  Intervention  ×  Group;  Time  ×  Group;  Group  ×  Intervention  ×  Time).  The 
interactions  indicate  if  the  shapes  of  the  time  profiles  for  HEC,  AT‐HEC  and  SAL,  for  D  and  C, 
respectively were different or not. In Study II following factors and interactions were included: Effect 
of  telmisartan  treatment  (placebo  vs.  telmisartan)  and  Effect of hyperinsulinaemia  (0 min  vs. 120 
min) as  the within  factors,  subject  factor  (inter‐individual variability of  subjects) and  telmisartan × 
Švehlíková, Mechanisms of insulin resistance 
  ‐ 35 ‐ 
Hyperinsulinaemia  interaction.  The  differences  between  subgroups  in  all  studies  were  evaluated 
using LSD multiple comparisons. Additionally  in Study  I., separate ANOVA models  for Diabetes and 
Control  groups  were  performed  for  comparison  of  the  interventions  within  the  group.  The 
significances of the separate models and LSD are described in the text.  
The statistical significance p<0.05 was chosen for both ANOVA testing and multiple comparisons. Due 
to  non‐Gaussian  data  distribution  in  all  dependent  variables,  the  data  underwent  power 
transformations to attain distributional symmetry and a constant variance  in  the data as well as  in 
residuals. The non‐homogeneities were detected using residual diagnostics. The experimental points 












To  investigate  the  effect  of  acutely  induced hyperinsulinaemia with  and without  acute ARB using 









Part A.  In  random  order,  the  healthy  subjects  (H)  underwent  two  hyperinsulinaemic  euglycaemic 












plasma  glucose  concentrations  (4.68±0.32  vs.  4.75±0.20  mmol.l‐1)  with  coefficient  of  variation 
3.37±0.55  vs.  3.42±1.87 %.  Although  the mean  IRI  levels were  different  comparing  both  clamps 
(65.11±7.53 vs. 75.28±6.95 μIU.ml‐1; p<0.05), the parameters of insulin sensitivity did not significantly 
differ  between  HEC  and  AT‐HEC,  being  expressed  as  the  glucose  disposal  (M):  (9.55±0.56  vs. 
9.15±1.68 mg.kg‐1.min‐1),  as well  as  calculated  as  the  insulin  sensitivity  index M/I  (0.15±0.01  vs. 
0.13±0.01 mg.kg‐1.min‐1/μIU.ml‐1).  
Plasma  concentrations  of  resistin  during HEC  and AT‐HEC  are  shown  in  Figure  2a. ANOVA model 























during HEC  and AT‐HEC.  The  bars with  error  bars  represent  retransformed mean  values with  their  95 % 
confidence  intervals.  F  in  the  embedded  table  symbolizes  the  Fisher’s  statistics  for  individual  factors  and 
interactions.  The  asterisks  correspond  to  significant  difference  between  the  basal  and  stimulated  values 
(p<0.05). Hashes denote significant difference between HEC and AT‐HEC in individual stages (p<0.05). 
 
No  changes  in plasma  adiponectin were detected  (Figure 3a). Relative  expressions of  adiponectin 
(Figure 3b) differed in terms of time profiles between HEC and AT‐HEC (treatment × time interaction: 
























comparable  within  as  well  as  between  D  and  C  groups  in  terms  of  the  mean  plasma  glucose 
concentrations with coefficients of variation below 3%, the mean  IRI and NEFA  levels. As expected, 
the  insulin  sensitivity  expressed  as M was  significantly  higher  in  C  compared  to D  group  (Group 
effect: p<0.01). No differences in M were detected between HEC and AT‐HEC in any group.  
During SAL control intervention the total fluid volume administered was comparable to HEC and AT‐





HEC  AT‐HEC  HEC  AT‐HEC   
Mean plasma glucose (mmol.l‐1)  5.18±0.12  5.23±0.10  5.35±0.20  5.17±0.13  NS 
Coefficient of glucose variation (%)  2.23±0.27  2.65±0.17  2.60±0.32  2.86±0.41  NS 
Mean insulin (µU.ml‐1)  71.87±4.89  77.13±6.25  80.58±5.58  79.56±7.55  NS 
NEFA (mmol.l‐1)  0.059±0.01  0.099±0.04  0.094±0.02  0.083±0.02  NS 









HEC and  reached  concentrations  comparable  to D, while during  SAL plasma  leptin only  tended  to 
decrease (Intervention effect: p<0.001; Intervention × Time Interaction: p<0.05 in ANOVA model for 
controls).  In  D  group,  the  changes  in  leptin  during  HEC  and  SAL  were  not  significant.  Leptin 
expression  in  SAT  (Figure  4c)  was  higher  in  D  (Group  effect:  p<0.001)  and  was  not  affected  by 
hyperinsulinaemia.  
The time profile of plasma leptin during HEC and AT‐HEC is depicted in Figure 4b. Again, basal leptin 
concentrations were higher  in D  (p<0.05  in  LSD post‐tests).  In C,  acute ARB did not  influence  the 
increase in leptin concentrations during hyperinsulinaemia (Time effect: p<0.01 in ANOVA model for 
controls and p<0.05 in LSD post‐tests, Intervention effect NS). A different regulation was observed in 
D  group  (Group  ×  Time  Interaction:  p<0.01  in  full  ANOVA model):  leptin  concentrations  declined 







In  summary, baseline plasma  concentrations and SAT expressions of  leptin are higher  in diabetes. 
Insulin  increases  circulating  concentrations of  leptin  in healthy  subjects, while  in diabetes plasma 
leptin  declines  during  hyperinsulinaemia.  Differential  regulation  of  circulating  leptin  cannot  be 
explained by  its expression  in SAT, which  implicates the  involvement of other fat depots as a  leptin 














expression  of  leptin  (c)  during  HEC  vs.  AT‐HEC.  The  empty  and  full  symbols  with  error  bars  represent 
retransformed mean  values  with  their  95  %  confidence  intervals  for  C  and  D  groups,  respectively.  The 
asterisks  correspond  to  significant  difference  between  the  basal  and  stimulated  values  (p<0.05).  Hashes 




Plasma  concentrations  of  total  adiponectin  during  HEC  and  SAL  (depicted  in  Figure  5a)  revealed 
unexpected differences. During HEC, the concentrations were comparable between groups without 
any  dynamic  changes  (an  observation  which  is  in  line  with  further  results).  During  SAL,  basal 
adiponectin concentrations were higher compared to HEC  in C group (Intervention effect: p<0.05  in 
full ANOVA model and  in model for controls, p<0.05  in LSD post‐tests). On the contrary  in D group, 
total adiponectin concentrations were decreased both at baseline and 240 min of SAL (Intervention 
effect: p<0.05 and Diabetes ×  Intervention  interaction: p<0.001  in  full ANOVA model;  Intervention 









d) HEC vs. AT‐HEC. The empty and  full symbols with error bars  represent  retransformed mean values with 






Surprisingly,  adiponectin  expression  in  SAT  was  even  higher  in  D  compared  to  C  (Group  effect: 
p<0.001). We also assessed  relative expressions of adiponectin  receptors AdipoR1 and AdipoR2  in 
SAT.  Both  receptors  showed  higher  expressions  in  C  compared  to  D  (Group  effect:  p<0.05  and 
p<0.001,  resp.  for  AdipoR1  and  AdipoR2,  respectively).  AdipoR2  expression  rates  in  SAT  were 
approximately  3  times  higher  than  AdipoR1  mRNA.  During  hyperinsulinaemia,  adiponectin 
expressions were stable in C group, whereas in D they showed an increase (Group × Time Interaction: 
p<0.05  in  full  ANOVA  model).  AdipoR1  and  AdipoR2  expressions  were  not  influenced  by 
hyperinsulinaemia  in both  groups.  For expression of  adiponectin  and  its  receptors please  refer  to 
Table 5. 
On the other hand during AT‐HEC, a consistently higher total and HMW adiponectin concentrations 
(Figure 5b  and  Figure 5d,  resp.)  (Intervention  effect: p<0.01  and p<0.001,  respectively)  as well  as 
higher adiponectin mRNA expression (Intervention effect: p<0.01) compared to HEC were detected in 
both groups.   The  insulin‐stimulated  increase  in adiponectin expression  in D group was not  further 




and  remain unclear. Adiponectin expression  in SAT was even higher  in D group, while adiponectin 
receptors  were  more  expressed  in  C  group.  Hyperinsulinaemia  had  no  effect  on  adiponectin 
concentrations, whereas adiponectin expressions were stimulated by insulin in D but not in C. Acute 







































































Table  5  Relative  expressions  of  adiponectin, AdipoR1  and AdipoR2  in  SAT. Data  are means  (5%‐95%  CI). 






Plasma  concentrations  of  resistin  were  comparable  between  groups.    However,  group‐specific 
changes  in  plasma  resistin  were  found  during  HEC  and  SAL  (Figure  6a).  In  D,  basal  resistin 
concentrations were increased in SAL compared to HEC (p<0.05 in LSD post‐tests) and they remained 
stable at 240 min of SAL. During HEC,  the D group showed a clear  increase  in plasma  resistin  that 
reached  concentrations  comparable  to 240 min of  SAL  (Time effect: p<0.01  in  full ANOVA model; 
p<0.05 in LSD post‐tests). In C, a general increase in plasma resistin was found during both HEC and 
SAL (Time effect: p<0.01  in full ANOVA model), but there was also a significant difference between 
the  interventions  in  this group. Both at baseline and 240 min of HEC,  resistin concentrations were 
lower  than  in SAL  (Intervention effect: p<0.05 and p=0.08  in ANOVA model  for Controls and  in  full 
model,  respectively; p<0.05  in LSD post‐tests). These observations  suggest  that  in diabetes,  insulin 
increases plasma resistin, whereas in healthy subjects an increase in resistin is also seen in SAL and as 
such  cannot  be  attributed  to hyperinsulinaemia. However, plasma  resistin was  suppressed during 
HEC  in  control  subjects.  Relative  expression  of  resistin  in  SAT  was  found  to  be  higher  in  D; 
hyperinsulinaemia did not affect resistin expression in either group (Figure 6c).  
Accordingly, comparing HEC and AT‐HEC clamps (Figure 6b), a significant  increase  in plasma resistin 
was detected  in D group  (Time effect: p<0.001  in ANOVA model for Diabetes, which accounted for 
Time effect: p<0.001 in full ANOVA model). Basal resistin concentrations in AT‐HEC were reduced in 
D (p<0.05  in LSD post‐tests), but an  increase during clamp compensated for the  initial  lower  levels. 
On the other hand in controls, only a non‐significant trend for increase in resistin was demonstrated 














expression  of  resistin  (c)  during  HEC  vs.  AT‐HEC.  The  empty  and  full  symbols with  error  bars  represent 
retransformed mean  values  with  their  95  %  confidence  intervals  for  C  and  D  groups,  respectively.  The 
asterisks  correspond  to  significant  difference  between  the  basal  and  stimulated  values  (p<0.05).  Hashes 





resistin expression  in SAT  is  increased  in diabetes.  In diabetes,  insulin  increases plasma resistin. On 
the contrary, in controls the increase in resistin is observed also during SAL and thus it is not caused 
by insulin. However, during hyperinsulinaemia plasma resistin was suppressed in C. Losartan reduces 
basal  resistin  concentrations  in  D  but  not  in  C.  Resistin  expression  in  SAT  is  not  affected  by 
hyperinsulinaemia or losartan. 
TNFα 
Plasma  concentrations  of  TNFα  (Figure  7) were  higher  in D  compared  to  C  group  (Group  effect: 
p<0.001 in full ANOVA model).  In C, TNFα levels were comparable within and between HEC and SAL, 
whereas  in  D  an  unexpected  difference  between  HEC  and  SAL  was  measured.  In  SAL,  TNFα 
concentrations were substantially  lower both at baseline and 240 min  in the D group  (Intervention 
effect: p<0.01 and p<0.001  in  full ANOVA model and  in model  for Diabetes,  respectively; Group × 
Intervention  Interaction:  p<0.001  in  full  model).  No  dynamic  changes  during  HEC  or  SAL  were 
detected  in D.  TNFα  relative  expressions  in  SAT  (Figure  7c) were  also higher  in D  compared  to C 
(Group  effect:  p<0.001  in  full ANOVA model). Acute  hyperinsulinaemia  resulted  in  an  increase  in 














expression  of  TNFα  (c)  during  HEC  vs.  AT‐HEC.  The  empty  and  full  symbols  with  error  bars  represent 
retransformed mean  values  with  their  95  %  confidence  intervals  for  C  and  D  groups,  respectively.  The 
asterisks  correspond  to  significant  difference  between  the  basal  and  stimulated  values  (p<0.05).  Hashes 








baseline of AT‐HEC compared  to HEC  (p<0.05  in LSD post‐tests), while  the  insulin‐stimulated TNFα 
expressions were comparable between clamps (Intervention × Time  Interaction: p=0.056; LSD post‐
test  NS).  In  D,  the  increase  in  TNFα  expression  during  hyperinsulinaemia was  not  influenced  by 
losartan. 
In  summary, TNFα  circulating  concentrations and expressions are  increased  in diabetes. However, 




Plasma  levels of visfatin (Figure 8) were surprisingly  lower  in D compared to C group (Group effect: 







Figure 8 Visfatin plasma  concentrations during  interventions:  (a) HEC vs. SAL and  (b) HEC vs. AT‐HEC. The 
empty and  full  symbols with  error bars  represent  retransformed mean  values with  their 95 %  confidence 
intervals  for  C and D groups,  respectively.  The asterisks  correspond  to  significant difference between  the 
basal and  stimulated values  (p<0.05). Hashes denote  significant difference between  interventions  (HEC vs. 
SAL  and  HEC  vs.  AT‐HEC,  respectively)  in  individual  stages  (p<0.05).  Embedded  tables  summarize  the 
significant factors of full ANOVA model.   
RBP4 







(Group  effect:  p<0.01)  despite  of  comparable  baseline  values.  The  decrease  in  RBP4  in  controls 
during hyperinsulinaemia was confirmed  in  the analysis of HEC vs. AT‐HEC  (Time effect:   p<0.05  in 
model for Controls), while no effect of losartan was shown. On the other hand in diabetes, RBP4 time 
profile differed between clamps: RBP4 was stable during HEC, while during AT‐HEC decreased basal 
concentrations  reversed 240 min  (Intervention effect: p<0.05  in  full ANOVA model  and model  for 
Diabetes; Group × Time Interaction: p<0.01). The measurement of RBP4 expressions in SAT samples 
was not possible. 
Although  RBP4  plasma  concentrations  are  comparable  between  diabetes  and  controls,  they  are 











Both MCP‐1  plasma  concentrations  and  SAT  expressions  (Figure  10)  were  increased  in  diabetes 
(Group effect: p<0.001  in both  full ANOVA models).  In both groups, plasma MCP‐1 concentrations 
were stable and  lower during SAL compared to HEC  (Intervention effect: p<0.001  in  full ANOVA,  in 
model for Controls and for Diabetes). While hyperinsulinaemia did not change MCP‐1  levels  in C,  it 
Švehlíková, Mechanisms of insulin resistance 
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expression  of MCP‐1  (c)  during  HEC  vs.  AT‐HEC.  The  empty  and  full  symbols  with  error  bars  represent 
retransformed mean  values  with  their  95  %  confidence  intervals  for  C  and  D  groups,  respectively.  The 
asterisks  correspond  to  significant  difference  between  the  basal  and  stimulated  values  (p<0.05).  Hashes 
denote  significant  difference  between  interventions  (HEC  vs.  SAL  and  HEC  vs.  AT‐HEC,  respectively)  in 
individual stages (p<0.05). Embedded tables summarize the significant factors of full ANOVA model.   
IL‐1ra plasma (Table 6) concentrations were higher  in diabetes compared to controls (Group effect: 
p<0.001  in  full  ANOVA model).  Changes  in  IL‐1ra  during  and  between  all  interventions were  not 
significant in either group. 
Plasma concentrations of RANTES  (Table 6) were paradoxically decreased  in diabetes compared  to 
controls (Group effect: p<0.001 in full ANOVA model). In both groups, RANTES concentrations were 









































































































Table 6 Plasma concentrations of  IL‐1ra, RANTEs and VEGF during  interventions. Data are means  (5%‐95% 
CI). Statistical significance (in bold): Group effect – difference between groups; a Intervention effect p<0.001 – 






was detected during HEC  (Time  effect:  p<0.05  in  full ANOVA  and  in  LSD post‐test:  p<0.05), while 
during SAL no difference in A‐FABP concentrations could be shown. This implicates that the decline in 






higher  in D  group  (Group  effect:  p<0.001), while  no  dynamic  changes  in  the  course  of HEC were 
observed (Time and Intervention effects and all interactions were not significant). 
























%  confidence  intervals  for C and D groups,  respectively. The asterisks  correspond  to  significant difference 





were  increased during AT‐HEC  (Intervention effect: p<0.05  in Full ANOVA model and  in model  for 
Diabetes). A  parallel  decrease  in  plasma A‐FABP was  detected  in D  during  both HEC  and AT‐HEC 
(Time effect: p<0.05  in ANOVA model for Diabetes and LSD post‐test: p<0.05).  In C, plasma A‐FABP 
was  stable  during  HEC,  whereas  during  AT‐HEC  increased  basal  A‐FABP  reversed  at  240  min 
(Intervention effect: p<0.05 in Full ANOVA and LSD post‐test: p<0.05). 
Regarding  the effect of ARB on A‐FABP expressions, A‐FABP mRNA  levels were  stable during both 
clamps  in  both  groups.  Higher  E‐FABP  expressions  during  AT‐HEC  in  C  but  not  in  D  could  be 





































































































Both  A‐FABP  plasma  concentrations  and  expressions  correlated  positively  with  BMI,  waist 
circumference,  fasting plasma glucose,  fasting  insulin and negatively with M; additionally, positive 
correlation of A‐FABP mRNA and HbA1c was found. The A‐FABP/E‐FABP mRNA ratio correlated with 
fasting  plasma  glucose  and  HbA1c.  E‐FABP  mRNA  expressions  were  negatively  correlated  with 
HbA1c; relations to other parameters of metabolic syndrome were not significant. 
In multivariate  regression, which  reflects  the weight  of  individual  factors without  contribution  of 
other  factors  included  in  the model, BMI, waist,  fasting  glycaemia,  insulinaemia  and M  remained 
significant  predictors  (p<0.05)  of  both  A‐FABP  plasma  concentrations  and  expression  (detailed 















BMI  0.85***  0.65***  0.03  0.40 
Waist circumference  0.86***  0.56**  ‐0.07  0.34 
Fasting glucose  0.46*  0.73***  ‐0.35  0.74*** 
Fasting insulin  0.50*  0.48*  ‐0.11  0.39 
Fasting NEFA  0.13  0.17  ‐0.09  ‐0.33 
Fasting TG  0.19  0.24  ‐0.05  0.23 
Total cholesterol  ‐0.05  0.21  ‐0.08  ‐0.21 
HDL‐cholesterol  ‐0.06  ‐0.28  0.04  ‐0.10 
LDL‐cholesterol  ‐0.10  0.17  ‐0.18  0.22 
HbA1c  0.08  0.46*  ‐0.56*  0.65** 
M  ‐0.64**  ‐0.53**  +0.18  ‐0.35 
 













12  subjects  with  impaired  fasting  glucose  as  an  obligate  criterion  of metabolic  syndrome  were 
recruited for the study (see Appendix 3). 
Study protocol 
This  randomized,  double‐blind,  placebo  controlled,  cross‐over  trial  consisted  of  two  treatment 
periods. After a 4‐week  run‐in period,  the  subjects were  randomly assigned  to  receive  telmisartan 
160 mg (T) daily (Micardis 80 mg; Boehringer Ingelheim Pharma GmbH, Germany) or placebo (P) for 3 




during  the  whole  study  duration.  At  the  end  of  both  3‐week  treatment  periods  all  patients 
underwent  a  two‐hour  euglycaemic  hyperinsulinaemic  clamp  (HEC)  combined  with  indirect 
calorimetry and adipose tissue biopsies. These procedures are described above. 
Results 
T  compared  to  P  treatment  induced  no  differences  in  body weight  (89.8±19  vs.  89.8±18  kg)  but 
resulted  in  lower  blood  pressure,  both  systolic  (126±10  vs.  135±12 mmHg;  p<0.03)  and  diastolic 
(81±10  vs.  90±10  mmHg;  p<0.01),  lower  fasting  plasma  glucose  (p<0.05)  and  higher  fasting  IRI 
(p<0.05) (See Appendix 3, Figure 1).  
The  clamps  performed  after  treatment with  T  versus  P were  comparable  in  terms  of  the mean 
plasma  glucose  concentrations  (5.29±1.9  vs.  5.34±0.3 mmol/l),  coefficient  of  variation  of  glucose 
(2.89±1.9 vs. 2.56±1.2 %) and mean  IRI  levels.  Insulin action was  comparable after T and P:   MCR 
(4.15±1.0 vs. 4.08±1.9 ml.kg‐1.min‐1), M (4.4±1.8 vs. 3.9±1.7 mg.kg‐1.min‐1) and non‐oxidative glucose 





Time  profiles  of  adipokines  during  clamp  experiments.  For  detailed  description  and  Figures  see 
Appendix 3, Figures 2‐5).  
Plasma concentrations of TNFα were decreased  in T as compared to P (Telmisartan effect: p<0.05), 





detected,  implicating  the  suppression  of  TNFα  expression  by  insulin  which  is  not  influenced  by 
telmisartan.   
 
Plasma  adiponectin  concentrations  have  shown  a  different  time  course  during  insulin‐stimulated 
conditions  in T  and P, documented by  the  significant Telmisartan × Hyperinsulinaemia  interaction 
(p<0.05). A significant  increase  in plasma adiponectin was detected by LSD multiple comparisons  in 
120 min of HEC (0 min vs. 120 min: p<0.05) after telmisartan treatment while no changes were seen 
after  P.  Relative  expressions  of  adiponectin were  comparable  during  both  treatment  periods  and 
clamps, both Telmisartan and Hyperinsulinaemia factors were not significant.  
Both basal and  insulin‐stimulated plasma  leptin concentrations were  significantly  increased after T 
treatment compared to P  (Telmisartan effect: p<0.001), while telmisartan did not alter the relative 
expressions of  leptin  in  SAT. There was a  significant decrease  in  leptin expressions during  insulin‐
stimulated conditions (Hyperinsulinaemia factor: p<0.001).  
The telmisartan treatment resulted in an increase in plasma resistin concentrations, as documented 
by  the  significant  Telmisartan  factor  (p<0.01). During  insulin‐stimulated  conditions  an  increase  in 
resistin plasma concentrations was detected (Hyperinsulinaemia factor: p<0.001), while the effect of 


















In  both  parts  A  and  B,  the  subjects  underwent  a  24‐h  infusion  of  lipid  emulsion  (Intralipid  20%; 
Fresenius Kabi AB, Uppsala, Sweden) as  it was described previously. Blood  samples  for estimation 
plasma concentrations of selected adipokines were collected at 0 min, 30 min, 240 min and 24 hours 
of the infusion. In the Part B of the study, plasma concentrations of visfatin, RBP4, HMW adiponectin 
and  A‐FABP  were  measured  at  time  points  0  min,  240  min  and  24  hours.  To  assess  relative 





To  validate  the  effectiveness  of  lipid  infusion  plasma  levels  of  TG,  NEFA,  glucose  and  IRI  were 
monitored. TG  increased almost 8‐fold and NEFA about 3.5‐fold  in the 4th hour and they remained 




TNFα  plasma  concentration  did  not  change  during  the  first  4  h  of  hypertriglyceridaemia  but  a 
significant  increase  after  24  h  was  detected  (p<0.001;  Figure  12a).  The  expression  of  TNFα  in 
subcutaneous  adipose  tissue  did  not  change  (see Appendix  4,  Figure  2).  Plasma  concentration  of 
resistin  significantly  increased  at  30 min  of  infusion  and  remained  elevated  throughout  the  24  h 
(p<0.01;  Figure  12b).  The  expression  of  resistin  in  the  subcutaneous  adipose  tissue  tended  to 
increase, but  the  change was not  significant  (see Appendix 4,  Figure 2). Plasma  concentrations of 
leptin  and  adiponectin  (Figure  12c‐d)  did  not  show  any  significant  changes  and  their  expressions 





Figure  12  Plasma  levels  of  selected  adipokines  during  24‐hour  lipid  infusion.  The  bars  with  error  bars 
represent re‐transformed means with their 95 % confidence  intervals. F  in the embedded tables represents 
Fisher’s statistics for individual factors. R2 (squared correlation coefficient of the linear model) symbolize the 









Towards  the  end  of  experiment  (starting  at  16.  hour)  the  triglycerides  concentrations  remained 
elevated  in D group, while  in  the  control group a decline was observed. The NEFA  concentrations 
were comparable between groups with a 4‐fold increase at 240 min and a sustained 2‐fold elevation 
until the 24 hour (Time effect: p<0.001).  The blood glucose levels were higher in D group compared 
to  controls  (Group  effect:  p<0.001).  Blood  glucose  was  stable  during  the  24  hours  in  C  group, 
whereas in D group, blood glucose decreased between 3rd and 6th hour to a plateau of approximately 






























Both  TNFα  plasma  concentrations  and  SAT  expressions  (displayed  in  Figure  14) were  significantly 
higher  in  D  (Group  effect:  p<0.001  for  both  plasma  concentrations  and  expressions).  During 
hypertriglyceridaemia  plasma  TNFα  remained  stable  in D  group, whereas  in  C  group  TNFα  levels 
increased over 24 hours  (Time effect: p<0.01; Group x Time  Interaction: p<0.01). Changes  in TNFα 
expression in SAT were not significant in any group. 
Resistin 
Resistin plasma concentrations and  its expression  in SAT  is shown  in Figure 15. Plasma  resistin did 
not differ between groups. An  increase  in resistin concentrations during hypertriglyceridaemia was 




































Plasma concentrations of  leptin  (Figure 16a) were higher  in D group  (Group effect: p<0.001).   The 
plasma  leptin  time profiles during hypertriglyceridaemia are displayed  in Figure 16a. They differed 
between  groups  (Group  x  Time  Interaction:  p<0.001;  Time  effect:  p<0.01)  as  follows:  in D  group, 
leptin rapidly declined in 30 min and 240 min of infusion but it reversed to the basal concentrations 
after  24  hours  of  hypertriglyceridaemia.  On  the  contrary  in  C  group,  leptin  concentrations were 




















Plasma concentrations of  total adiponectin  (Figure 17) were unexpectedly  found  to be higher  in D 
group compared  to C group  (Group effect: p<0.001). No changes  in  total adiponectin  levels during 
hypertriglyceridaemia were detected  in either group. On  the other hand,  concentrations of HMW 


















Figure  17  Adiponectin  plasma  concentrations  (a)  and  SAT  expressions  (b)  and  HMW  Adiponectin 





Plasma  concentrations  of  both  visfatin  and  RBP4  (Table  9)  were  comparable  between  groups. 




0 h  4 h  24 h  0 h  4 h  24 h 
Visfatin [ng/ml]  5.31±0.75  5.52±0.66  5.82±0.85  8.68±2.71  7.52±1.03  7.67±0.65 









































1)  11  overweight/obese  patients with  type  2  diabetes  (D);  2)  12  overweight/obese  patients with 
metabolic  syndrome  with  impaired  fasting  glucose  (IFG)  as  an  obligate  criterion  and  3)  11  age‐
matched  healthy  control  subjects  (C).  For  confirmation  of  their  glucose  tolerance  status  and 
exclusion of overt diabetes, C and  IFG groups underwent an oral glucose  tolerance  test with 75 g 
glucose.  Diabetes  was  confirmed  based  on  medical  records  in  the  D  group.  The  baseline 
characteristics and differences between the study groups are summarized in Table 10.  







Age  (years)  48.05 ± 1.38 50.5 ± 1.74  50.27 ± 1.38 0.260  0.317  0.916
Weight (kg)  77.63 ± 3.85 90.42 ± 5.28 93.72 ± 2.48 0.035  0.011  0.572
Body mass index (kg.m‐2)   24.63 ± 0.98 29.19 ± 1.21 30.02 ± 0.58 0.002  0.001  0.553
Waist circumference (cm) 89.09 ± 2.61 103.83 ± 2.17 101.8 ± 2.37 0.000  0.000  0.551
Fasting blood glucose 
(mmol.l‐1) 
5.2 ± 0.06  6.08 ± 0.10  7.49 ± 0.43  0.024  0.000  0.000 
Blood glucose at 120 min of 
OGTT (mmol.l‐1) 
5.56 ± 0.34  6.98 ± 0.58  ‐  0.025  ‐  ‐ 
Fasting insulin (µU.ml‐1)  5.06 ± 0.59 12.67 ± 2.00 8.42 ± 1.05 0.000  0.087  0.034
Fasting C‐peptide (  0.61 ± 0.09 1.27 ± 0.18 1.06 ± 0.17 0.004  0.036  0.324
HbA1c (%)   5.47 ± 0.10 5.69 ± 0.11 6.48 ± 0.41 0.529  0.008  0.030
Total cholesterol (mmol.l‐1) 4.86 ± 0.22 5.48 ± 0.30 5.58 ± 0.27 0.110  0.072  0.796
Triglyceride (mmol.l‐1)  1.15 ± 0.17 2.60 ± 0.41 2.61 ± 0.49 0.011  0.012  0.999
HDL‐cholesterol (mmol.l‐1) 1.20 ± 0.05 1.06 ± 0.05 1.10 ± 0.04 0.056  0.171  0.583
LDL‐cholesterol (mmol.l‐1) 3.25 ± 0.20 3.20 ± 0.37 3.57 ± 0.17 0.906  0.413  0.342
Fasting NEFA (mmol.l‐1)  0.458 ± 0.05 0.444 ± 0.05 0.502 ± 0.12 0.838  0.093  0.213
Table 10 Clinical and biochemical characteristics of the study groups. Data shown as mean ± SEM  
IFG and D group were comparable in terms of weight, BMI and waist circumference, whereas C group 
was  leaner.  Regarding  glucose metabolism,  fasting  blood  glucose  differed  between  all  groups  as 
defined, HbA1c was  comparable between C and  IFG groups and higher  in D group.  Insulin and C‐
Švehlíková, Mechanisms of insulin resistance 
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patients were  treated with  stable dose of  statin. Six patients  received antihypertensive  treatment 
(calcium‐channel  blockers, diuretics or ACEIs). ACEIs were  replaced with  calcium‐channel  blockers 
prior to study procedures. IFG group was treatment‐naive with regard to oral antidiabetic medication 









Steady  state  periods  characteristics  of  2‐hour  hyperinsulinaemic  euglycaemic  clamp  and  the 
differences between groups are shown  in Table 11. The mean plasma glucose concentrations were 
higher  in D  compared  to C and  IFG, while  the mean  IRI  levels were higher  in  IFG  compared  to C.  












5.18±0.05  5.29±0.10  5.64±0.16  0.493  0.006  0.031 
Coefficient of glucose 
variation (%) 
2.07±0.24  2.90±0.59  2.38±0.34  0.170  0.599  0.388 
Mean IRI (µIU.ml‐1)  68.09±5.25  95.43±10.86  75.30±6.77  0.018  0.492  0.076 
NEFA (mmol.l‐1)  0.10±0.03  0.08±0.02  0.09±0.01  0.437  0.750  0.650 
M (mg.kg‐1.min‐1)  9.04±0.92  3.89±0.49  4.92±0.48  0.000  0.000  0.270 
MCR (ml. kg‐1.min‐1)  9.64±0.94  4.47±0.66  4.88±0.49  0.000  0.000  0.686 
M/I  
(mg.kg‐1.min‐1 per µIU.ml‐1) 
0.145±0.021  0.044±0.009  0.073±0.010  0.000  0.002  0.196 
MCR/I  
(ml. kg‐1.min‐1 per µIU.ml‐1) 





Adipokines Plasma  concentrations of  leptin were  increased  in  IFG  compared  to both other groups 
(p<0.001  vs.  C  and  p<0.01  vs.  D).  Leptin  levels  tended  to  be  higher  in  D  compared  to  C  group, 




Figure 19 Leptin plasma concentrations  (a) and mRNA expressions  in SAT  (b). Data shown as mean ± 95% 
confidence interval. *p<0.05; **p<0.01; ***p<0.001 
Unexpectedly, plasma  concentrations of both  total  and HMW  adiponectin did not differ between 
groups (Table 12 shows adiponectin concentrations and expressions of the protein and its receptors). 
Relative expressions of adiponectin were comparable between C and IFG and even higher in D group 










Total adiponectin [µg/ml]  4.77±0.52  6.42±0.67  5.61±0.86  0.103  0.408  0.416 
HMW adiponectin [µg/ml]  4.18±0.44  3.59±0.75  4.11±0.89  0.542  0.946  0.611 
Adiponectin mRNA [AU]  18.86±2.41  28.50±2.39  46.97±8.30  0.198  0.002  0.043 
AdipoR1 mRNA [AU]  81.79±7.51  69.76±4.38  74.82±7.75  0.227  0.481  0.576 
AdipoR2 mRNA [AU]  238.74±24.49  145.43±8.34  184.64±21.79  0.002  0.048  0.130 









TNFα plasma  concentrations  (Figure 20c) were  lowest  in C  (p<0.01  vs.  IFG  and p<0.05  vs. D)  and 
comparable  between  IFG  and  D.  However,  the  relative  expressions  of  TNFα  in  SAT  (Figure  20d) 
differed among all groups with lowest expressions in C, higher in IFG and highest rates in D group. 
Plasma  visfatin was  found  to be  lower  in D group  compared  to C group  (p<0.05  for C  vs. D). The 
differences between D and IFG, as well as between C and IFG were not significant (Table 13). Plasma 
concentrations of RBP4 were comparable between all three groups (Table 13). 











concentrations were measured  in D group  (p<0.05 vs. C and p=0.053 vs.  IFG), while no differences 
between C and IFG were observed. 






Visfatin [ng/ml]  8.10±1.70  6.24±0.44  4.33±0.64  0.222  0.025  0.235 
RBP4 [ng/ml]  46.37±3.73  44.37±5.16  46.79±3.80  0.743  0.949  0.707 
E‐FABP mRNA [AU]  269.97±25.25  186.64±16.28  212.91±22.98  0.012  0.081  0.361 
PPARγ mRNA [AU]  176.02±19.23  161.23±13.63  137.29±24.46  0.611  0.196  0.370 
MCP‐1 [pg/ml]  136.68±14.81  229.05±20.86  203.98±30.75  0.005  0.043  0.437 
IL‐1ra [pg/ml]  436.45±103.4  973.54±208.7  959.31±391.9  0.118  0.147  0.968 
VEGF [pg/ml]  5.91±1.26  9.22±2.09  7.27±3.780  0.308  0.705  0.573 
RANTES [pg/ml]  9723±1636  9615±1062  5629±1302  0.954  0.048  0.053 











Relationship  of  endocrine  activity  of  adipose  tissue  with  anthropometric  and metabolic 
parameters  
For  correlation analysis of potential  relationships  (summarized  in Table 14), all  three groups were 






expression was positively  related  to BMI and  triglycerides. Plasma TNFα was negatively  related  to 
insulin sensitivity (MCR) but did not display any relation to parameters of obesity. In contrast, TNFα 
expressions were positively  correlated with BMI, waist  circumference,  triglycerides,  fasting plasma 
glucose, HbA1c and negatively with MCR. Plasma visfatin was surprisingly positively related to insulin 
sensitivity (MCR) and negatively to fasting plasma glucose.  





AdipoR2  were  also  highly  interrelated  (r=0.88;  p<0.05).  In  addition,  TNFα  expressions  were 
associated with expressions of leptin (r=0.66; p<0.05) and resistin (r=0.76; p<0.05), while no relations 
between  circulating  adipokines  could  detected. We  did  not  find  any  association  between  plasma 
levels and SAT expressions of leptin, resistin and TNFα. 
A‐FABP plasma concentrations  showed positive  relation  to obesity  (BMI, waist circumference) and 
hyperinsulinaemia and negative correlation with MCR. A‐FABP expressions were positively related to 
BMI  and  additionally  to  fasting  plasma  glucose  and  HbA1c  but  the  relation  to  MCR  was  not 
significant.  Additional  positive  correlations  between  A‐FABP  expression  and  expressions  of  TNFα 
(r=0.77;  p<0.05),  resistin  (r=0.62;  p<0.05),  leptin  (r=0.54;  p<0.05)  and  also  adiponectin  (r=0.54; 
p<0.05)  were  found.  No  significant  relation  between  A‐FABP  expressions  in  SAT  and  its  plasma 
concentrations or expression of E‐FABP and PPARγ could be demonstrated. 
PPARγ  expression was not  related  to  any of  the  anthropometric or metabolic parameters, but  its 
negative correlations with plasma TNFα  (r=‐0.59; p<0.05) and plasma resistin  (r=‐0.45; p<0.05) and 
positive  correlations  with  expressions  of  adiponectin  receptors  AdipoR1  (r=0.72;  p<0.05)  and 
AdipoR2 (r=0.67; p<0.05) were demonstrated. 
MCP‐1 was  positively  related  to waist  circumference  and  negatively  to MCR.  IL‐1ra  showed  also 
positive  correlations  with  obesity,  fasting  plasma  glucose  and  insulin.  In  contrast,  RANTES  was 
unexpectedly  found  to  be  positively  associated with MCR  and  negatively with BMI.  Exploring  the 
relations of  inflammatory markers  to adipokines, positive correlations between MCP‐1 and plasma 



























































p‐Leptin  0.49  0.56  ‐0.47  0.25  0.04  0.34  ‐0.10  ‐0.53 
Leptin mRNA  0.52  0.60  ‐0.11  0.27  0.49  0.46  0.31  ‐0.44 
Resistin mRNA  0.38  0.34  ‐0.16  0.42  0.33  0.09  0.27  ‐0.13 
p‐TNFα  0.24  0.26  ‐0.11  0.16  0.24  0.12  0.18  ‐0.57 
TNFα mRNA  0.51  0.44  ‐0.16  0.38  0.61  0.10  0.43  ‐0.36 
p‐Visfatin  ‐0.19  ‐0.19  0.07  ‐0.22  ‐0.39  0.01  ‐0.17  0.42 
p‐ A‐FABP  0.39  0.47  ‐0.12  0.15  0.15  0.40  ‐0.10  ‐0.43 
A‐FABP mRNA  0.38  0.39  ‐0.11  0.28  0.77  0.09  0.51  ‐0.31 
MCP‐1  0.24  0.41  ‐0.29  0.25  0.10  0.13  ‐0.03  ‐0.40 
IL‐1ra  0.44  0.40  ‐0.12  0.05  0.43  0.48  0.24  ‐0.32 
RANTES  ‐0.41  ‐0.32  0.28  ‐0.22  ‐0.22  ‐0.09  ‐0.07  0.36 



























Changes  in  endocrine  activity  of  adipose  tissue  ­  Effects  of metabolic  status  and 
hyperinsulinaemia 




Resistin.  In young healthy subjects (Part A) acute hyperinsulinaemia  induces an  increase  in resistin 
plasma concentration and stimulates the expression of resistin  in subcutaneous adipose tissue. This 
finding  is consistent with several studies  in rodent models [64] or  in vitro studies [64, 232]. On the 
contrary, other groups showed the opposite in mice and in 3T3‐L1 adipocytes [64]. Only few studies 
have  investigated  the effect of  insulin  in vivo  in humans; Heilbronn  [233] observed an  increase  in 
serum  resistin  concentrations  in  response  to  supraphysiological doses of  insulin  (164±5 mIU.l‐1)  in 
obese  subjects  with  and  without  diabetes.  However,  clinical  studies  in  humans  do  not  show  a 
consistent link between serum resistin and either insulin resistance or obesity [21, 46, 68, 234]. 
Comparing D and C groups in part B of the study, plasma concentrations of resistin were not different 
between  groups, whereas  resistin  expression  in  SAT was  increased  in  diabetes.  The  comparable 
circulating  concentrations  of  resistin  are  in  line with most  other  studies  [66,  233,  235],  although 
several reports were able  to confirm a difference between diabetic and non‐diabetic subjects  [66]. 
Similarly,  the  available  human  data  on  resistin  expression  in  diabetes  are  controversial  [66]. Our 
finding of increased resistin expression in SAT that is not accompanied with difference in circulating 
levels  implicates  an  involvement  of  other  source  of  plasma  resistin,  such  as  other  fat  depot  or 
mononuclear cells. Since the macrophages are recognized as a primary source of resistin in humans, 
the  differences  in  expression might  relate more  to  different  degree  of macrophage  infiltration  in 
adipose tissue than to diabetes per se.    
In part B of the study, group‐specific regulation of plasma resistin  in response to hyperinsulinaemia 




increase  in  resistin  is observed also during SAL and as  such  it  cannot be attributed  to  insulin. We 
might  speculate  on  possible  effects  of  prolonged  fasting  or  circadian  rhythm  on  resistin.  Resistin 
expression in SAT is not affected by hyperinsulinaemia in any group. As mentioned above, literature 
evidence on resistin regulation by insulin is controversial and not exhaustive. Even if insulin does not 
appear  to play a significant direct  regulatory  role  in  resistin expression  in humans  [66],  the group‐
specific changes in circulating resistin demonstrated in our study might be indirect based on different 
activation of inflammatory pathways during hyperinsulinaemia between groups. 
Another  unclear  observation  is  the  lower  baseline  resistin  concentration  in  both  groups  in  HEC 





Adiponectin.  In  young  healthy  subjects  (part  A),  adiponectin  plasma  concentrations  were  not 
affected by hyperinsulinaemia, whereas  its expression was stimulated by  insulin. These findings are 
in  agreement  with  the  evidence  that  circulating  adiponectin  per  se  is  not  a  subject  to  acute 
regulation,  but  its  expression  seems  to  be  regulated  acutely  [55],  preceding  thereby  systemic 
changes. Similar results in vivo were shown in some studies [236‐238], but other groups reported a 7‐







increase  in  adiponectin mRNA  in  isolated human  visceral  adipose  tissue  [243], but  a  reduction of 
adiponectin  expression  was  detected  in  3T3‐L1  adipocytes  [244].  Although  the  secretion  of 
adiponectin  from visceral and  subcutaneous depots appears comparable  [74],  the  regulations may 
exhibit some depot specificity [55].     
The comparison of D and C groups  in  the part B of  the  study yielded unexpected  results.   Plasma 
concentrations of both  total and HMW adiponectin were not different between patients with well 
controlled  type 2 diabetes  and healthy  control  subjects.  This  finding  is  in  strong  contrast with  all 
published data  [54, 56],  including Caucasian population  [43]  that report a consistent association of 
hypoadiponectinaemia with metabolic syndrome, IR, obesity and type 2 diabetes. In our study group, 
adiponectin concentrations in healthy subjects were lower than reported in literature and moreover, 
the absolute values are similarly  low also  in young healthy subjects  in part A. Even  if small sample 
size  has  to  be  considered,  one  might  speculate  on  potential  regional  differences  in  circulating 
adiponectin.  Unfortunately,  the  total  adiponectin  concentrations  during  SAL  are  not  in  line with 
previously described results and remain unclear.  
Additionally,  adiponectin  expression  in  SAT  appears  even  increased  in  diabetic  patients,  which 





in  well‐controlled  diabetes  may  be  partly  explained  as  a  compensatory  mechanism  for  the 
diminished cellular response to adiponectin demonstrated by down‐regulation of receptors. 
In accordance with  Study  I  ‐ part A and  the  literature discussed above, hyperinsulinaemia had no 
effect  on  adiponectin  concentrations  in  both  D  and  C  group.  On  the  other  hand,  adiponectin 
expressions  were  stimulated  by  insulin  in  diabetes  but  surprisingly  not  in  healthy  controls.  This 
finding  is opposite to the previously discussed study [236], however other authors did not find any 
changes  in  adiponectin  expression  during  hyperinsulinaemia  in  healthy  subjects  [245,  246].  The 
insulin‐induced  increase  in  adiponectin  expression  may  represent  a  protective  mechanism  to 
hyperinsulinaemia  in  early  phase  of  type  2  diabetes,  similarly  to  the  report  that  higher  insulin‐
induced  up‐regulation  of  adiponectin  expression  in  adipose  tissue  explants  is  associated  with  IR 
[247].  Expression of adiponectin receptors in SAT was not affected by acute hyperinsulinaemia. 
Leptin.  In  accordance with  general  agreement  [44,  52],  baseline  plasma  concentrations  and  SAT 
expressions  of  leptin were  higher  in  diabetes,  suggesting  the  presence  of  leptin  resistance  in  the 
group of overweight/obese  type 2 diabetic patients.  Insulin  increases circulating  concentrations of 
leptin in healthy subjects, while in diabetes plasma leptin declines during hyperinsulinaemia.  Even if 
most  reports document an  insulin‐stimulated  increase  in plasma  leptin  in  lean, obese and diabetic 
subjects [228, 229], other authors did not detect any changes in circulating leptin during clamp [248‐





hyperinsulinaemia  in  vivo  are  reported  [252].    In  line  with  published  data  [251],  differential 
regulation of circulating leptin cannot be explained by its mRNA expression in SAT, which implicates 
the  involvement  of  other  fat  depots  as  a  leptin  source  or  specific  regulation  at  the  level  of 
posttranslational modification or secretion.  
TNFα.    In  line with  the  literature  evidence  [57],  TNFα  circulating  concentrations  and  expressions 
were  increased  in diabetes. However,  the  low TNFα concentrations  in SAL  in diabetic  subjects are 
controversial  and  remain  unclear.  Plasma  TNFα  were  not  affected  by  insulin,  whereas  TNFα 
expression was stimulated by hyperinsulinaemia to a greater extent  in diabetic patients. Analogous 
regulations were reported in healthy subjects [253]. However, other groups using hyperinsulinaemic 
clamp  technique  did  not  demonstrate  any  insulin‐dependent  changes  in  TNFα mRNA  expressions 
[242] or interstitial concentrations [230]. Circulating TNFα does not seem to be acutely regulated by 






[256]  or  diabetes  [257].  Visfatin  appears  not  to  be  regulated  by  acute  hyperinsulinaemia  in  any 
group, which  is a novel observation  in vivo. However,  the  increased visfatin concentrations  in SAL 
both  at  baseline  and  240  min  in  both  groups  remain  unclear.  Since  the  difference  cannot  be 





RBP 4. Among  the equivocal data on RBP4 association with obesity and  type 2 diabetes  [43], our 
results  correspond  to  those who did not prove any difference  in  circulating RBP4 between obese, 
non‐obese and diabetic patients  [94, 95, 97, 258]. Although RBP4 concentrations were comparable 





SAT  expressions were  increased  in  overweight/obese  diabetic  patients. On  the  other  hand,  other 
groups were not able to reproduce  this difference  in circulating MCP‐1  [100‐102] or adipose tissue 
expressions [101]. This controversy may be at least in part explained by the differences in the groups 
examined,  since  some  studies  included  obese  non‐diabetic  patients  [101]  and  increased MCP‐1 
concentrations were found specifically in patients with diabetes [260]. 
In both groups, stable and lower MCP‐1 concentrations were demonstrated during SAL compared to 
HEC.  This  observation  remains  unclear.  However,  the  finding  is  consistent  in  both  groups  and 
throughout  the  interventions.  Hyperinsulinaemia  did  not  affect MCP‐1  levels  in  healthy  subjects, 
whereas it stimulated MCP‐1 in diabetes.  MCP‐1 expression was not changed by hyperinsulinaemia 
in any group.  It was already shown that  insulin regulation of MCP‐1  in vivo differs between  insulin‐





diabetic obese women were not age‐matched  to  the  insulin‐sensitive group) may account  for  the 
discrepant results. Since the changes in plasma MCP‐1 are not accompanied with changes in MCP‐1 
expression, we suggest that SAT is not the major determinant of circulating MCP‐1 in humans. 
IL­1ra.  In  agreement  with  recent  literature  [115‐117],  plasma  concentrations  of  IL‐1ra  were 
increased  in  overweight/obese  diabetic  patients.  Circulating  IL‐1ra  does  not  appear  to  be  acutely 




compared  to controls. This observation  is  in contrast with data  in both obese and diabetic cohorts 
[102, 122, 262, 263] and thus needs further clarification.  Insulin suppressed RANTES in controls but 
not in diabetic patients. Recently, low‐dose insulin infusion (2 IU/h) with final insulin concentrations 
approximately 50 µU/ml has been  shown  to decrease RANTES  concentrations  in diabetic patients 
[231]. Using standardized hyperinsulinaemic clamp technique, we confirmed this suppressive effect 
of insulin only in healthy subjects, suggesting differential regulations of RANTES between groups. 






Acute ARB did not  influence the parameters on  insulin sensitivity  in any of the three groups. Based 
on the pharmacokinetics of  losartan and  its active metabolite  (biological period of 2 and 6‐9 hours 
respectively),  effective  circulating  concentrations  during  the  clamp  period  should  have  been 
achieved.  However  the  plasma  levels may  not mirror  effective  tissue  concentrations,  which  are 
crucial for potential metabolic effects. Since the active losartan metabolite EXP3179 shows a partial 
PPARγ  agonism  [182],  the  absence  of  acute  changes  in  insulin  sensitivity  do  not  exclude  positive 
metabolic effects of  losartan  in  long‐term administration. Supportive for this hypothesis  is a recent 
finding that chronic  losartan treatment results  in serum  levels of metabolite EXP3179 sufficient  for 
PPARγ activation that was demonstrated by up‐regulation of PPARγ genes in monocytes [206].  
The effect of acute ARB on insulin sensitivity has not been studied in humans so far. Clinical studies 
using  long‐term  administration  of  ARBs  with  hyperinsulinaemic‐euglycaemic  clamp  technique 
reported  both  increase  [135,  194,  195]  and  no  changes  [199,  264]  in  glucose  disposal  in  insulin 
resistant subjects.  
Changes  in  endocrine  activity  of  adipose  tissue  ­  Effect  of  acute  losartan 
administration 
Resistin.  In  young healthy  subjects  (Study  I  ‐ part A), plasma  concentrations of  resistin  increased 
during hyperinsulinaemia independently on ARB. On the contrary, the insulin‐stimulated expressions 
of  resistin  in SAT were attenuated by  losartan. The  finding of  increased plasma  resistin  in  spite of 
decreased expression in subcutaneous fat implicates a role of another source of circulating resistin – 
a  different  fat  depot  or  potential  non‐adipose  sources  (e.g.  stromal  vascular  fraction  of  adipose 
tissue, macrophages or endothelium). Other studies in rodents and humans [21, 64] found increased 
expression of resistin in visceral fat depots compared to subcutaneous at basal conditions, although 
the  source  of  resistin  was  thought  to  be  non‐adipocytes.  In  part  B  of  the  study,  the  promising 
losartan  effect  on  resistin  expression  has  not  been  reproduced.  Losartan  reduced  basal  resistin 
concentrations  only  in  D  but  not  in  C  group.  Resistin  expression  in  SAT was  neither  affected  by 
hyperinsulinaemia nor by losartan. Nevertheless the suggested changes in resistin concentrations or 
expressions following acute ARB may intensify with long‐term losartan treatment. 
Adiponectin.  An  increase  in  circulating  adiponectin  after  2‐month  treatment  with  losartan  in 
hypertensive  patients  has  been  reported  [204]  and  there  are  other  experimental  data  showing 
enhanced  adiponectin  expression  in  response  to  long‐term  ARB  [174,  181],  possibly  via  PPARγ 
activation.  All  the  experiments  and  clinical  studies  tested  different  ARB  substances  in  different 
models of  insulin  resistance and  there  is no evidence about  the  regulations  in healthy  subjects.  In 
part  A  of  the  study,  we  have  observed  that  acute  losartan  administration  does  not  influence 
circulating adiponectin but  it attenuates  the  insulin‐induced expression of adiponectin  in SAT. This 
unexpected trend in young healthy subjects was not confirmed in part B in middle‐aged man. In both 
diabetic patients and healthy controls, acute losartan administration led to increase in both total and 
HMW  adiponectin  in  plasma,  as  well  as  in  its  expression  in  SAT,  whereas  it  did  not  influence 
expression  of  adiponectin  receptors.  Thus  stimulation  of  adiponectin might  represent  one  of  the 
underlying mechanisms of positive metabolic effects of sartans. 
Leptin. Acute losartan administration suppressed plasma leptin levels in diabetes but not in healthy 





the present  leptin resistance. To our knowledge,  the effect of  losartan  treatment on plasma  leptin 
was tested only in hypertensive subjects so far [205, 265] in whom no changes in leptin were found. 
Therefore, further studies with chronic  losartan administration  in different populations are needed, 
ideally  also  in diabetic  patients with  different  levels of blood  glucose  control  and broad  range of 
adiposity. 
TNFα.  In agreement with studies  in hypertensive subjects with  long‐term  losartan  treatment  [205, 
266], plasma TNFα was not acutely regulated by losartan in any group. There are virtually no data on 
effect of losartan on TNFα expression in SAT. In diabetes, TNFα expression was stimulated by insulin 





clamp  in controls. On  the other hand  in diabetes,  losartan  reduced baseline RBP4  levels  that were 
reversed by insulin to the concentrations observed during HEC. Since there is no literature available 
regarding losartan effect on RBP4, our finding is novel. 
MCP­1.  In animal models  [267] and cell cultures  [268, 269]  losartan has been shown  to effectively 
reduce MCP‐1 production. Accordingly, 6‐8 weeks of losartan treatment reduced circulating MCP‐1 in 
hypertensive patients [204, 270].  In our study, acute  losartan administration did not affect the  low 
plasma MCP‐1  in healthy  subjects, but  in diabetes  it attenuated  the  insulin‐stimulated  increase  in 









the  losartan effect only  in diabetic group might be related to the degree of RAS activation, which  is 
assumed  to be higher  in patients with diabetes  and  treated hypertension.    Importantly,  losartan‐
induced increase in both total and HMW adiponectin as well as in adiponectin expressions suggests 
another  potential  mechanism  for  metabolic  effects  of  losartan.  This  hypothesis  needs  to  be 
confirmed in further studies with chronic losartan administration in different populations.  
A­FABP and related gene expression 
To our knowledge, this  is  the  first clinical study analyzing A‐FABP plasma concentrations  in parallel 
with  its  expressions  in  SAT.  Showing  higher  plasma  concentrations  and  expression  of  A‐FABP  in 
overweight/obese patients with  type 2 diabetes  compared  to healthy  subjects, our  findings are  in 
accordance  with  current  evidence  on  circulating  A‐FABP  [140‐143,  274].  In  addition  to  plasma 
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concentrations,  our  results  confirm  an  equivalent  difference  in  A‐FABP  expressions  between  the 
groups  studied. This  fact has not been  sufficiently clarified  in previous  studies  [144, 146‐148]. The 












Additionally, we measured relative expressions of PPARγ, which  is  involved  in regulation of A‐FABP 
gene expression. Conversely A‐FABP enhances PPARγ  activity  [144]. The  studies  comparing PPARγ 
expression between lean and obese/type 2 diabetic patients reveal inconsistent data with reports of 
decreased, unchanged or increased PPARγ expression in obese subjects [236, 278‐280]. We report a 
down‐regulation  of  PPARγ  expression  in  diabetes. We were  not  able  to  show  any  relationship  of 
PPARγ  expression  to  A‐FABP  plasma  concentrations  or  expressions,  while  a  positive  correlation 






insulin  resistance  defined  by means  of  hyperinsulinaemic‐euglycaemic  clamp.  Additionally,  the  A‐
FABP mRNA and A‐FABP/E‐FABP mRNA ratio was positively correlated with HbA1c. The association 












demonstrated  in the control group where no changes during hyperinsulinaemia, but an  increase  in 







circulating  A‐FABP  by  insulin was  described  [281],  showing  a  decrease  in  A‐FABP  also  in  healthy 
controls. The difference to our study may be explained by the well‐described gender differences in A‐
FABP  plasma  concentrations  [140‐143,  274].  The  higher  A‐FABP  levels  in  women  may  be  also 
differentially regulated compared to men, which has been already demonstrated by an independent 
association  of  A‐FABP  with  carotid  intima‐media  thickness  in  women  but  not  in  men  [282]. 
Expressions of both E‐FABP and PPARγ  in SAT were not affected by hyperinsulinaemia  in our study 
population. 
We could demonstrate distinct effects of ARB on FABPs:  in healthy  subjects acute ARB  stimulated 








on A‐FABP.  Plausibility  of  such  a  hypothesis  has  been  recently  supported  by  an  observation  of  a 
cross‐sectional study with patients submitted for coronary angiograms [283]. Those patients treated 
with ACEIs or angiotensin II type 1 receptor blockers revealed significantly higher A‐FABP levels.   
In  conclusion  in young healthy  subjects, acute hyperinsulinaemia  stimulates an  increase  in plasma 
concentration  and  expression of  resistin  in  subcutaneous  adipose  tissue. While  the ARB does not 
modify  the  insulin‐induced  changes  in  plasma  resistin,  it  attenuates  the  response  of  resistin 
expression  in adipose tissue. Acute hyperinsulinaemia  is associated with an  increase  in adiponectin 
expression,  but  not  in  its  plasma  levels.  Losartan  reduces  the  insulin‐stimulated  expression  of 
adiponectin. 
To  conclude  the  findings  in  overweight/obese  patients  with  well‐controlled  diabetes,  plasma 
concentrations  and/or  SAT  expressions  of  resistin,  leptin,  TNFα, MCP‐1  and  IL‐1ra  are  increased, 
whereas  plasma  levels  of  adiponectin,  RBP4  and  VEGF  are  comparable  with  healthy  subjects. 
Unexpectedly,  increased  adiponectin  SAT  expressions  in  diabetic  subjects  are  accompanied  with 
lower expression of adiponectin receptors. 
Insulin differentially  regulates circulating  resistin,  leptin, RBP4, MCP‐1 and RANTES  in diabetes and 
healthy  subjects, while  plasma  adiponectin,  TNFα,  visfatin,  IL‐1ra  and  VEGF  do  not  appear  to  be 
acutely regulated by insulin. Stimulatory effect of insulin on SAT expressions was demonstrated only 
for TNFα and adiponectin, expressions other adipokines were not influenced by hyperinsulinaemia. 
Suppressive  effect  of  losartan  on  plasma  concentrations  of  resistin,  leptin,  RBP4  and MCP‐1 was 
demonstrated  in diabetic patients already  following acute  treatment, while no acute  regulation of 
the adipokines’ expression was detected.  Importantly,  losartan‐induced  increase  in both  total and 
HMW  adiponectin  as  well  as  in  adiponectin  expressions  suggests  a  potential  mechanism  for 
metabolic effects of losartan. 
Changes  in  plasma  adipokines  and  cytokines  cannot  be  explained  by  changes  in  their  SAT 




Circulating  A‐FABP  as  well  as  its  expressions  in  subcutaneous  adipose  tissue  are  closely  and 











[284]  that  telmisartan decreases  the  fasting plasma  glucose  and blood pressure, while  the  insulin 





There  are  still  controversial  results  regarding  the  effect  of  telmisartan  or  other  ARBs  on  insulin 
sensitivity  in vivo  in humans  [212, 219, 284, 285]. Telmisartan  is considered  to be a partial PPARγ 
agonist and there  is experimental evidence  that  it has superior metabolic advantages compared to 
other sartans [179]. However, a recent study evaluating the long‐term effect of telmisartan on insulin 
sensitivity  suggests  that  the  magnitude  of  PPARγ  stimulation  by  telmisartan  may  be  modest 
compared with  TZDs  [219].  On  the  other  hand,  some metabolic  effects  of  telmisartan  could  be 
mediated  independently  of  PPARγ  [286].  In  addition  in  a  rat  model  of  metabolic  syndrome,  it 
increases  energy  expenditure  and  protects  against  dietary  induced  obesity  [287].  Although 
telmisartan has gained much attention as one of most metabolically potent ARB compounds, there 
are virtually no clinical studies evaluating the effect of telmisartan on insulin sensitivity and substrate 
utilization using  the  clamp  technique  combined with  indirect  calorimetry. The homeostasis model 
assessment–index (HOMA) has been used in most of them [209, 284] and thus, our study may be the 
first of its kind. 
In  our  study  we  have  failed  to  show  a  statistically  significant  effect  of  telmisartan  on  insulin 
sensitivity and  substrate utilization but our  results might be  influenced by  the  short period of  the 
study and the small number of patients included.  Insulin secretion has not been carefully evaluated 
in our study, but  the  improvement  in blood glucose  level after  telmisartan could be related  to  the 
improvement  in  β‐cell  function.  It  has  been  shown  in  experimental  animals  that  treatment with 
telmisartan reduces oxidative stress and protects against islet β‐cell damage and dysfunction [203]. 
The main finding of the present study is the significant short‐term effect of telmisartan on adipokine 
production  during  insulin‐stimulated  conditions.  Adiponectin,  leptin  and  resistin  plasma 
concentrations increased while a decrease in TNFα had been found after telmisartan treatment. We 
also found an increase in basal leptin concentrations. The changes in plasma adipokines could not be 





concentrations  during  insulin‐stimulated  conditions.  The  expressions  of  TNFα  in  subcutaneous  fat 
declined during hyperinsulinaemia but were not affected by telmisartan treatment. The results are in 
agreement  with  the  decrease  in  fasting  TNFα  in  plasma  reported  after  8  month  telmisartan 
treatment  in  hypertensive  patients  after  stent  implantation  [288]  and  after  6  and  12  month 
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administration  of  telmisartan  in  patients  with  metabolic  syndrome  [209].  In  addition, 
proinflammatory properties of TNFα could be attenuated by telmisartan.  Inhibition of TNFα‐induced 
interleukin‐6  expression  in  vascular  smooth  muscle  cells  has  been  reported  after  telmisartan 
treatment [289].   
Adiponectin.  In  our  study  telmisartan  increased  the  plasma  adiponectin  concentrations  during 





conditions. ARBs  induced activation of PPARγ  is advocated  [181].  In addition,  it has been shown  in 
3T3‐L1  adipocytes  that  telmisartan may  stimulate  adiponectin  gene  transcription  independent  on 
PPARγ [286].  
Leptin. An overall increase in circulating leptin following the telmisartan treatment was documented 
in  the  present  study.  Telmisartan  had  no  significant  effect  on  leptin  expressions  in  SAT,  but  the 
expression  declined  during  hyperinsulinaemia.  The  decline  was  independent  on  telmisartan 
treatment.  In  the  literature, both  increase  [284] and decrease  [209] or no changes  [219]  in  fasting 
leptin  concentrations  have  been  reported  after  long‐term  administration  of  telmisartan  in 
hypertensive and type 2 diabetic patients. Telmisartan‐induced increase in plasma concentrations of 
leptin might attenuate body weight gain by reduced food intake with HOMA‐IR improvement [284]. 






treatment  in  type  2  diabetic  patients.  However,  only  fasting  concentrations  were  assessed,  the 
treatment  period  was  much  longer  (6  and  12  months)  and  the  subjects  were  treated  also  by 
rosiglitazone  [290].  In  our  study,  resistin  expression  decreased  during  the  hyperinsulinaemia 
independently on telmisartan treatment.  
The changes  in  the plasma concentrations and  tissue expressions of adiponectin, TNFα,  leptin and 
resistin  during  hyperinsulinaemia  are  discordant  and  the  expressions  in  SAT  cannot  explain  the 









a  few  studies  have  investigated  the  effect  of  insulin  in  vivo  in  humans.    It  has  been  shown  by 





other  hand,  the  increase  in  plasma  resistin  concentrations  has  been  confirmed.    An  increase  in 
plasma  resistin  during  clamp‐induced  hyperinsulinaemia  was  reported  in  our  previous  study  in 
healthy  subjects  [183].  Similarly,  Heilbronn  et  al.  [233]  found  an  increase  in  serum  resistin 
concentrations  in  response  to  supraphysiological doses of  insulin  (164±5 mIU.l‐1)  in obese  subjects 
with  and  without  diabetes.  Contrary  to  the  result  of  Westerbacka  [236],  the  expressions  of  
adiponectin did not change and expressions of TNFα,  leptin and  resistin were even  suppressed by 
acute  hyperinsulinaemia.  However,  the  present  cross‐over  study was  not  designed  to  assess  the 









of  the  short  treatment period. The  timing of biopsy at 30 min before equilibrium  status had been 
achieved, might have an impact on the results.  
In  conclusion,  we  firstly  describe  that  in  patients  with  impaired  fasting  glucose  a  short‐term 
telmisartan  treatment  increases  plasma  adiponectin,  leptin  and  resistin  concentrations  and 
decreases plasma TNFα  levels. These effects appear to be  important during hyperinsulinaemia. The 
changes  in  plasma  concentrations  of  adipokines  cannot  be  explained  by  their  expressions  in 
subcutaneous adipose tissue. The results support the hypothesis that the changes in selected plasma 






In  this  study  the  plasma  levels  of  adipose  tissue  cytokines  and  their  expression  in  adipose  tissue 








natural  difference  between  groups  (IR,  lower  clearance  of  TG  and  accelerated  hepatic 
gluconeogenesis  in  diabetic  subjects).  The  between‐group  comparison  of  baseline  plasma 
concentrations and expressions of the adipokines is discussed in the Study I. 
TNFα. Consistently  in both parts A and B of the study, an  increase  in TNFα plasma concentrations 




or circulating monocytes. Previously, Nisoli  [291]  reported an  increase  in TNFα gene expression  in 
subcutaneous  gluteal  fat  tissue  after  a  5‐hour  Intralipid/heparin  infusion  in  healthy  subjects.  The 
discrepancy to our results may lie in fat depot‐specific expressions and their regulation, since higher 
TNFα expression in visceral fat has been shown [74, 141].  
Resistin.  In  both  parts  A  and  B  (in  all  groups),  lipid  infusion  stimulated  an  increase  in  plasma 
concentrations of resistin, which did not differ between C and D. This  is  in accordance with reports 
from animal models [294, 295] where  Intralipid/heparin  infusion  induced hepatic and peripheral  IR 
and was associated with elevated plasma resistin levels. In humans, only one available shorter study 
did not show any changes  in resistin following 5‐hour  lipid/heparin  infusion [293]. Since changes  in 
resistin mRNA  in  subcutaneous adipose  tissue were not  significant  in any group, we  can  conclude 
that this fat depot  is not responsible for the regulation of plasma resistin  in response to  lipid  load. 
Similarly to TNFα, circulating monocytes appear to be an important source of resistin [70]. 
Leptin.  In young healthy subjects  (part A), plasma concentration and expressions of  leptin did not 
show any changes during hypertriglyceridaemia. On the other hand  in part B, lipid  infusion resulted 
in  group‐specific  time  profiles  of  circulating  leptin:  the  initial  decrease  in  leptin was  followed  by 
reversal to initial levels at 24 hours in diabetic patients, whereas in healthy controls a late decline at 
24  hours  was  detected.  Leptin  expressions  were  not  affected  by  lipid  infusion.  Both  plasma 
concentrations and expressions of leptin were increased in diabetes. The different response between 
the groups of healthy  subjects might be  related  to age. Most previous  studies  in healthy  subjects 
have not  shown any changes  in  leptin  in  response  to  lipid  infusion  [296‐299], even  if one have  to 
note  that  the  interventions  were  shorter  (3‐5  hours).  Other  studies  reported  increased  leptin 
concentrations [293] or stable plasma  levels with  increase  in  leptin RNA expression  in adipocytes  in 
gluteal region during 5‐hour lipid/heparin infusion [291], while 7‐hour lipid/heparin infusion  already 
induced a decline plasma  leptin  [292]. Here we  first demonstrate a direct  comparison of patients 
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unchanged  plasma  concentrations  was  observed  during  7‐hour  Intralipid/heparin  infusion  [300] 
[293]. Paradoxically higher plasma levels of total adiponectin and higher adiponectin expression rates 
and  comparable HMW  adiponectin  concentrations were  found  in  diabetes.  For  discussion  of  this 
unclear finding please refer to Study I. 
Visfatin and RBP4. In agreement with a previous study in healthy subjects [256], circulating visfatin 
is  not  affected  by  lipid  load  in  any  group. Due  to  interindividual  variability  plasma  visfatin  levels 
tended to be  lower  in diabetes (similarly to previous results [256]) but the difference did not reach 
statistical  significance.  Plasma  RBP4 was  not  influenced  by  lipid  infusion  either, which  is  a  novel 
finding in vivo. 
A­FABP.  In  line with  study  I, plasma  concentrations and expressions of A‐FABP were  increased  in 
diabetes. Since there are no data available on A‐FABP regulation by hyperlipidaemia, we first report a 
suppressive effect of  lipid  load on circulating A‐FABP  in both diabetic and healthy subjects that was 
not accompanied by adequate changes in A‐FABP expression in SAT.       
Lipid  infusion  resulting  in  a  subsequent  increase  in NEFA  plasma  concentrations  is  a well  known 
method used for inducing IR [301‐303]. Therefore, although we have not measured insulin sensitivity, 
we assume that changes we have observed might be implicated in the pathogenesis of lipid‐induced 
IR. For TNFα, our results are  in agreement with a theory that  it  is  implicated  in NEFA  induced  IR as 
shown in vitro [304]. For resistin it is an unclear result as it is often found not to be associated with IR 
[305],  although  clinical  studies  are  often  limited  to  correlations  between  resistin  and  various 
measures  of metabolic  syndrome.  The  decrease  in  leptin  in  healthy  subjects may  represent  an 
adaptive reaction to prolonged hypertriglyceridaemia that was initiated but reversed in diabetes. The 
impact of decline in A‐FABP concentrations on IR in response to lipid load remains to be clarified. 
There  are  several  limitations of  this  study.  Increase  in plasma  lipid  concentrations by  intravenous 
infusion  certainly  differs  from  dietary  and  lifestyle  induced  hyperlipidaemia  observed  in  real  life. 
Small number of subjects examined and the lack of placebo control are other factors that should be 
considered. Placebo control was not  included because of  the confounding effect of a 24‐hour  long 
fasting that induces IR per se. Circadian variations were partly assessed by 24‐hour duration. Glycerol 






are not affected by hyperlipidaemia and  thus, other  sources  such as other  fat depot or circulating 








Leptin.  In  line with  recent agreement  [44],  leptin  concentrations as well as SAT expressions were 
lowest  in  healthy  subjects  compared  to both other  groups. Both plasma  levels  and  expression of 
leptin were also positively related to adiposity and negatively to glucose disposal, which suggest the 
presence  of  leptin  resistance  connected  with  obesity  and  IR.  Supportive  to  this  hypothesis,  an 
additional  association  of  plasma  leptin  with  HDL‐cholesterol  and  leptin  expressions  with  fasting 
glucose and  insulin were demonstrated. However, an unexpected elevation of plasma  leptin  in  IFG 
compared to both other groups cannot be explained by leptin expression in SAT that was comparable 
between  IFG  and D.  Thus,  other  fat  depots  have  to  be  involved  as  a  source  of  circulating  leptin. 
Moreover,  other  factors  may  contribute  to  the  observed  difference  in  plasma  leptin,  such  as 











groups,  as  total  adiponectin  showed more  associations within  adiponectin  system,  but  total  and 
HMW  adiponectin  levels  were  related.  Expression  of  both  AdipoR1  and  AdipoR2  was  highly 
interrelated  and  seems  to  depend  on  circulating  adiponectin  (inverse  relation)  but  not  on  its 
expression.  Similar  association  has  been  recently  found  demonstrated  for  hepatic  adiponectin 
receptors [311]. Further regulations of AdipoRs expression are suggested by association with PPARγ 
expression and  inverse  relation  to  circulating TNFα. We  speculate  that  the  comparable  circulating 
adiponectin  in  IFG  and diabetes  and  increased  SAT expression  in well‐controlled diabetes may be 
partly explained as a compensatory mechanism for the diminished cellular response to adiponectin 
demonstrated by down‐regulation of the dominant AdipoR2 receptor. The group‐specific adiponectin 
mRNA  levels  in  SAT  implicate  different  contribution  of  particular  fat  depots  to  the  comparable 
circulating adiponectin concentrations in IFG and diabetes. 
Resistin.  IFG  group  displayed  surprisingly  decreased  resistin  plasma  concentrations  compared  to 
both  C  and  D  groups where  plasma  resistin was  equal.  This  IFG‐specific  difference  in  circulating 
protein  is not mirrored  in  resistin expressions  in SAT  that showed an  increase  in diabetes but was 
comparable between IFG and C. Resistin expression was associated with adiposity and triglycerides. 
The  human  data  regarding  relation  of  resistin  to  IR,  obesity  and  diabetes  are  controversial  [66] 
showing either comparable [232, 233] or increased [66] plasma resistin in obesity, IFG and/or type 2 
diabetes.  Since mononuclear  cells  and macrophages  are  found  to  be more  important  source  of 
circulating resistin in humans [66], resistin secretion from monocytes reflecting inflammatory status 
may be  responsible  for  the observed difference  in plasma  resistin among groups. Accordingly,  the 
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enhanced  expression  of  resistin  in  SAT  of  diabetic  patients might  be  a  consequence  of  increased 
macrophage  infiltration  and  adipose  tissue  inflammation  connected  to  overt  diabetes  which  is 
supported by association between resistin and TNFα expressions. 
TNFα.  In  accordance with  literature  [57], TNFα plasma  concentrations  as well  as  SAT expressions 
were  lowest  in healthy subjects.  Interestingly, diabetic subjects were characterized by higher TNFα 
expression  in  SAT  compared  to  IFG  despite  of  comparable  TNFα  plasma  levels.    In  the  literature, 
comparison  of  subjects  with  different  stages  of  glucose  intolerance  reveals  equivocal  results, 
showing  comparable  plasma  levels  and  expressions  [312],  increased  plasma  TNFα  just  in  diabetic 
subjects  [313] or  subsequent  increase  in plasma TNFα during progression  to overt diabetes  [314]. 




TNFα  expression  and  secretion  is  altered  during  the  progression  of  glucose  intolerance.  The 
importance of  TNFα on  the  local/paracrine  level  is  supported by  substantial  associations of  TNFα 
mRNA  expressions with measures  of  obesity,  insulin  resistance,  hyperglycaemia  and  triglycerides, 
whereas plasma  TNFα was only  related  to  insulin  resistance.  In  addition,  the  association of  TNFα 
expressions  with  plasma  IL‐1ra  and  expressions  of  leptin  and  resistin  suggests  the  potential 
involvement of TNFα in endocrine and inflammatory activity of SAT.  
Visfatin  and  RBP4.  Plasma  concentrations  of  visfatin  were  unexpectedly  found  to  be  lower  in 
diabetes compared to both other groups and were inversely associated with IR and hyperglycaemia. 
Even if visfatin was initially declared as an IR factor with increased concentrations and expression in 
obesity  and/or  diabetes  [226,  255,  315],  there  are  several  reports  showing  opposite  results 




metabolic  parameters  or  other  cytokines,  similarly  to  other  groups  who  did  not  confirm  the 
postulated  association  of  RBP4 with  IR  and  diabetes  [94,  95,  97,  258]. On  the  other  hand,  other 




We  first demonstrate A‐FABP plasma  concentrations and mRNA expressions  in parallel  in  subjects 
with  different  categories  of  glucose  intolerance.  A‐FABP  expression  and  secretion  appear  to  be 
differentially  regulated  in  different  source  tissues  and  depots  during  the  progression  of  glucose 
intolerance:  while  A‐FABP  plasma  concentrations  were  comparable  in  IFG  and  D,  the  A‐FABP 
expressions  in SAT were higher  in D, which suggests  the  involvement of other  important source of 
circulating A‐FABP in IFG than SAT. Here, other fat depots or circulating monocytes may substantially 
contribute  to  the  whole‐body  A‐FABP  balance.  E‐FABP,  the  minor  adipose  tissue  FABP  isoform 
displayed higher expression in healthy subjects compared to both other groups. This finding is in line 







parameters  of  obesity  [144].  Insulin  resistance  appears  to  be more  related  to  circulating A‐FABP, 
whereas hyperglycaemia is an important determinant of A‐FABP expressions in SAT. Additionally, A‐
FABP expressions were  found  to be associated with expressions of  leptin,  resistin, TNFα, but also 
adiponectin,  suggesting  an  involvement  of A‐FABP  pathways  in  endocrine  activity  of  SAT.  E‐FABP 
expressions do not seem to be associated with selected metabolic parameters in our cohorts, while 
PPARγ  expression was  found  to  be  associated  inversely with  plasma  concentrations  of  TNFα  and 





this  difference  [100‐102].  MCP‐1  levels  are  enhanced  already  in  IFG  and  overt  diabetes  is  not 
associated  with  further  increase  in  circulating  MCP‐1,  similarly  to  a  recent  report  [260].  The 
association of plasma MCP‐1 with waist circumference and MCR also supports  the hypothesis  that 
circulating MCP‐1  is  related  to  obesity  and  IR,  but  not  to  dysregulation  of  glucose metabolism. 
Moreover,  the  association  of MCP‐1  with  plasma  leptin  and  A‐FABP  suggests  that  inflammatory 
mediators may affect other adipose tissue pathways and endocrine activity. 
Although  IL‐1ra  concentrations  did  not  differ  between  groups  (possibly  due  to  small  number  of 
subjects),  its  circulating  levels  were  positively  related  to  parameters  of  obesity,  fasting  plasma 
glucose  and  insulinaemia,  suggesting  increased  activation  of  IL‐1  system  in  obesity  and  glucose 
intolerance. Additionally,  showing positive  association with  expressions of  TNFα  and  leptin,  IL‐1ra 
may also play a role in endocrine activity of adipose tissue.  








The  IFG  and D  groups  actually differed only  in parameters of  glucose metabolism  (fasting plasma 
glucose  and  HbA1c).  IFG  displayed  more  pronounced  fasting  hyperinsulinaemia  compared  to  D 
group, which may be related to differences in concomitant medications between the groups. Patients 











circulating  concentrations  and  SAT expressions during  the progression of  glucose  intolerance. The 
between‐group differences  in plasma concentrations are not mirrored  in SAT expressions and  they 








interventions  are  not  accompanied with  parallel  changes  in  SAT  expressions.  Thus,  other  sources 
such as other fat depots or circulating monocytes importantly contribute to the systemic balance of 
these adipokines and cytokines. Alternatively, regulatory mechanisms on other than transcriptional 
level may be  involved,  such as posttranscriptional, posttranslational modifications or  regulation of 
adipokine  secretion.  Since we  only  addressed  the  transcriptional  level,  the  interpretation  of  the 
changes  found  cannot  be  exhaustive.  A  parallel  analysis  of  tissue  proteins  or  concentrations  of 
proteins  in  interstitial  fluid may be useful  to get more complex  insight  into  the  in vivo regulations. 
Additionally,  characterising  the  SAT  infiltration with macrophages  (by means  of  analysis  of  CD68 
expression or SAT histology) or separate analysis of isolated adipocytes and stromal‐vascular fraction 













stress  prior  to  saline  infusion  where  no  SAT  biopsies  were  awaited).  As  a  potential  explanation 
intraindividual variability in cytokine concentrations should be also mentioned.   
Another unclear observation was  the comparable  levels of  total and HMW adiponectin  in patients 
with  well‐controlled  type  2  diabetes  and  healthy  subjects.  We  cannot  exclude  a  potential  bias 
induced by selection of healthy subjects who even if did not fulfil the criteria of metabolic syndrome, 
were partly overweight and had e.g. comparable  total and LDL‐cholesterol  levels with  the diabetic 
group, while the diabetic patients had very well‐controlled diabetes and were treated with protective 
concomitant medication. These  factors might have attenuated  the difference between  the groups. 





in  larger  populations  as well  as  experimental  studies with  cell  and  tissue  cultures  are  needed  to 







induced  changes  in  plasma  resistin,  it  attenuates  the  response  of  resistin  expression  in  adipose 
tissue. Acute hyperinsulinaemia  is associated with an  increase  in adiponectin expression, but not  in 
its plasma levels. Losartan reduces the insulin‐stimulated expression of adiponectin.  
Study I – part B 
In obese patients with well‐controlled diabetes, plasma  concentrations  and/or  SAT  expressions of 
resistin,  leptin, TNFα, MCP‐1 and  IL‐1ra are  increased, whereas plasma  levels of adiponectin, RBP4 
and  VEGF  are  comparable  with  healthy  subjects.  Unexpectedly,  increased  adiponectin  SAT 
expressions in diabetic subjects are accompanied with lower expression of adiponectin receptors. 
Insulin differentially  regulates circulating  resistin,  leptin, RBP4, MCP‐1 and RANTES  in diabetes and 
healthy  subjects, while  plasma  adiponectin,  TNFα,  visfatin,  IL‐1ra  and  VEGF  do  not  appear  to  be 
acutely regulated by insulin. Stimulatory effect of insulin on SAT expressions was demonstrated only 
for TNFα and adiponectin, expressions other adipokines were not influenced by hyperinsulinaemia. 
Suppressive  effect  of  losartan  on  plasma  concentrations  of  resistin,  leptin,  RBP4  and MCP‐1 was 
demonstrated  in diabetic patients already  following acute  treatment, while no acute  regulation of 
the adipokines’ expression was detected.  Importantly,  losartan‐induced  increase  in both  total and 
HMW  adiponectin  as  well  as  in  adiponectin  expressions  suggests  a  potential  mechanism  for 
metabolic effects of losartan. 
Changes  in  plasma  adipokines  and  cytokines  cannot  be  explained  by  changes  in  their  SAT 
expressions.  Therefore,  other  sources  such  as  other  fat  depots  and/or  circulating monocytes  are 
implicated in regulation of systemic adipokine balance. 
Circulating  A‐FABP  as  well  as  its  expressions  in  subcutaneous  adipose  tissue  are  closely  and 






These  effects  appear  to  be  important  during  hyperinsulinaemia.  The  changes  in  plasma 





decline  in  plasma  leptin  and  A‐FABP.  Expressions  of  adipokines  in  SAT  are  not  affected  by 
hyperlipidaemia  and  thus,  other  sources  such  as  other  fat  depot  or  circulating monocytes  are  of 





The selected adipokines  including A‐FABP display differential  regulations on  the  level of circulating 







Providing  a  comprehensive  evaluation  of  adipose  tissue  endocrine  activity  in  vivo under  different 
experimental conditions, the presented studies broaden the recent knowledge on the role of adipose 
tissue  in pathophysiology of  insulin resistance  in humans. Type 2 diabetic patients, healthy subjects 
and also patients with IFG differed in terms of baseline plasma concentrations and SAT expressions of 
selected adipokines and cytokines. We have also demonstrated differential group‐specific regulations 
of  adipokines’  concentrations  and  expressions  in  response  to  hyperinsulinaemia  and 
hypertriglyceridaemia  as  well  as  to  treatment  with  losartan  or  telmisartan.  The  changes  in 
adipokines’ plasma concentrations are not accompanied by parallel changes  in SAT expressions and 
thus other  sources of  circulating adipokines have  to be  involved  in  the  regulation of  the  systemic 
adipokine  balance.  Nevertheless,  the  presented  results  support  the  role  of  adipokines  in  the 
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Effect of acute hyperinsulinaemia with and without angiotensin
II type 1 receptor blockade on resistin and adiponectin
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Objective: The potential insulin-sensitizing function of angiotensin II type 1 receptor blockade (ARB)
with regard to selected adipokines is not fully explained so far. Our study aimed to explore the influence
of acute hyperinsulinaemia and acutely induced ARB on resistin and adiponectin concentrations and
expressions in healthy subjects.
Design and methods: Plasma adipokines were measured: 1) at 0, 30 and 240 min of hyperinsulinaemic
(1 mU/kg per min) euglycaemic (5 mmol/l) clamp (HEC), and 2) during HEC after acute ARB (losartan
200 mg; AT-HEC) using the same protocol, in eight healthy subjects. Needle biopsy of abdominal s.c.
fat was performed at 0, 30 and 240 min of both clamps to assess the adipokines’ expressions.
Results: Comparing the glucose disposals of HEC and AT-HEC, no difference in insulin sensitivity was
found. Plasma resistin increased equally during HEC and AT-HEC (P!0.05). The expression of resistin
in s.c. fat increased during HEC (P!0.05), while no significant changes in expression were observed
during AT-HEC. Plasma levels of adiponectin did not change during both clamps. Adiponectin
expression increased during HEC (P!0.05), while it did not change during AT-HEC.
Conclusions: In healthy subjects, acute hyperinsulinaemia is associated with an increase in plasma
resistin independently of ARB, while plasma adiponectin is not influenced by insulin or ARB. The
expressions of both resistin and adiponectin in s.c. adipose tissue are stimulated by acute
hyperinsulinaemia, whereas losartan attenuates their insulin-stimulated expressions. This suggests
a potential effect of losartanon adipokines’ expression.
European Journal of Endocrinology 157 443–449Introduction
Resistin is an adipocyte-secreted peptide hormone that
has been proposed to link obesity with insulin
resistance. It was identified as a factor impairing glucose
homeostasis and inducing hepatic insulin resistance in
mice (1). Recent studies in rodent models and humans
show contradictory results (2–6). Mouse resistin is
predominantly expressed in white adipose tissue,
whereas human resistin expression in adipocytes is
significantly lower and there are other important
sources of resistin, e.g. mononuclear cells, endothelial,
vascular smooth cells (2) or islets of Langerhans (7).
The receptor for resistin, its signalling pathway, target
tissues and its biological effect and regulation in human
physiology have not been clearly identified up to now.
Adiponectin is an insulin-sensitizing adipokine speci-
fically and abundantly expressed in adipose tissue (8, 9).
It is present in the circulation at high concentrations in
the form of different multimeric complexes, amongn Journal of Endocrinologywhich the high-molecular weight (HMW) multimers
exert the predominant action. Two adiponectin
receptors, AdipoR1 and AdipoR2, have been identified
that up-regulate AMP-activated protein kinase activity.
Adiponectin directly increases hepatic insulin sensi-
tivity, promotes fuel oxidation in skeletal muscle and
decreases vascular inflammation. Hypoadiponectin-
aemia is known to be consistently related to insulin
resistance, obesity, type 2 diabetes, coronary heart
disease, hypertension and atherosclerosis based on both
experimental and clinical studies (10, 11). Up-regula-
tion of adiponectin is a partial cause of the insulin-
sensitizing action of thiazolidinediones.
Evidence has accumulated that insulin resistance
may be improved by interrupting renin–angiotensin
system (RAS). Angiotensin-converting enzyme (ACE)
inhibitors and angiotensin II type 1 receptor antagon-
ists are able to interfere with the adverse metabolic
effects of angiotensin II on insulin signalling, tissue
blood flow, oxidative stress, sympathetic activity orDOI: 10.1530/EJE-07-0034
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Body mass index (kg/m2) 24.96G0.60
Waist circumference (cm) 88.50G1.78
Fasting blood glucose (mmol/l) 4.51G0.23
Blood glucose at 120 min of OGTT (mmol/l) 4.55G0.24
Fasting IRI (mIU/l) 4.15G0.91
HbA1c (%), according to IFCC 2.58G0.22
Albuminuria (mg/min) 2.52G0.91
Creatinine (mmol/l) 86.95G3.71
Total cholesterol (mmol/l) 4.24G0.26
Triglycerides (mmol/l) 0.87G0.11
HDL cholesterol (mmol/l) 1.45G0.12
LDL cholesterol (mmol/l) 2.48G0.20
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ACE inhibitors may be largely mediated through
increases in bradykinin levels, nitric oxide and the
GLUT4 glucose transporter (13).
The effect of angiotensin II type 1 receptor blockade
(ARB) on glucose metabolism and insulin resistance
remains controversial, and the mechanisms are not fully
understood. Experimental and in vitro studies showed
that ARB may improve insulin sensitivity via decreasing
adipocyte size (14), promotion of adipocyte differen-
tiation and preventing ectopic lipid deposition (15).
Several randomized, placebo-controlled studies using
the HEC technique have found little positive or no effect
of ARB on insulin action in rodents (16, 17) and humans
(18, 19). Clinical trials using ARB have provided indirect
support for the possibility that ARB per semight improve
insulin sensitivity and decrease incidence of type 2
diabetes (LIFE, CHARM and VALUE) (20).
It has been shown that treatment with losartan does
not influence plasma leptin levels (21) and that RAS
blockade (22) or losartan (23) increases adiponectin
levels, but the effect of losartan on expressions of
adipokines in human adipose tissue under conditions of
hyperinsulinaemia has not been studied yet.
The aims of our study were twofold: to determine
resistin and adiponectin plasma concentrations
together with their expressions in abdominal s.c.
adipose tissue and also to test their responses to acutely
induced hyperinsulinaemia with and without acute
ARB in healthy subjects.Subjects and methods
Subjects
We examined eight healthy men who had normal
glucose tolerance (confirmed by an oral glucose
tolerance test), blood pressure and serum lipids. Only
male subjects participated because of the variable
insulin sensitivity in women according to the menstrual
cycle and with respect to sexual dimorphism of plasma
adiponectin levels. Clinical and physiological charac-
teristics of the study group are summarized in Table 1.
The subjects were not taking any drugs and none had a
family history of diabetes. They were euthyroid and
none had a concomitant disease. Informed consent was
obtained from all the individuals after the purpose,
nature and potential risks of the study had been
explained. The study was approved by the local ethics
committee.Study protocol
The subjects were examined on an outpatient basis,
after overnight fasting with only tap water allowed ad
libitum. They were instructed to adhere to their ordinary
lifestyle, avoid any changes in food intake or alcoholwww.eje-online.orgconsumption and to refrain from strenuous physical
activity for a period of 24 h before the experiment. The
subjects underwent two HECs at least 4 weeks apart,
both taking 4 h to complete, in random order:
Study 1 The HEC was conducted as previously described
(24). Briefly, a Teflon cannula (Venflon; Viggo, Helsing-
borg, Sweden) was inserted into an antecubital vein for
the infusion of all test substances. A second cannula was
inserted retrogradely into a wrist vein for blood sampling
and the hand was placed in a heated (65 8C) box in order
to achieve venous blood arterialization. A primed
continuous insulin infusion (1 mU/kgpermin ofActrapid
HM (NovoNordisk, Copenhagen, Denmark) dissolved in
0.9% NaCl) was administered to acutely raise and
maintain the plasma concentrations of insulin. Plasma
glucose concentrations during the clamp were main-
tained at the 5 mmol/l level by continuous infusion of
15% glucose. To prevent hypokalaemia during insulin
infusion, potassium chloride was added to the 15%
glucose infusion (30 mmol/l KCl). To assess plasma levels
of selected adipokines, blood samples were taken at 0, 30
and 240 min of the clamp study.
Needle biopsy of abdominal s.c. adipose tissue was
performed at 0, 30 and 240 min of the clamp. Under
local anaesthesia (1% trimecain in a field block pattern),
an incision (3–4 mm) was made through the skin at the
lower abdomen and an s.c. fat specimen (300 mg) was
obtained by needle aspiration. The samples were
washed in 0.9% natrium chloride solution, immediately
frozen by liquid nitrogen and stored at K80 8C until
used for RNA extraction.
Study 2 An identical clamp study was performed after
acute ARB (AT-HEC). Losartan 2!100 mg was given
per os prior to the study (8 h and immediately prior to
the clamp) and a hyperinsulinaemic (1 mU/kg per min)
euglycaemic (5 mmol/l) clamp was conducted as
described previously. Blood samples and adipose tissue
biopsies were collected at 0, 30 and 240 min of the
Hyperinsulinaemia and AT-1 receptor blockade 445EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 157clamp to determine plasma concentrations and
expressions of selected adipokines.Analytical methods
Plasma concentrations of glucose were measured using
the Beckman analyzer (Beckman Instruments Inc.,
Fullerton, CA, USA) with the glucose oxidase method.
Immunoreactive insulin (IRI) was determined by the RIA
method using an IMMUNOTECH Insulin IRMA kit
(IMMUNOTECH AS, Prague, Czech Republic) with an
analytical sensitivity 0.5 mIU/ml, and intra-assay and
inter-assay coefficients of variation below or equal to 4.3
and 3.4% respectively. Glycosylated haemoglobin was
measured by HPLC method using the Variant II HbA1c
Program (Bio-Rad Laboratories GmbH), and for
calibration, a method approved by International Federa-
tion of Clinical Chemistry and Laboratory Medicine was
used (25). Plasma concentrations of resistin were
measured according to manufacturer’s instructions by
Human Resistin ELISA kit (BioVendor Lab. Med. Inc.,
Brno, Czech Republic; the detection limit was 0.033 ng/
ml and intra-assayand inter-assaycoefficients of variation
are 2.8–3.4 and 5.1–6.9% respectively). For analysis of
total adiponectin plasma levels, Human Adiponectin
ELISA kit was used (BioVendor Lab. Med. Inc.; the
detection limit was 210 ng/ml and intra-assay and
inter-assay coefficients of variation are 6.4–7.0 and
7.3–8.2% respectively).
Expression of adipokines was analysed by the real-
time PCR (RT-PCR) using the following protocol:
(1) The RNA was isolated from the liquid nitrogen
frozen biopsy of the human fat tissue using the
RNeasy Lipid Tissue Mini Kit and QIAzol Lysis
Reagent (Qiagen). The starting amount of
100 mg tissue was excised from the biopsy, and
homogenized in 1 ml QIAzol Lysis Reagent
(guanidine thiocyanate–phenol solution) for
2 min. From the homogenate, the RNA was
isolated by extraction on silica gel-based column,
according to the kit handbook. Possible contami-
nation of RNA with genomic DNA remains was
taken off by DNase digestion (RNase-free DNase
Set; Qiagen). This step is supposed to prevent any
later DNA amplification. Beyond this, the




Resistin AY207314 HRETN-F: 5 0-ATA AGC AGC AT
CTG G-3 0
Adiponectin XM_290602 HACRP30-F: 5 0-GGT TCA ATG G
TTG C-30
Cyclophilin XM_090070 HCLPNa-F: 5 0-CAA ATG CTG G
ACA CA-30reaction and there was just one product present
in all the measurements.
(2) The cDNA was synthesized using a recombinant
Omniscript Reverse Transcriptase (Qiagen), RNase
inhibitor from human placenta (Sigma) and
(dT)16 oligonucleotides.
(3) RT-PCR procedure itself was carried out on the DNA
Engine Opticon 2 System (MJ Research, Waltham,
MA, USA). HotStar Taq DNA polymerase and SYBR
Green fluorescent dye (QuantiTec SYBR Green PCR
Kit; Qiagen) were used for the RT-PCR procedure.
To eliminate the influence of primer dimers, negative
controls were used. To account for differences in
cDNA loading, the results were expressed relative
to the expression of human cyclophilin (used as
a reference gene). There is no evidence of insulin
or ARB influence on cyclophilin, which is a house-
keeping gene encoding a cytoskeleton protein.
Primers used for RT-PCR are given in Table 2.
(4) The data were processed by Q-gene 96 software.Calculations
Insulin action was estimated as the glucose disposal (M)
calculated during the last 30 min of the clamp as the
rate of glucose infusion after correction for changes in
glucose pool size and urinary glucose loss. Insulin
sensitivity index M/I (glucose disposal normalized by
plasma insulin during steady-state period) was calcu-
lated to correct for any variations in plasma insulin.Statistical analysis
The data are expressed as meanGS.E.M., unless provided
otherwise. Steady-state periods of both clamps were
compared using Wilcoxon’s paired test. The differences
between time courses of both clamps were evaluated by
repeated measures ANOVA model, including following
factors and interactions: effects of treatment (HEC versus
AT-HEC) and time (the effect of hyperinsulinaemia) as
the within factors, subject factor (represents the
interindividual variability of subjects) and treatment!
time interaction. The last term indicated if the shapes of
the time profiles for HEC and AT-HEC were different or
not. The differences between subgroups were evaluatedReverse primer
T GGC HRETN-R: 5 0-TGG CAG TGA CAT GTG
GTC T-3 0
CT TGT HACRP30-R: 5 0-TCA TCC CAA GCT GAT
TCT G-30
AC CCA HCLPNa-R: 5 0-TGC CAT CCA ACC ACT
CAG TC-30
www.eje-online.org
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statistical significance of P!0.05 was chosen for both
ANOVA testing and multiple comparisons. Due to non-
Gaussian data distribution in all dependent variables, the
data underwent power transformations to attain dis-
tributional symmetry and a constant variance in the
data as well as in residuals. The non-homogeneities were
detected using residual diagnostics. The experimental
points with absolute values of studentized residual (after
data transformation) O3 were excluded from the
analysis. The fraction of such points never exceeded 5%
of the total number. Statistical software Statgraphics
Plus v. 5.1 (Manugistics; Rockville, MD, USA) was used
for the data analysis.Figure 1 Resistin during HEC and AT-HEC as (a) plasma
concentration and (b) relative expression levels. Data shown as
retransformed means with 95% confidence intervals. F, Fisher’s
statistics for individual factors and interactions. *P!0.05 between
basal and stimulated values, #P! 0.05 between HEC and AT-HEC
in individual stages.Results
Acute ARB had no impact on diuresis, systolic and
diastolic blood pressure in our study group (data not
shown).
During the steady-state periods of HEC versus AT-HEC,
the clampswere comparable in terms of themean plasma
glucose concentrations (4. 68G0.32 vs 4.75G
0.20 mmol/l) with coefficient of variation 3.37G0.55
vs 3.42G1.87%. Although the mean IRI levels were
different when comparing both the clamps (65.11G
7.53 vs 75.28G6.95 mIU/ml; P!0.05), the parameters
of insulin sensitivity did not significantly differ between
HEC andAT-HEC, being expressed as the glucose disposal
(M; 9.55G0.56 vs 9.15G1.68 mg/kg per min), as
well as calculated as the insulin sensitivity index M/I
(0.15G0.01 vs 0.13G0.01 mg/kg permin/mIU perml).
Plasma concentrations of resistin during HEC and
AT-HEC are shown in Fig. 1a. The ANOVA model
indicated a significant increase in plasma resistin during
both clamps. The time factor was significant (P!0.05),
while the treatment factor as well as the interaction
between the factors time and treatment were not.
Despite the multiple comparisons reaching significance
only for the difference between basal value and 240 min
for AT-HEC (P!0.05), the time trend did not signi-
ficantly differ between the clamps.
Figure 1b shows relative expressions of resistin. Here,
the time effect, as well as the treatment effect, was not
significant. On the other hand, the shapes of the
expressions’ time profiles differed significantly between
HEC and AT-HEC (treatment!time interaction;
P!0.05): resistin expression increased during HEC, as
also documented by multiple comparisons (0 vs
240 min; P!0.05), while duringAT-HEC the expression
did not change.Moreover, at 240 min ofAT-HEC, resistin
expression was significantly lower when compared with
HEC (P!0.05 by multiple comparisons).
In plasma adiponectin, no factor or interaction
reached significance (Fig. 2a). In addition, the multiple
comparisons did not show any significant differenceswww.eje-online.orgbetween clamps for basal (0 min) or stimulated
(240 min) values.
Figure 2b represents relative expressions of adipo-
nectin. In this variable, both time and treatment effects
were not significant. However, the shapes of the time
profiles differed between HEC and AT-HEC (as docu-
mented by significant treatment!time interaction;
P!0.05). Adiponectin expression increased during
HEC, as also confirmed by multiple comparisons (0 vs
240 min; P!0.05), while it did not change during
AT-HEC. Multiple comparisons found no significant
differences between clamps for basal (0 min), as well as
stimulated (240 min) values.Discussion
Our study shows that in healthy subjects, acute
hyperinsulinaemia induces an increase in resistin
plasma concentration and stimulates the expression of
resistin in s.c. adipose tissue, which is a novel
observation in vivo. Our finding is consistent with
Figure 2 Adiponectin during HEC and AT-HEC as (a) plasma
concentration and (b) relative expression levels. Data shown as
retransformed means values with 95% confidence intervals. F,
Fisher’s statistics for individual factors and interactions. *P! 0.05
between the basal and stimulated values.
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(26, 2). To the contrary, other groups showed the
opposite in mice and 3T3-L1 adipocytes (2). Few studies
have investigated the effect of insulin in vivo in humans;
Heilbronn (27) observed an increase in serum resistin
concentrations in response to supraphysiological doses
of insulin (164G5 mIU/l) in obese subjects with and
without diabetes. However, clinical studies in humans
do not show a consistent link between serum resistin
and either insulin resistance or obesity (3–6).
In our study group, adiponectin plasma concen-
trations were not affected by hyperinsulinaemia,
whereas its expression was stimulated by insulin.
These findings are in agreement with recent evidence
that circulating adiponectin per se is not a subject for
acute regulation, but its expression seems to be
regulated acutely (9), preceding thereby systemic
changes. Consistent results in vivo were shown by
Westerbacka et al. (28), who found an increased
adiponectin expression in s.c. fat after 6 h of hyper-
insulinaemia in insulin-sensitive subjects, which was
not accompanied by any changes in serum levels of
adiponectin. However, in the literature, a 7–8% declineof circulating adiponectin during hyperinsulineamia in
healthy men (29–31) is reported, which is more
pronounced (16–20% decrease) when a twofold higher
insulin infusion rate is used (32, 33). To the contrary,
other groups did not find any changes in plasma
adiponectin in response to insulin (34, 35), which is in
agreement with our results. The source of such
discrepancies might lie partly in diverse analyses that
were used or different ethnic groups that were studied
(there is a broad range of reported absolute values for
serum adiponectin: 2–20 mg/ml). Another point that
should be specified accurately is a potential confound-
ing factor of haemodilution during clamp. To further
distinguish the regulations in vivo, it will be necessary to
measure the adiponectin isoforms selectively, since the
HMW form is known to be the most active one (8) and it
correlates better with glucose disposal (36).
In accordance with previously mentioned study (28),
we report an increase in adiponectinmRNA in s.c. adipose
tissue in response to insulin in vivo. A 24-hour insulin
treatment induced an increase in adiponectin mRNA in
isolated human visceral adipose tissue (37), but a
reduction of adiponectin expression was detected in 3T3-
L1 adipocytes (38). Although the secretion of adiponectin
from visceral and s.c. depots appears comparable (39), the
regulations may exhibit some depot specificity (9). It will
be important to further elucidate the effect of insulin on
adiponectin production in different fat depots and in
different stages of insulin resistance.
Acute ARB did not change the parameters of insulin
sensitivity in our study group, that can be defined as
insulin sensitive. Interruption of angiotensin II signal-
ling was reached by administration of losartan 2!
100 mg total, which ensured linear pharmacokinetics
within the biological period of the drug (2 h) and its
active metabolite (6–9 h). However, the plasma levels
maynotmirror effective tissue concentrations,which are
crucial for potential metabolic effects. Recently, it was
proved that the active losartanmetabolite EXP3179 also
shows a partial PPARg agonistic effect (40).
The effect of acute ARB on insulin sensitivity has not
been studied in humans thus far; clinical trials using long-
term administration of ARBs (other than telmisartan)
with the HEC technique reported both increases (41, 22)
and no effect (42, 43) on glucose disposal in insulin-
resistant subjects. Hence, it is necessary to compare our
findings inhealthycontrolswith insulin-resistant subjects.
Independent of ARB, plasma concentrations of resistin
increased during hyperinsulinaemia, and adiponectin
plasma levels were not influenced. To the contrary, the
insulin-stimulated expressions of resistin and adiponec-
tin in s.c. adipose tissue were attenuated by losartan.
Our finding of increased plasma resistin in spite of
decreased expression in s.c. fat implicates a role of
another source of circulating resistin – a different fat
depot or potential non-adipose sources (e.g. stromal
vascular fraction of adipose tissue, macrophages or
endothelium). Other studies in rodents and humanswww.eje-online.org
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visceral fat depots when compared with s.c. at
basal conditions, although the source of resistin
was thought to be non-adipocytes. Nevertheless, the
attenuation of insulin-stimulated resistin expression
following acute ARB implies a positive role of
losartan in endocrine activity of adipose tissue.
An increase in circulating adiponectin after 2-month
treatment with losartan in hypertensive patients has
been reported (23), and there are other experimental
data showing enhanced adiponectin expression in
response to long-term ARB (44, 45), possibly via
PPARg activation. All the experiments and clinical
studies tested different ARB substances in different
models of insulin resistance, and there is no evidence
about the regulations in healthy subjects. We have
observed that acute losartan administration attenuates
the insulin-induced expression of adiponectin. This
unexpected trend in adiponectin expression should be
proven in long-term treatment to distinguish acute and
long-term regulations in vivo. However, the limited
sample size of our study should be considered as well.
Further studies are needed to support the hypothesis
that losartan exerts its positive effects on insulin
sensitivity through other mechanisms than stimulation
of adiponectin.
Recently, it was proven that the beneficial metabolic
effect of ARB goes beyond simple interruption of RAS
(12). Our results suggest potential effects of losartan on
resistin and adiponectin expression that might influence
further metabolic or proinflammatory factors.
Paradoxically, higher insulin plasma levels were
detected in the steady-state period of AT-HEC when
compared with HEC. There were no changes in body
weight between the clamps, and therefore, the insulin
infusion rates were comparable for both clamps. Higher
insulin levels after losartan administration cannot be
explained by involvement of insulin secretion, because
angiotensin II receptor activation, not inhibition, was
shown to stimulate insulin secretion (46). Impairment
of insulin clearance in liver by ARB cannot be excluded,
but there is no corresponding data available. However,
the beneficial effects of losartan in our study were seen
despite higher insulin levels.
We can conclude that in healthy subjects, acute
hyperinsulinaemia stimulates an increase in plasma
concentration and expression of resistin in s.c. adipose
tissue. While the ARB does not modify the insulin-
induced changes in plasma resistin, it attenuates the
response of resistin expression in adipose tissue. Acute
hyperinsulinaemia is associated with an increase in
adiponectin expression, but not in its plasma levels.
Losartan reduces the insulin-stimulated expression of
adiponectin.
These findings have to be further investigated in
larger cohorts in comparison with insulin-resistant
subjects, by short- or long-term ARB administration,
together with analysis of non-adipose sources of resistin.www.eje-online.orgAcknowledgements
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Abstract	  
Aims/hypothesis:	  To	  explore	  the	  role	  of	  adipocyte	  
fatty	   acid-­‐binding	   protein	   (A-­‐FABP,	   coded	   by	  
FABP4	  gene)	  in	  insulin	  resistance,	  we	  investigated	  
its	   plasma	   concentrations	   and	   expressions	   in	  
subcutaneous	  adipose	  tissue	  (SAT)	   in	  response	  to	  
hyperinsulinaemia	   and	   acute	   angiotensin	   type	   1	  
receptor	  blockade	  (ARB)	  in	  type	  2	  diabetes.	  
Methods:	  Eleven	   type	   2	   diabetic	   patients	   and	   12	  
healthy	   age-­‐matched	   controls	   underwent:	   1)	  
hyperinsulinaemic-­‐euglycaemic	   clamp	   (HEC);	   2)	  
HEC	   after	   acute	   losartan	   treatment	   (AT-­‐HEC);	   3)	  
saline	   infusion	   (SAL)	   as	   a	   control	   examination.	  At	  
baseline	  and	  240	  min	  of	  the	  interventions,	  plasma	  
A-­‐FABP	  was	  measured	  and	  biopsies	  of	  abdominal	  
SAT	  were	  performed	  to	  analyse	  gene	  expression.	  	  
Results:	   In	  diabetes,	  A-­‐FABP	  concentrations	  were	  
higher	   compared	   to	   controls	   (p<0.001),	   they	  
showed	   a	   parallel	   decrease	   during	   both	   clamps,	  
but	  no	  changes	  during	  SAL;	  during	  AT-­‐HEC	  plasma	  
A-­‐FABP	   was	   increased.	   In	   controls,	  
hyperinsulinaemia	   prevented	   the	   increase	   in	  
plasma	   A-­‐FABP	   detected	   during	   SAL;	   in	   AT-­‐HEC	  
increased	   A-­‐FABP	   basal	   concentrations	   were	  
reversed	   at	   240	   min.	   A-­‐FABP	   expressions	   were	  
higher	  in	  diabetes	  (p<0.001)	  without	  any	  dynamic	  
changes	   in	   either	   group.	   Plasma	   A-­‐FABP	  
correlated	   with	   its	   expression	   (p<0.01)	   and	   both	  
correlated	   with	  BMI,	   waist	   circumference,	  
glycaemia,	   insulinaemia	   and	   glucose	   disposal.	   E-­‐
FABP	   (epidermal-­‐FABP,	   coded	   by	   FABP5	   gene)	  
showed	  higher	  expressions	  in	  controls	  (p<0.01).	  	  
Conclusions/interpretation:	   Both	   A-­‐FABP	   plasma	  
concentrations	   and	   expressions	   are	   increased	   in	  
type	  2	  diabetes.	  They	  are	  independently	  associated	  
with	  parameters	  of	   obesity,	   insulin	   resistance	  and	  
hyperglycaemia.	   Acute	   hyperinsulinaemia	  
suppresses	  plasma	  A-­‐FABP	  but	  does	  not	   influence	  
its	  expression	  in	  SAT.	  Acute	  ARB	  stimulates	  basal	  A-­‐
FABP	  plasma	  concentrations	  without	  any	  effect	  on	  
its	  expression.	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  registration:	  ClinicalTrials.gov	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ACEI:	  inhibitors	  of	  angiotensin-­‐converting	  enzyme	  
A-­‐FABP:	  adipocyte	  fatty	  acid-­‐binding	  protein	  
ARB:	  angiotensin	  type	  1	  receptor	  blockade	  
AT-­‐HEC:	   hyperinsulinaemic	   euglycaemic	   clamp	  
after	  ARB	  	  
C:	  healthy	  control	  subjects	  
D:	  type	  2	  diabetic	  subjects	  
E-­‐FABP:	  epidermal	  fatty	  acid-­‐binding	  protein	  
FABPs:	  fatty	  acid-­‐binding	  proteins	  
HEC:	  hyperinsulinaemic-­‐euglycaemic	  clamp	  
IRI:	  immunoreactive	  insulin	  
KCl:	  potassium	  chloride	  
LSD:	  least	  significant	  difference	  
M:	  glucose	  disposal	  
NaCl:	  natrium	  chloride	  
OPLS:	  orthogonal	  projections	  to	  latent	  structures	  	  
PPAR-­‐γ:	  peroxisome	  proliferator-­‐activated	  receptor	  
gamma	  	  
RT-­‐PCR:	  real-­‐time	  polymerase	  chain	  reaction	  
SAL:	  infusion	  of	  natrium	  chloride	  0.9%	  solution	  
SAT:	  subcutaneous	  adipose	  tissue	  
TG:	  triacylglycerol	  
Introduction	  
Low-­‐grade	   inflammation	   is	  considered	   to	  be	  a	  key	  
feature	   of	   obesity	   and	   type	   2	   diabetes,	   playing	   a	  
significant	   role	   in	   the	   pathogenesis	   of	   metabolic	  
abnormalities	  related	  to	  insulin	  resistance	  [1].	  Due	  
to	   its	   secretory	   functions,	   adipose	   tissue	  
represents	   a	   critical	   site	   for	   metabolic-­‐
inflammatory	   interactions.	   Indeed,	   the	   disturbed	  
endocrine	  activity	  of	  adipose	   tissue	   is	   consistently	  
found	  in	  obesity	  and	  type	  2	  diabetes	  [2].	  
An	  important	  molecular	  pathway,	  which	  integrates	  
metabolic	  and	  inflammatory	  response	  involves	  the	  
fatty	   acid-­‐binding	   proteins	   (FABPs)	   commonly	  
present	   in	   adipocytes	   and	   macrophages	   in	   two	  
isoforms	  –	  adipocyte	  FABP	  (A-­‐FABP)	  and	  epidermal	  
FABP	   (E-­‐FABP)	   coded	  by	  FABP4	   and	  FABP5	   genes,	  
respectively	   [3].	   As	   cytoplasmic	   lipid	   chaperons	  
FABPs	   are	   responsible	   for	   cellular	   trafficking	   of	  
fatty	   acids.	   Moreover,	   experimental	   evidence,	  
based	   on	   comprehensive	   research	   on	   knock-­‐out	  
mice	   models,	   supports	   the	   role	   of	   A-­‐FABP	   in	  
systemic	   regulation	   of	   lipid	   and	   glucose	  
metabolism	   and	   inflammation,	   since	   A-­‐FABP	  
deficiency	   prevents	   the	   development	   of	   obesity,	  
insulin	   resistance	   and	   atherosclerosis	   [4-­‐6].	   In	  
human	   studies,	   A-­‐FABP	   was	   found	   to	   be	   also	  
present	   in	   plasma	   [7],	   although	   its	   physiological	  
function	   or	   mechanisms	   of	   its	   appearance	   in	  
circulation	  have	  not	  been	  elucidated	  until	  now.	  A-­‐
FABP	   plasma	   concentrations	   are	   increased	   in	  
patients	   with	   obesity	   and/or	  metabolic	   syndrome	  
[7-­‐9]	   and	   it	   is	   suggested	   as	   a	   novel	   risk	   marker	  
predicting	  development	  of	  metabolic	  syndrome	  [8]	  
or	   type	   2	   diabetes	   [10].	   On	   the	   contrary,	   clinical	  
studies	   focused	   on	   adipose	   tissue	   expression	   are	  
inconclusive	  [11]	  –	  they	  report	  no	  differences	  in	  A-­‐
FABP	   expression	   or	   a	   decrease	   in	   E-­‐FABP	  
expression	   in	  obese	   subjects	   [12-­‐14].	  Additionally,	  
no	   consistent	   association	   between	   A-­‐FABP	  
expression	   and	   measures	   of	   obesity	   or	   insulin	  
resistance	   has	   been	   found	   [13,	   15].	   Plasma	  
concentrations	  and	  adipose	  tissue	  expression	  of	  A-­‐
FABP	   have	   never	   been	   shown	   in	   parallel	   so	   far.	  
Similarly,	   there	   is	   little	   evidence	   about	   their	  
regulation	   by	   insulin	   in	   vivo	   in	   humans	   or	   about	  
possible	   differences	   in	   these	   regulations	   between	  
healthy	  subjects	  and	  patients	  with	  type	  2	  diabetes.	  	  	  	  	  	  	  
	  
A	   number	   of	   experimental	   and	   clinical	   studies	  
indicate	  that	  angiotensin	  type	  1	  receptor	  blockade	  
(ARB)	  might	  improve	  insulin	  resistance	  and	  thereby	  
decrease	   incidence	   of	   new	   onset	   type	   2	   diabetes	  
[16-­‐18].	   The	   underlying	   mechanisms	   are	   not	   fully	  
clarified.	   Apart	   from	   inhibition	   of	   adverse	  
metabolic	   effects	   of	   angiotensin	   II	   on	   insulin	  
signalling,	   tissue	   blood	   flow,	   oxidative	   stress,	  
sympathetic	   activity,	   pancreatic	   beta	   cell	  
dysfunction	   or	   adipogenesis	   [16,	   19],	   ARB	   is	  
supposed	  to	  dispose	  of	  effects	  that	  extend	  beyond	  
the	  angiotensin-­‐receptor	  blockade	  [20],	  depending	  
on	   properties	   of	   particular	   ARB	   compounds,	   e.g.	  
activation	   of	   peroxisome	   proliferator-­‐activated	  
receptor	   gamma	   (PPAR-­‐γ).	   Experimental	   studies	  
showed	   that	   ARB	   influences	   lipid	   metabolism	   in	  
adipose	   tissue	   by	   promoting	   adipose	   tissue	  
rearrangement,	   decreasing	   adipocyte	   size	   and	  
modulating	   adipokine	   expression	   and	   release	   [21-­‐
23].	  	  
	  
We	  hypothesized	  that	  ARB	  would	  influence	  A-­‐FABP	  
plasma	   concentrations	   or	   its	   expressions	   due	   to	  
the	   potential	   effects	   of	   ARB	   in	   adipose	   tissue	  
metabolism.	  Therefore	  the	  aims	  of	  this	  study	  were:	  
1)	   to	   assess	   A-­‐FABP	   plasma	   concentrations	   in	  
parallel	   with	   expressions	   of	   A-­‐FABP	   and	   selected	  
related	   genes	   (E-­‐FABP,	   PPAR-­‐γ)	   in	   abdominal	  
subcutaneous	   adipose	   tissue	   (SAT);	   and	   2)	   to	  
investigate	   their	   responses	   to	   acutely	   induced	  
hyperinsulinaemia	  with	   and	  without	   acute	   ARB	   in	  
patients	  with	   type	   2	   diabetes	   and	   healthy	   control	  
subjects.	  
	  
Subjects	  and	  methods	  
Subjects	  
Eleven	   overweight/obese	  male	   patients	  with	   type	  
2	   diabetes	   and	   12	   age-­‐matched	   healthy	   male	  
subjects	   were	   enrolled	   in	   the	   study.	   Clinical	  
characteristics	   of	   both	   groups	   are	   summarized	   in	  
Table	   1.	   The	   type	   2	   diabetic	   patients	   (D)	   were	  
treated	   with	   diet	   or	   oral	   agents	   (except	   of	  
thiazolidinediones)	   in	   stable	   dosing	   over	   three	  
months	   prior	   to	   the	   study.	   Subjects	   treated	   with	  
insulin,	   having	   micro-­‐	   or	   macrovascular	  
complications	   of	   diabetes,	   acute	   or	   chronic	  
inflammatory	  or	   other	  major	   organ	  diseases	  were	  
excluded	   from	   the	   study.	   Six	   of	   the	   diabetic	  
patients	  were	  treated	  with	  antihypertensive	  drugs	  
(calcium-­‐channel	  blockers,	  diuretics	  or	  angiotensin-­‐
converting	   enzyme	   inhibitors-­‐	   ACEI).	   The	   ACEIs	  
were	   replaced	   with	   calcium-­‐channel	   blockers	   two	  
weeks	   prior	   to	   clamp	   procedures	   and	  maintained	  
for	  the	  whole	  study	  duration.	  	  
Healthy	   control	   subjects	   (C)	   had	   normal	   glucose	  
tolerance	   confirmed	   by	   OGTT,	   normal	   blood	  
pressure	   and	   serum	   lipids.	   None	   had	   a	   family	  
history	   of	   diabetes.	   All	   control	   subjects	   were	  
euthyroid	   without	   any	   concomitant	   disease	   or	  
medication.	   Informed	   consent	  was	   obtained	   from	  
all	   the	   individuals	   after	   explaining	   the	   purpose,	  
nature,	   and	   potential	   risks	   of	   the	   study.	   The	   local	  




Variable	   C	  (n=12)	   D	  (n=11)	   p	  value	  
Age	  	  (years)	   48.75	  ±	  1.45	   50.27	  ±	  1.38	   NS	  
Weight	  (kg)	   93.73	  ±	  2.48	   79.0	  ±	  3.77	   **	  
Body	  mass	  index	  (kg.m-­‐2)	   25.65	  ±	  1.16	   30.23	  ±	  0.60	   **	  
Waist	  circumference	  (cm)	   90.91	  ±	  3.00	   100.91	  ±	  2.71	   *	  
Fasting	  blood	  glucose	  (mmol.l-­‐1)	   5.2	  ±	  0.08	   7.56	  ±	  0.53	   **	  
Blood	  glucose	  at	  120	  min	  	  
of	  OGTT	  (mmol.l-­‐1)	  
5.56	  ±	  0.34	   -­‐	   	  
Fasting	  insulin	  (µU.ml-­‐1)	   5.50	  ±	  0.70	   8.42	  ±	  1.05	   *	  
HbA1c	  (%)	  	   5.46	  ±	  0.09	   6.48	  ±	  0.41	   *	  
Albuminuria	  (μg.min-­‐1)	   3.66	  ±	  0.84	   5.54	  ±	  1.54	   NS	  
Creatinine	  (μmol.l-­‐1)	   87.37	  ±	  1.88	   80.83	  ±	  2.30	   NS	  
Total	  cholesterol	  (mmol.l-­‐1)	   4.81	  ±	  0.20	   5.60	  ±	  0.27	   *	  
Triacylglycerol	  (mmol.l-­‐1)	   1.14	  ±	  0.15	   2.61	  ±	  0.49	   *	  
HDL-­‐cholesterol	  (mmol.l-­‐1)	   1.19	  ±	  0.04	   1.09	  ±	  0.04	   NS	  
LDL-­‐cholesterol	  (mmol.l-­‐1)	   3.22	  ±	  0.19	   3.59	  ±	  0.17	   NS	  
Fasting	  NEFA	  (mmol.l-­‐1)	   0.284	  ±	  0.04	   0.502	  ±	  0.12	   NS	  
	  
Table	  1.	  Clinical	  and	  physiological	  characteristic	  of	  the	  study	  groups.	  Data	  are	  means	  ±	  SEM.	  	  
*	  p<0.05,	  **	  p<0.01;	  	  
	  
Study	  protocol	  
The	   subjects	   were	   examined	   on	   an	   outpatient	  
basis,	   after	   overnight	   fast	   with	   only	   tap	   water	  
allowed	  ad	  libitum.	  They	  were	  instructed	  to	  adhere	  
to	   their	   ordinary	   lifestyle,	   avoid	   changes	   in	   food	  
intake,	   alcohol	   consumption	   and	   to	   refrain	   from	  
strenuous	  physical	  activity	  for	  24	  hours	  before	  the	  
experiment.	   In	   random	   order	   the	   subjects	  
underwent	   three	   examinations	   at	   least	   3	   weeks	  
apart,	  all	  taking	  4	  hours	  to	  complete:	  	  
Study	  1.	  The	  hyperinsulinaemic	  euglycaemic	  clamp	  
(HEC)	  was	  conducted	  as	  previously	  described	  [24].	  
Briefly,	   a	   Teflon	   cannula	   (Venflon;	   Viggo,	  
Helsingborg,	   Sweden)	   was	   inserted	   into	   an	  
antecubital	   vein	   for	   administration	   of	   infusions.	   A	  
second	   cannula	   was	   inserted	   retrogradely	   into	   a	  
wrist	   vein	   for	   blood	   sampling	   and	   the	   hand	   was	  
placed	   in	  a	  heated	  (650	  C)	  box	   in	  order	   to	  achieve	  
venous	  blood	   arterialization.	  A	  primed-­‐continuous	  
insulin	   infusion	   (1	   mU.kg-­‐1.min-­‐1	   of	   Actrapid	   HM;	  
NovoNordisk,	  Copenhagen,	  Denmark	  -­‐	  dissolved	  in	  
0.9%	  natrium	  chloride	  [NaCl])	  was	  administered	  to	  
acutely	   raise	   and	   maintain	   the	   plasma	  
concentrations	   of	   insulin.	   Plasma	   glucose	  
concentrations	  during	   the	   clamp	  were	  maintained	  
at	   the	   5	   mmol.l-­‐1	   level	   by	   continuous	   infusion	   of	  
15%	   glucose.	   To	   prevent	   hypokalaemia	   during	  
insulin	   infusion,	   potassium	   chloride	   (KCl)	   was	  
added	   to	   the	   15%	   glucose	   infusion	   (30	   mmol.l-­‐1	  
KCl).	   To	   assess	   plasma	   levels	   of	   A-­‐FABP,	   blood	  
samples	   were	   obtained	   at	   0	   min	   and	   240	   min	   of	  
the	  clamp	  study.	  	  
Needle	  biopsy	  of	  abdominal	  SAT	  was	  performed	  at	  
0	   min	   and	   240	   min	   of	   the	   clamp.	   Under	   local	  
anaesthesia	  (1%	  trimecain	   in	  a	  field	  block	  pattern)	  
an	  incision	  (3-­‐4	  mm)	  was	  made	  through	  the	  skin	  at	  
the	   lower	   abdomen	   and	   a	   subcutaneous	   fat	  
specimen	   (300	   mg)	   was	   obtained	   by	   needle	  
aspiration.	  The	  samples	  were	  washed	  in	  0.9%	  NaCl	  
solution,	  immediately	  frozen	  by	  liquid	  nitrogen	  and	  
stored	  at	  -­‐80ºC	  until	  used	  for	  RNA	  extraction.	  
Study	   2.An	   identical	   clamp	   study	   was	   performed	  
after	  acute	  ARB	   (AT-­‐HEC).	   Losartan	  2x	  100mg	  was	  
given	   per	   os	   prior	   to	   the	   study	   (8	   hours	   and	  
immediately	   prior	   to	   the	   clamp)	   and	   a	  
hyperinsulinaemic	  (1	  mU.kg-­‐1.min-­‐1)	  euglycaemic	  (5	  
mmol.l-­‐1)	   clamp	   was	   conducted	   as	   it	   is	   described	  
above.	   Using	   the	   mentioned	   dosing,	   the	  
interruption	   of	   angiotensin	   II	   signalling	   was	  
reached	   due	   to	   losartan	   linear	   pharmacokinetics	  
within	   the	   active	   biological	   period	   of	   the	   drug	   (2	  
hours)	  and	  its	  active	  metabolite	  (6-­‐9	  hours).	  Blood	  
samples	  and	  adipose	  tissue	  biopsies	  were	  collected	  
at	   0	  min	   and	   240	  min	   of	   the	   clamp	   to	   determine	  
plasma	   concentrations	   of	   A-­‐FABP	   and	   expressions	  
of	  selected	  genes.	  
Study	  3.	  A	  0.9%	  NaCl	  infusion	  (SAL)	  was	  performed	  
as	   a	   control	   examination	   in	   order	   to	   distinguish	  
possible	   non-­‐specific	   volume	   (haemodilution)	   and	  
time	   effects	   during	   above	   described	   interventions	  
on	   plasma	   concentrations	   of	   proteins	   tested.	   The	  
total	   volume	  of	   infusions	   and	  water	   equivalent	   to	  
HEC	   was	   given	   per	   os	   and	   intravenously	   in	   the	  
course	  of	  4	  hours.	  Blood	  samples	  for	  measurement	  
of	   plasma	   A-­‐FABP	   were	   taken	   at	   0	   min	   and	   240	  
min.	   Based	   on	   an	   assumption	   that	   adipose	   tissue	  
expressions	   are	   not	   affected	   by	   haemodilution	  
during	  clamp,	  the	  adipose	  tissue	  biopsies	  were	  not	  
repeated	  during	  SAL	  volume	  control.	  	  	  	  
	  
Analytical	  Methods	  
Plasma	  glucose	   concentrations	  were	  measured	  on	  
a	   Beckman	   analyzer	   (Beckman	   Instruments	   Inc,	  
Fullerton,	  CA,	  USA)	  using	  glucose	  oxidase	  method.	  
Immunoreactive	   insulin	   (IRI)	   was	   determined	   by	  
radioimmunoassay	   method	   using	   an	  
IMMUNOTECH	  Insulin	  IRMA	  kit	  (IMMUNOTECH	  as,	  
Prague,	   Czech	   Republic)	   with	   analytical	   sensitivity	  
0.5	  μIU.ml-­‐1,	  intra-­‐assay	  and	  inter-­‐assay	  coefficient	  
of	   variation	   below	   or	   equal	   to	   4.3%	   and	   3.4%,	  
respectively.	  	  
Plasma	   concentrations	   of	   A-­‐FABP	   were	   measured	  
according	   to	   manufacturer‘s	   instructions	   using	  
Human	  A-­‐FABP	  ELISA	  kit	  (BioVendor	  Lab.	  Med.	  Inc.,	  
Brno,	  Czech	  Republic),	   the	  detection	   limit	  was	  0.1	  
ng.ml-­‐1,	   intra-­‐assay	   and	   inter-­‐assay	   coefficients	   of	  
variation	  of	  5.3%	  and	  3.9%,	  respectively.	  	  
Plasma	  concentrations	  of	  NEFA	  were	  estimated	  by	  
Half-­‐micro	  test	  Free	  fatty	  acids	   (Roche	  Diagnostics	  
GmbH,	   Penzberg,	   Germany).	   Triacylglycerol	   (TG)	  
plasma	  concentrations	  were	  assessed	  by	  enzymatic	  
assay	   (BIO-­‐LA-­‐TEST;	   PLIVA-­‐Lachema,	   Brno,	   Czech	  
Republic).	  	  
Relative	   expression	   of	   A-­‐FABP	   (FABP4),	   E-­‐FABP	  
(FABP5)	  and	  PPAR-­‐γ	  was	  analysed	  by	  the	  real-­‐time	  
polymerase	   chain	   reaction	   (RT-­‐PCR)	  method	  using	  
following	  protocol:	  	  
1)	   The	   RNA	  was	   isolated	   from	   the	   liquid	   nitrogen	  
frozen	   biopsy	   of	   the	   human	   fat	   tissue	   using	   the	  
RNeasy	   Lipid	   Tissue	   Mini	   Kit	   and	   QIAzol	   Lysis	  
Reagent	  (QIAGEN,	  Valencia,	  CA,	  USA).	  The	  starting	  
amount	   of	   100	   mg	   tissue	   was	   excised	   from	   the	  
biopsy	  and	  homogenized	   in	  1	  ml	  of	   a	  QIAzol	   Lysis	  
Reagent	   (Guanidin	   Thiocyanate	  –	  Phenol	   solution)	  
for	  2	  minutes.	  From	  the	  homogenate,	  the	  RNA	  was	  
isolated	   by	   extraction	   on	   silica-­‐gel	   based	   column,	  
according	   to	   the	   kit	   handbook.	   Possible	  
contamination	  of	  RNA	  with	  genomic	  DNA	  remains	  
was	   taken	   off	   by	   DNase	   digestion	   (RNase-­‐free	  
DNase	  Set;	  QIAGEN,	  Valencia,	  CA,	  USA).	  This	  step	  is	  
supposed	  to	  prevent	  any	  later	  DNA	  amplification.	  	  
2)	  The	  cDNA	  was	  synthesized	  using	  a	  recombinant	  
Omniscript	   Reverse	   Transcriptase	   (QIAGEN,	  
Valencia,	   CA,	   USA),	   Ribonuclease	   Inhibitor	   from	  
human	  placenta	   (SIGMA,	  St.	   Louis,	  MO,	  USA),	  and	  
(dT)16	  oligonucleotides.	  
3)	  RT-­‐PCR	  procedure	  itself	  has	  been	  carried	  out	  on	  
the	   DNA	   Engine	   Opticon	   2	   System	   (MJ	   Research,	  
Waltham,	  MA,	  USA).	  HotStar	  Taq	  DNA	  polymerase	  
and	   SYBR	   Green	   fluorescent	   dye	   (QuantiTec	   SYBR	  
Green	   PCR	   Kit;	   QIAGEN,	   Valencia,	   CA,	   USA)	   were	  
used	   for	   the	   RT-­‐PCR	   procedure.	   To	   eliminate	   the	  
influence	   of	   primer	   dimmers	   negative	   controls	  
were	   used.	   To	   account	   for	   differences	   in	   cDNA	  
loading,	  the	  results	  were	  expressed	  relative	  to	  the	  
expression	   of	   human	   cyclophilin	   (used	   as	   a	  
reference	   gene).Following	   primers	   were	   used	   for	  
RT-­‐PCR:	  	  
A-­‐FABP:	  	  
forward	  primer	  5’-­‐ATGGCCAAACCTAACATGA-­‐3‘	  	  
reverse	  primer	  5’-­‐CAAATTCCTGGCCCAGTATG-­‐3‘	  	  
E-­‐FABP:	   	  
forward	  primer	  5’-­‐AATGGCCAAGCCACATTGTA-­‐3‘	  	  
reverse	  primer	  5’-­‐CACTCCTGATGCTGA-­‐3‘	  
PPAR-­‐γ:	   	  
forward	  primer	  5’-­‐GAGCCCAAGTTTGAGTTTGC-­‐3‘	  	  
reverse	  primer	  5’-­‐CTGTGAGGACTCAGGGTGGT-­‐3‘	  	  
Cyclophilin:	  
forward	  primer	  5’-­‐CAAATGCTGGACCCACA-­‐3‘	  	  
reverse	  primer	  5’-­‐TGCCATCCAACCACTCAGTC-­‐3‘	  
PPAR-­‐γ	  primers	  were	  designed	  to	  cover	  all	  splicing	  
variants	  of	  PPAR-­‐γ	  mRNA.	  	  




Insulin	   action	   was	   estimated	   as	   the	   glucose	  
disposal	   (M)	   calculated	   during	   the	   last	   30	   min	   of	  
the	   clamp	   as	   the	   rate	   of	   glucose	   infusion	   after	  
correction	   for	   changes	   in	   glucose	   pool	   size	   and	  
urinary	  glucose	  loss.	  	  
	  
Statistical	  analysis	  
The	  data	  are	  expressed	  as	  means	  ±	   SEM	  or	  mean	  
(5%	   -­‐	   95%	   CI).	   The	   groups	   were	   compared	   using	  
Mann-­‐Whitney	   test.	   The	   differences	   between	   the	  
interventions	   and	   between	   the	   groups	   were	  
evaluated	   by	   repeated	   measures	   ANOVA	   model,	  
including	   following	   factors	  and	   interactions:	  Effect	  
of	  Group	  (D	  vs.	  C)	  as	  the	  between	  factor,	  Effects	  of	  
Intervention	   (HEC	   vs.	   SAL	   and	   HEC	   vs.	   AT-­‐HEC,	  
respectively)	   and	  Time	   (0	  min	   vs.	   240	  min)	   as	   the	  
within-­‐factors,	   Subject	   factor	   (represents	   the	  
interindividual	   variability	   of	   subjects)	   and	   their	  
interactions(Intervention	   ×	   Time;	   Intervention	   ×	  
Group;	   Time	   ×	   Group;	   Group	   ×	   Intervention	   ×	  
Time).	  The	  interactions	  indicate	  if	  the	  shapes	  of	  the	  
time	  profiles	  for	  HECvs.	  SAL	  or	  HEC	  vs.	  AT-­‐HEC	  and	  
for	  D	  and	  C,	  respectively	  were	  different	  or	  not.The	  
differences	   between	   subgroups	   were	   evaluated	  
using	   least	   significant	   difference	   (LSD)	   multiple	  
comparisons.	   Additionally,	   separate	   ANOVA	  
models	   for	   Diabetes	   and	   Control	   groups	   were	  
performed	   for	   comparison	   of	   the	   interventions	  
within	  the	  group.	  The	  significances	  of	  the	  separate	  
models	   and	   LSD	   are	   described	   in	   the	   text.	   The	  
statistical	   significance	   of	   p<0.05	   was	   chosen	   for	  
both	   ANOVA	   testing	   and	   multiple	   comparisons.	  
Due	   to	   non-­‐Gaussian	   data	   distribution	   in	   all	  
dependent	   variables,	   the	   data	   underwent	   power	  
transformations	   to	   attain	   distributional	   symmetry	  
and	   a	   constant	   variance	   in	   the	   data	   as	   well	   as	   in	  
residuals.	   The	   non-­‐homogeneities	   were	   detected	  
using	  residual	  diagnostics.	  The	  experimental	  points	  
with	  absolute	  values	  of	  Studentized	  residual	  (after	  
data	   transformation)	   greater	   than	   3,	   were	  
excluded	   from	   the	   analysis.	   The	   fraction	   of	   such	  
points	  never	  exceeded	  5%	  of	  the	  total	  number.	  To	  
evaluate	   relationships	   between	   the	   variables,	  
Spearman	  correlations	  and	  multivariate	  regression	  
with	  reduction	  of	  dimensionality	  using	  the	  method	  
of	   bidirectional	   orthogonal	   projections	   to	   latent	  
structure	   (O2PLS)	   were	   applied.	   For	   details	   of	  
O2PLS	  model	  see	  Supplementary	  file.	  	  
Statistical	   software	   SIMCA	   v.	   12.0.1.0.	   (Umetrics,	  
Umeå,	   Sweden)	   and	   Statgraphics	   Centurion	   v.	   XV	  
Statpoint	   Inc.;	  Herndorn,	  Virginia,	  USA)	  were	  used	  
for	  the	  data	  analysis.	  
	  
Results	  
Characteristics	   of	   the	   steady	   state	   periods	   of	  
interventions	  
Parameters	  characterising	  the	  steady	  state	  periods	  
of	   clamps	  are	   shown	   in	  Table	  2.	   The	   clamps	  were	  
comparable	   within	   as	   well	   as	   between	   groups	   in	  
terms	  of	   the	  mean	  plasma	  glucose	  concentrations	  
with	   coefficients	  of	   variation	  below	  3%,	   the	  mean	  
IRI	   and	   NEFA	   levels.	   As	   expected,	   the	   insulin	  
sensitivity	  expressed	  as	  M	  was	   significantly	  higher	  
in	   C	   compared	   to	  D	   group	   (Group	  effect:	  p<0.01).	  
No	   differences	   in	  M	  were	   detected	   between	   HEC	  
and	  AT-­‐HEC	  in	  both	  groups.	  	  
During	   SAL	   control	   intervention	   the	   total	   fluid	  
volume	  administered	  was	   comparable	   to	  HEC	  and	  
AT-­‐HEC.	   The	   steady-­‐state	   periods	   of	   SAL	   (last	   30	  
min)	   were	   characterised	   by	  mean	   plasma	   glucose	  
5.72±0.29	   and	   4.76±0.14	   mmol.l-­‐1(p<0.01);	   mean	  
IRI	   concentrations	  5.3±1.33	  and	  2.92±0.28	  µU.ml-­‐1	  
(NS);	   and	   mean	   NEFA	   concentrations	   0.48±0.04	  
and	  0.34±0.05	  mmol.l-­‐1	  (NS)	  in	  D	  vs.	  C,	  respectively.	  	  
	  
	  
C	  (n=12)	   D	  (n=11)	   p	  value	  
Variable	  
HEC	   AT-­‐HEC	   HEC	   AT-­‐HEC	   	  
Mean	  plasma	  glucose	  	  
(mmol.l-­‐1)	  
5.18±0.12	   5.23±0.10	   5.35±0.20	   5.17±0.13	   NS	  
Coefficient	  of	  glucose	  
variation	  (%)	  
2.23±0.27	   2.65±0.17	   2.60±0.32	   2.86±0.41	   NS	  
Mean	  insulin	  (µU.ml-­‐1)	   71.87±4.89	   77.13±6.25	   80.58±5.58	   79.56±7.55	   NS	  
NEFA	  (mmol.l-­‐1)	   0.059±0.01	   0.099±0.04	   0.094±0.02	   0.083±0.02	   NS	  
M	  (mg.kg-­‐1.min-­‐1)	   10.13±0.86	   10.68±0.94	   6.70±0.44	   6.35±0.59	   **	  
Table	  2.	  Characteristics	  of	  the	  steady	  state	  periods	  of	  HEC	  vs.	  AT-­‐HEC.	  Data	  are	  means	  ±	  SEM.	  	  
**	  p<0.01	  for	  D	  vs.	  C.	  	  
	  
The	  effect	  of	  metabolic	  status	  and	  insulin	  on	  	  
A-­‐FABP	  plasma	  concentrations	  and	  SAT	  expressions	  	  
Plasma	   concentrations	   of	   A-­‐FABP	   during	   HEC	   and	  
SAL	  are	  displayed	   in	  Figure	  1a.	  They	  were	  1.6-­‐fold	  
higher	   in	   D	   group	   compared	   to	   C	   group	   (Group	  
effect:	  p<0.001).	   In	  D,	   a	   significant	   decrease	   in	   A-­‐
FABP	  was	  detected	  during	  HEC	  (Time	  effect:	  p<0.05	  
in	   full	  ANOVA	  and	   in	  LSD	  post-­‐test:	  p<0.05),	  while	  
during	  SAL	  no	  difference	  in	  A-­‐FABP	  concentrations	  
could	  be	  shown.	  This	  implicates	  that	  the	  decline	  in	  
plasma	   A-­‐FABP	   during	   clamp	   is	   independent	   on	  
haemodilution	   and	   is	   attributed	   to	  
hyperinsulinaemia.	   In	   C,	   no	   changes	   in	   plasma	   A-­‐
FABP	  were	  demonstrated	  during	  HEC.	  During	  SAL,	  
the	  basal	  A-­‐FABP	  was	  comparable	  to	  HEC,	  while	  at	  
240	   min	   higher	   concentrations	   compared	   to	   HEC	  
were	   measured	   (Intervention	   effect:	   p<0.05	   in	  
ANOVA	  for	  Controls	  and	  in	  LSD).	  
Relative	   expressions	   of	   selected	   genes	   in	   SAT	   are	  
summarized	   in	   Table	   3.	   Similarly	   to	   plasma	  
concentrations,	  the	  relative	  expressions	  of	  A-­‐FABP	  
in	   SAT	   were	   3.0-­‐fold	   higher	   in	   D	   group	   (Group	  
effect:	  p<0.001),	  while	  no	  dynamic	  changes	   in	   the	  
course	   of	   HEC	   were	   observed	   (Time	   and	  
Intervention	   effects	   and	   all	   interactions	   were	   not	  
significant).	  
The	   relative	   expressions	   of	   E-­‐FABP	   were	   opposite	  
to	   A-­‐FABP.	   Higher	   E-­‐FABP	   expressions	   were	  
detected	   in	   C	   compared	   to	   D	   (Group	   effect:	  
p<0.01).	  During	  HEC	  no	  changes	  were	  measured.	  	  	  
The	   A-­‐FABP/E-­‐FABP	   mRNA	   ratio	   reflecting	   the	  
relative	   contribution	   of	   both	   FABP	   isoforms	  
secreted	   by	   adipose	   tissue	   was	   higher	   in	   D	  
compared	  to	  C	  (Group	  effect:	  p<0.001)	  and	  showed	  
no	   differences	   during	   HEC	   (Time,	   Intervention	  
effect	  and	  all	  interactions	  not	  significant).	  	  
Relative	   expression	   of	   PPAR-­‐γ	   was	   higher	   in	   C	  
compared	  to	  D	  (Group	  effect:	  p<0.01),	  no	  dynamic	  
changes	  during	  HEC	  were	  detected	  in	  either	  group	  
(Time,	   Intervention	   effect	   and	   all	   interactions	   not	  
significant).	  
	  
The	  effect	  of	  ARB	  on	  A-­‐FABP	  plasma	  concentrations	  
and	  SAT	  expressions	  	  
A-­‐FABP	  plasma	  concentrations	  during	  HEC	  and	  AT-­‐
HEC	   are	   shown	   in	   Figure	   1b.	   In	   D,	   A-­‐FABP	  
concentrations	   were	   increased	   during	   AT-­‐HEC	  
(Intervention	   effect:	   p<0.05	   in	   Full	   ANOVA	  model	  
and	   in	  model	   for	  Diabetes).	  A	  parallel	   decrease	   in	  
plasma	  A-­‐FABP	  was	  detected	  in	  D	  during	  both	  HEC	  
and	  AT-­‐HEC	   (Time	  effect:	  p<0.05	   in	  ANOVA	  model	  
for	  Diabetes	  and	  LSD	  post-­‐test:	  p<0.05).	  
In	   C,	   plasma	   A-­‐FABP	   was	   stable	   during	   HEC,	  
whereas	   during	   AT-­‐HEC	   increased	   basal	   A-­‐FABP	  
reversed	  at	  240	  min	  (Intervention	  effect:	  p<0.05	  in	  
Full	  ANOVA	  and	  LSD	  post-­‐test:	  p<0.05).	  
For	   mRNA	   expressions	   of	   selected	   genes	   during	  
HEC	   and	   AT-­‐HEC	   see	   Table	   3.	   The	   A-­‐FABP	  
expressions	  were	  stable	  during	  both	  clamps	  in	  both	  
groups.	   Higher	   E-­‐FABP	   expressions	   during	   AT-­‐HEC	  
in	   C	   but	   not	   in	   D	   could	   be	   demonstrated	  
(Intervention	  effect:	  p<0.05),	  while	  the	  Time	  factor	  
and	   all	   interactions	   were	   not	   significant.	   The	   A-­‐
FABP/E-­‐FABP	   mRNA	   ratio	   did	   not	   differ	   between	  
HEC	  and	  AT-­‐HEC	   in	  either	  group.	  Similarly,	  PPAR-­‐γ	  
mRNA	   expression	   was	   comparable	   between	  





Figure	  1.	  Plasma	  concentrations	  of	  A-­‐FABP	  during	  interventions:	  a	  HEC	  (○/●)	  and	  SAL	  (∆/▲);	  b	  HEC	  (○/●)	  and	  
AT-­‐HEC	  (□/■).	  The	  empty	  and	  full	  symbols	  with	  error	  bars	  represent	  retransformed	  mean	  values	  with	  their	  95	  
%	   confidence	   intervals	   for	   C	   and	   D	   groups,	   respectively.	   The	   asterisks	   correspond	   to	   significant	   difference	  
between	  the	  basal	  and	  stimulated	  values	  (p<0.05).	  Hashes	  denote	  significant	  difference	  between	  interventions	  
(HEC	  vs.	  SAL	  and	  HEC	  vs.	  AT-­‐HEC,	  respectively)	   in	   individual	  stages	  (p<0.05).	  Embedded	  tables	  summarize	  the	  
significant	  factors	  of	  full	  ANOVA	  model.	  	  	  
	  
	  
C	  (n=12)	   D	  (n=11)	  
Variable	  





















































































Table	  3.	  Relative	  expressions	  of	  A-­‐FABP,	  E-­‐FABP	  and	  PPAR-­‐γ	  mRNA	  in	  subcutaneous	  adipose	  tissue.	  Data	  are	  
means	  (5%-­‐95%	  CI).	  Statistical	  significance	  (in	  bold):	  Group	  effect	  –	  difference	  between	  groups;	  aIntervention	  




Relationship	   of	   A-­‐FABP	   to	   anthropometric	   and	  
metabolic	  parameters	  	  
A-­‐FABP	   plasma	   concentrations	   were	   positively	  
correlated	   with	   its	   expression	   in	   SAT	   (r	   =	   0.59;	  
p<0.01).	  The	  correlation	  analysis	  of	  A-­‐FABP	  and	  E-­‐
FABP	   combined	   for	   both	   groups	   is	   summarized	   in	  
Table	   4.	   Both	   A-­‐FABP	   plasma	   concentrations	   and	  
expressions	   correlated	   positively	   with	   BMI,	   waist	  
circumference,	   fasting	   plasma	   glucose,	   fasting	  
insulin	  and	  negatively	  with	  M;	  additionally,	  positive	  
correlation	  of	  A-­‐FABP	  mRNA	  and	  HbA1c	  was	  found.	  
The	   A-­‐FABP/E-­‐FABP	   mRNA	   ratio	   correlated	   with	  
fasting	   plasma	   glucose	   and	   HbA1c.	   E-­‐FABP	  mRNA	  
expressions	   were	   negatively	   correlated	   with	  
HbA1c,	  relations	  to	  other	  parameters	  of	  metabolic	  
syndrome	  were	  not	  significant.	  
In	   multivariate	   regression,	   which	   reflects	   the	  
weight	  of	  individual	  factors	  without	  contribution	  of	  
other	   factors	   included	   in	   the	   model,	   BMI,	   waist,	  
fasting	   glycaemia,	   insulinaemia	   and	   M	   remained	  
significant	   predictors	   (p<0.05)	   of	   both	   A-­‐FABP	  
plasma	   concentrations	   and	   expression	   (detailed	  
analysis	   in	   Supplementary	   file).	   This	   confirms	   that	  
A-­‐FABP	  is	  closely	  linked	  to	  dysregulation	  of	  glucose	  
metabolism	   and	   insulin	   resistance	   independently	  
of	  obesity	  per	  se.	  
Analyzing	  the	  relation	  between	  PPAR-­‐γ	  mRNA	  and	  
FABPs,	  we	  were	  able	   to	  detect	   significant	  positive	  
correlation	   between	   PPAR-­‐γ	   mRNA	   and	   E-­‐FABP	  
mRNA	   (r	  =	  0.80;	  p<0.001).	  Neither	  plasma	  A-­‐FABP,	  




To	   our	   knowledge,	   this	   is	   the	   first	   clinical	   study	  
analyzing	  A-­‐FABP	  plasma	  concentrations	  in	  parallel	  
with	  its	  expressions	  in	  SAT.	  Showing	  higher	  plasma	  
concentrations	   and	   expression	   of	   A-­‐FABP	   in	  
overweight/obese	   patients	   with	   type	   2	   diabetes	  
compared	   to	   healthy	   subjects,	   our	   findings	   are	   in	  
accordance	  with	  current	  evidence	  on	  circulating	  A-­‐
FABP	   [7-­‐10,	   25].	   In	   addition	   to	   plasma	  
concentrations,	   our	   results	   confirm	   an	   equivalent	  
difference	   in	   A-­‐FABP	   expressions	   between	   the	  
groups	   studied.	   This	   fact	  has	  not	  been	   sufficiently	  
clarified	  in	  previous	  studies	  [11,	  13-­‐15].	  The	  strong	  
positive	   correlation	   of	   plasma	   A-­‐FABP	   with	   its	  
expression	  in	  SAT	  indicates	  that	  SAT	  is	  a	  substantial	  
source	   of	   circulating	   A-­‐FABP.	   The	   contribution	   of	  
other	   fat	   depots	   cannot	   be	   excluded,	   however	  
previous	   studies	   showed	   higher	   or	   comparable	  A-­‐
FABP	   expression	   in	   SAT	   in	   comparison	   to	   visceral	  
adipose	   tissue	   [26,	  27].	  Additionally,	  macrophages	  
might	   also	   play	   a	   role	   in	   whole-­‐body	   A-­‐FABP	  
balance	   [28].	   Their	   contribution	   to	   circulating	   A-­‐
FABP	  levels	  has	  not	  been	  addressed	  in	  our	  study.	  	  
The	   minor	   adipocyte	   isoform	   -­‐	   E-­‐FABP	   revealed	  
higher	   expression	   rates	   in	   healthy	   subjects.	   Here,	  
the	   literature	  evidence	   is	  modest	  and	   inconclusive	  
[11].	   A-­‐FABP/E-­‐FABP	   mRNA	   ratio	   suggested	   by	  
Fisher	   and	   co-­‐workers	   [14]	   as	   a	   summarizing	  
measure	   for	   FABPs	   in	   adipose	   tissue	   was	   3-­‐fold	  
higher	  in	  the	  overweight/obese	  diabetic	  patients.	  It	  
could	   be	   hypothesized	   that	   in	   obesity	   and	   type	   2	  
diabetes,	  the	  E-­‐FABP	  expression	   is	  down-­‐regulated	  
in	   order	   to	   at	   least	   partially	   compensate	   for	  
increase	   in	   A-­‐FABP.	   The	   clarification	   of	   FABPs’	  
regulations	   in	   obesity	   and	   type	   2	   diabetes	   awaits	  
definitely	  further	  studies.	  	  	  
Additionally,	   we	  measured	   relative	   expressions	   of	  
PPAR-­‐γ,	  which	   is	   involved	   in	   regulation	   of	  A-­‐FABP	  
gene	   expression.	   Conversely	   A-­‐FABP	   enhances	  
PPAR-­‐γ	  activity	  [11].The	  studies	  comparing	  PPAR-­‐γ	  
expression	   between	   lean	   and	   obese/type	   2	  
diabetic	   patients	   reveal	   inconsistent	   data	   with	  
reports	   of	   decreased,	   unchanged	   or	   increased	  
PPAR-­‐γ	   expression	   in	   obese	   subjects[29-­‐32].We	  
report	   a	   down-­‐regulation	   of	  PPAR-­‐γ	   expression	   in	  
diabetes.	   We	   were	   not	   able	   to	   show	   any	  
relationship	   of	   PPAR-­‐γ	   expression	   to	   A-­‐FABP	  
plasma	   concentrations	   or	   expressions,	   while	   a	  
positive	  correlation	  between	  PPAR-­‐γ	  mRNA	  and	  E-­‐
FABP	  mRNA	  suggests	  that	  the	  expressions	  of	  PPAR-­‐
γ	   and	   the	  minor	  FABP	   isoform	  are	   closely	   related,	  
at	   least	   in	  SAT.	  Further	   interventional	  studies	  with	  
PPAR-­‐γ	   agonists	   are	   needed	   to	   disclose	   the	  
possible	   causal	   relationship	   suggested	   by	   the	  
finding	   of	   Cabre[25],	   who	   showed	   an	   increase	   in	  
plasma	  A-­‐FABP	  after	  treatment	  with	  rosiglitazone.	  
	  
Another	  important	  finding	  of	  our	  study	  is	  the	  close	  
association	   of	   both	   A-­‐FABP	   plasma	   concentration	  
and	  expression	  not	  only	  with	  measures	  of	  obesity,	  
but	   also	   with	   fasting	   plasma	   glucose,	   insulin	   and	  
insulin	   resistance	   defined	   by	   means	   of	  
hyperinsulinaemic-­‐euglycaemic	   clamp.	  
Additionally,	   the	   A-­‐FABP	   mRNA	   and	   A-­‐FABP/E-­‐
FABP	   mRNA	   ratio	   was	   positively	   correlated	   with	  
HbA1c.	   The	   association	   with	   hyperglycaemia,	  
insulinaemia	   and	   glucose	   disposal	   remained	  
significant	   also	   in	   multivariate	   regression	   analysis	  
suggesting	   that	   the	   relation	   of	   A-­‐FABP	   to	   insulin	  
resistance	   and	   blood	   glucose	   is	   independent	   of	  
obesity.	  
	  
In	   our	   study	   groups,	   acute	   hyperinsulinaemia	  
suppressed	  circulating	  A-­‐FABP	  in	  D	  and	  C,	  while	  no	  
direct	   impact	   on	   A-­‐FABP	   expression	   in	   SAT	   was	  
detected	  in	  either	  group.	  This	  discrepancy	  between	  
changes	  in	  plasma	  and	  expression	  in	  SAT	  implicates	  
a	   role	  of	   another	  A-­‐FABP	   source	   (macrophages	  or	  
other	  fat	  depot)	  in	  the	  response	  to	  insulin.	  
To	  our	  knowledge,	  the	  presented	  study	   is	  also	  the	  
first	  one	  using	   the	   control	   volume	  examination	   to	  
distinguish	  non-­‐specific	  time	  and	  volume	  effect	  on	  
A-­‐FABP	   during	   clamp.	   In	   type	   2	   diabetes,	   the	  
decline	   in	   A-­‐FABP	   during	   hyperinsulinaemia	   is	  
accordance	  with	  a	  recent	  report	  [33].	  Using	  the	  SAL	  
control	   examination,	   during	   which	   no	   changes	  
were	   detected,	   the	   direct	   regulation	   of	   plasma	  A-­‐
FABP	  by	  insulin	  in	  diabetes	  was	  confirmed.	  
Importance	  of	  volume	  control	  examinations	  can	  be	  
even	   better	   demonstrated	   in	   the	   control	   group	  
where	   no	   changes	   during	   hyperinsulinaemia,	   but	  
an	  increase	  in	  plasma	  A-­‐FABP	  during	  saline	  infusion	  
were	   measured.	   Since	   neither	   secretion	  
mechanisms,	  nor	   function	  of	   circulating	  A-­‐FABP	   in	  
vivo	   in	   humans	   are	   elucidated,	   the	   interpretation	  
of	   the	   observation	   during	   SAL	   is	   not	   clear	   –	   we	  
might	  speculate	  on	  effects	  of	  prolonged	  fasting	  or	  
circadian	  rhythm	  on	  plasma	  A-­‐FABP.	  Moreover,	  the	  
stable	  A-­‐FABP	  concentrations	  during	  HEC	  might	  be	  
interpreted	   as	   an	   influence	   of	   insulin	   that	  
prevented	  the	  increase	  in	  A-­‐FABP	  seen	  in	  SAL.	  	  
Recently,	  direct	  regulation	  of	  circulating	  A-­‐FABP	  by	  
insulin	  was	   described	   [33],	   showing	   a	   decrease	   in	  
A-­‐FABP	  also	   in	  healthy	   controls.	   The	  difference	   to	  
our	   study	  may	  be	  explained	  by	   the	  well-­‐described	  
gender	   differences	   in	   A-­‐FABP	   plasma	  
concentrations	  [7-­‐10,	  25].	  The	  higher	  A-­‐FABP	  levels	  
in	   women	   may	   be	   also	   differentially	   regulated	  
compared	   to	   men,	   which	   has	   been	   already	  
demonstrated	  by	  an	  independent	  association	  of	  A-­‐
FABP	   with	   carotid	   intima-­‐media	   thickness	   in	  
women	  but	  not	  in	  men	  [34].	  	  
Expressions	   of	   both	   E-­‐FABP	   and	   PPAR-­‐γ	   in	   SAT	  
were	   not	   affected	   by	   hyperinsulinaemia	   in	   our	  
study	  population.	  
	  
Acute	   ARB	   did	   not	   influence	   the	   parameters	   on	  
insulin	   sensitivity	   in	   either	   group.	   Based	   on	   the	  
pharmacokinetics	   of	   losartan	   and	   its	   active	  
metabolite,	   effective	   circulating	   concentrations	  
during	   the	   clamp	   period	   should	   have	   been	  
achieved.	   However	   the	   plasma	   levels	   may	   not	  
mirror	   effective	   tissue	   concentrations,	   which	   are	  
crucial	   for	   potential	   metabolic	   effects.	   The	   acute	  
ARB	   had	   no	   effect	   on	   glucose	   disposal	   in	   healthy	  
subjects	   [35].	   Clinical	   studies	   using	   long-­‐term	  
administration	   of	   ARBs	   with	   hyperinsulinaemic-­‐
euglycaemic	   clamp	   technique	   reported	   both	  
increase	  [36,	  37]	  and	  no	  changes	  [38,	  39]	  in	  insulin	  
sensitivity	  in	  insulin	  resistant	  subjects.	  	  
We	   could	   demonstrate	   distinct	   effects	   of	   ARB	   on	  
FABPs:	   in	   healthy	   subjects	   acute	   ARB	   stimulated	  
basal	   A-­‐FABP	   plasma	   concentrations,	   which	   were	  
reversed	   by	   insulin	   during	   clamp.	   In	   type	   2	  
diabetes,	   the	   stimulatory	  effect	  of	  ARB	  on	  plasma	  
A-­‐FABP	  was	   independent	   of	   hyperinsulinaemia.	   In	  
healthy	   subject,	   the	   expression	  of	  E-­‐FABP	   but	   not	  
A-­‐FABP	  in	  SAT	  was	  also	  stimulated	  after	  acute	  ARB.	  
In	   type	   2	   diabetes,	   regulation	  A-­‐FABP	   and	  E-­‐FABP	  
expressions	   by	   acute	   ARB	   has	   not	   been	   proven.	  
The	  different	  changes	   in	  plasma	  and	  expression	   in	  
SAT	   suggest	   an	   involvement	   of	   another	   A-­‐FABP	  
source	  in	  the	  response	  to	  ARB.	  	  
Considering	   the	   potential	   PPAR-­‐γ	   activation	   by	  
sartans	  [20,	  21],	  long-­‐term	  exposure	  to	  ARB	  in	  vivo,	  
as	   well	   as	   experimental	   models	   have	   to	   be	  
evaluated	  in	  order	  to	  confirm	  the	  suggested	  effects	  
of	  ARB	  on	  A-­‐FABP.	  Plausibility	  of	  such	  a	  hypothesis	  
has	  been	  recently	  supported	  by	  an	  observation	  of	  a	  
cross-­‐sectional	   study	   with	   patients	   submitted	   for	  
coronary	   angiograms	   [40].	   Those	   patients	   treated	  
with	   ACEIs	   or	   angiotensin	   II	   type	   1	   receptor	  
blockers	   revealed	   significantly	   higher	   A-­‐FABP	  
levels.	  	  	  
	  
Even	  if	  the	  limited	  sample	  size	  of	  our	  study	  has	  to	  
be	   considered	   by	   interpretation,	   our	   results	   in	   a	  
cohort	   of	   overweight/obese	   men	   with	   type	   2	  
diabetes	   and	   healthy	   controls	   bring	   new	  
knowledge	  on	  in	  vivo	  regulations	  of	  plasma	  A-­‐FABP	  
and	  expressions	  of	  A-­‐FABP	  and	  E-­‐FABP	  in	  SAT.	  
In	   summary,	   our	   study	   has	   documented	   that	  
circulating	   A-­‐FABP	   as	   well	   as	   its	   expression	   in	  
subcutaneous	   adipose	   tissue	   are	   closely	   and	  
independently	  related	  to	  obesity,	  insulin	  resistance	  
and	   hyperglycaemia	   and	   suggested	   the	  
subcutaneous	   adipose	   tissue	   as	   a	   substantial	  
source	   of	   circulating	   A-­‐FABP	   in	   humans.	  
Hyperinsulinaemia	   suppresses	   plasma	   A-­‐FABP	   but	  
does	   not	   influence	   its	   expression.	   Acute	   ARB	  
stimulates	   basal	   A-­‐FABP	   plasma	   concentrations	  
without	  any	  effect	  on	  its	  expression.	  Despite	  of	  the	  
close	   associations	   found	   in	   the	   present	   study,	   a	  
causal	   relationship	   between	   A-­‐FABP	   and	  
development	   of	   insulin	   resistance	   cannot	   be	  
drawn.	   Therefore	   further	   studies	   are	   needed	   to	  
determine	   whether	   A-­‐FABP	   only	   represents	   a	  
biomarker	   of	   the	   developing	   insulin	   resistance	  
and/or	  type	  2	  diabetes	  or	  whether	  it	  is	  one	  of	  their	  




This	   study	   was	   supported	   by	   grant	   of	   the	   Health	  








A-­‐FABP	  mRNA	   E-­‐FABP	  mRNA	  
A-­‐FABP	  /	  
E-­‐FABP	  mRNA	  
BMI	   0.85***	   0.65***	   0.03	   0.40	  
Waist	  
circumference	  
0.86***	   0.56**	   -­‐0.07	   0.34	  
Fasting	  glucose	   0.46*	   0.73***	   -­‐0.35	   0.74***	  
Fasting	  insulin	   0.50*	   0.48*	   -­‐0.11	   0.39	  
Fasting	  NEFA	   0.13	   0.17	   -­‐0.09	   -­‐0.33	  
Fasting	  TG	   0.19	   0.24	   -­‐0.05	   0.23	  
Total	  cholesterol	   -­‐0.05	   0.21	   -­‐0.08	   -­‐0.21	  
HDL-­‐cholesterol	   -­‐0.06	   -­‐0.28	   0.04	   -­‐0.10	  
LDL-­‐cholesterol	   -­‐0.10	   0.17	   -­‐0.18	   0.22	  
HbA1c	   0.08	   0.46*	   -­‐0.56*	   0.65**	  
M	   -­‐0.64**	   -­‐0.53**	   0.18	   -­‐0.35	  
	  
Table	  4.	  The	  relationships	  (Spearman`s	  correlation	  coefficients)	  between	  A-­‐FABP,	  E-­‐FABP	  and	  selected	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Effect of telmisartan on selected adipokines, insulin sensitivity,
and substrate utilization during insulin-stimulated conditions in
patients with metabolic syndrome and impaired fasting glucose
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Objective: Telmisartan improves glucose and lipid metabolism in rodents. This study evaluated the effect
of telmisartan on insulin sensitivity, substrate utilization, selected plasma adipokines and their
expressions in subcutaneous adipose tissue (SAT) in metabolic syndrome.
Design and methods: Twelve patients with impaired fasting glucose completed the double-blind,
randomized, crossover trial. Patients received telmisartan (160 mg/day) or placebo for 3 weeks and
vice versa with a 2-week washout period. At the end of each period, a hyperinsulinemic euglycemic
clamp (HEC) combined with indirect calorimetry was performed. During HEC (0, 30, and 120 min),
plasma levels of adipokines were measured and a needle biopsy (0 and 30 min) of SAT was performed.
Results: Fasting plasma glucose was lower after telmisartan compared with placebo (P!0.05). There
were no differences in insulin sensitivity and substrate utilization. We found no differences in basal
plasma adiponectin, resistin and tumour necrosis factor a (TNFa), but an increase was found in basal
leptin, after telmisartan treatment. Insulin-stimulated plasma adiponectin (P!0.05), leptin and
resistin (P!0.001) were increased, whereas TNFa was decreased (P!0.05) after telmisartan
treatment. Expression of resistin, but not adiponectin, TNFa and leptin was increased after telmisartan
treatment.
Conclusions: Despite the decrease in fasting plasma glucose, telmisartan does not improve insulin
sensitivity and substrate utilization. Telmisartan increases plasma leptin as well as insulin-stimulated
plasma adiponectin, leptin and resistin, and decreases plasma TNFa during HEC. Changes in plasma
adipokines cannot be explained by their expressions in SAT. The changes in plasma adipokines might
be involved in the metabolic effects of telmisartan in metabolic syndrome.
European Journal of Endocrinology 163 573–583Introduction
Several large intervention trials have demonstrated
that angiotensin II type 1 receptor antagonists (ARBs)
reduce the incidence of new-onset diabetes by 20–25%
(1, 2). The protective effects of ARBs during the
development of diabetes are probably independent of
their antihypertensive properties (3, 4).
However, the mechanisms underlying the effect of
ARBs on glucose metabolism are not fully understood.
Experimental evidence has been accumulated that
insulin resistance (IR) may be improved by interrupting
renin–angiotensin system (5). All ARBs have been
shown to improve insulin sensitivity in experimental
and in vitro studies through multiple mechanisms,
including increase in muscle blood flow, decreased
sympathetic nervous activity, enhanced insulinndocrinologysignalling and adipose-tissue remodelling (5, 6). Angio-
tensin II inhibits pre-adipocyte differentiation into
mature adipocytes, which impairs the fat cells’ ability
to store fat (6). This in turn results in accumulation of
fats in the liver, the skeletal muscle, and the pancreas,
which worsens IR. Impaired fat cells produce excessive
amounts of pro-inflammatory cytokines (tumour necrosis
factor a (TNFa), interleukin (IL) 6, resistin, and others),
whereas the insulin-sensitizing cytokines such as
adiponectin are reduced (6). Blocking the angiotensin II
receptor with ARBs decreases the adipocyte size (7),
promotes differentiation of pre-adipocytes to mature
adipocytes, and prevents the ectopic fat accumulation
(8). In addition, ARBs may alter the adipokine profile.
It has been shown that ARBs increase the adipo-
nectin protein content in isolated adipocytes (9).
Increases in plasma adiponectin concentrations afterDOI: 10.1530/EJE-10-0436
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Systolic blood pressure (mmHg) 133.0G12.0
Diastolic blood pressure (mmHg) 91.3G10.0
HbAlc (%) 3.86G0.44
Total cholesterol (mmol/l) 5.51G1.1
HDL cholesterol (mmol/l) 0.99G0.12
LDL cholesterol (mmol/l) 3.2G1.22
Serum triglycerides (mmol/l) 2.71G1.4
Plasma glucose 120 min, OGTT (mmol/l) 7.6G1.8
Fasting plasma glucose (mmol/l) 6.1G0.43
OGTT, oral glucose tolerance test.
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subjects by some (10–12), but not all, groups (13).
The actual knowledge of the physiological roles of
resistin and TNFa in altering muscle glucose and lipid
metabolism is more controversial, but each has been
shown to directly impair insulin signalling and
consequently insulin-stimulated glucose uptake in
muscles (14). The role of resistin is less understood. It
is implicated in IR in rats but probably not in human
subjects. Moreover, other adipokines (such as adipo-
nectin and leptin) in physiological concentrations are
insulin sparing as they stimulate b oxidation of fatty
acids in skeletal muscle. The effect of ARBs on
adipokines in vivo in human subjects has not been
systematically evaluated until now.
Human studies investigating the effect of ARBs on
insulin sensitivity are not conclusive. Most of the
randomized, placebo-controlled or head-to-head studies
using the hyperinsulinemic euglycemic clamp (HEC)
technique for estimation of insulin sensitivity have
found no significant effect of ARBs on insulin action in
human subjects (5, 15, 16). However, there is evidence
that certain ARBs have a further effect on insulin
sensitivity, which is mediated through peroxisome
proliferator-activated receptor g (PPARG). PPARG is a
nuclear transcription factor which triggers the expression
of multiple genes involved in glucose and lipid metabolism
(17). Not all ARBs have been shown to bind to PPARG; the
strongest activity has been seen with telmisartan (4, 17,
18). Based on rodent experiments, it can be hypothesized
that the activation of PPARG may be involved in the ability
of telmisartan to increase muscle fatty acid oxidation and
energy expenditure (EE) (19). The in vivo effects of
telmisartan on insulin sensitivity and substrate oxidation
estimated by HEC combined with indirect calorimetry
have not been studied in human subjects so far.
The aim of our study was to evaluate in vivo effects of
telmisartan on insulin sensitivity, substrate utilization,
basal and insulin-stimulated plasma concentrations of
selected adipokines and their expressions in subcu-
taneous adipose tissue (SAT) in patients with impaired
fasting glucose and metabolic syndrome.Subjects and methods
Subjects
We enrolled 12 male patients with metabolic syndrome
defined according to the NCEP-ATPIII criteria, revised in
2005 (20). Impaired fasting glucose was an obligate
criterion for enrolment in the study. One patient had
both impaired fasting glucose and impaired glucose
tolerance (confirmed by an oral glucose tolerance test).
Only male subjects participated in the study in order to
exclude variability in insulin sensitivity in women
according to menstrual cycle and childbearing potential
and with respect to sexual dimorphism of adipokines.
Characteristics of study group are shown in Table 1.www.eje-online.orgPatients enrolled in the study were treatment-naive with
regard to oral antidiabetic medication. Antihypertensive
treatment was adjusted during the 4-week run-in period
as follows: angiotensin-converting enzyme and ARB
treatment had been stopped and replaced by metabolic
neutral calcium channel blockers. The dose of concomi-
tant calcium channel blocker (if required) was stable
during the whole study duration. None of the patients
had their dietary intake of salt or protein restricted.
Patients with overt diabetes (diagnosed by an oral glucose
tolerance test), acute or chronic inflammatory, or other
major organ diseases were excluded from the study.
All subjects gave their informed consent with the
study protocol that had been reviewed and approved
by the local ethics committee. The study was performed
in accordance with the Helsinki Declaration and
Title 45, Code of Federal Regulations, Part 46,
Protection of Human Subjects. The EudraCT number
2006-000490-29 had been issued for our Sponsor’s
Protocol Code No. 1, 1.1.2006.Study protocol
The study was a randomized, placebo-controlled,
double-blind, crossover trial consisting of two treatment
periods. After a 4-week run-in period, the subjects were
randomly assigned to receive telmisartan 160 mg daily
(Micardis 80 mg; Boehringer Ingelheim Pharma GmbH,
Ingelheim am Rhein, Germany) or placebo for 3 weeks.
After a 2-week washout period, the medication was
changed and continued for another 3 weeks. Randomiz-
ation was performed by standard procedure. The code
was not broken until all data were entered into a
database, which was locked for editing. Drug compli-
ance was assessed by the effect on blood pressure as well
as by the study drug accountability. Patients were
instructed to adhere to their ordinary lifestyle and avoid
changes in food intake, alcohol consumption and
exercise during the whole study duration.
At the end of both 3-week periods of treatment with
telmisartan or placebo, all patients underwent a 2 h
HEC combined with indirect calorimetry and adipose
tissue biopsies.
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were examined on an outpatient basis after an 8–10 h
overnight fast with only tap water allowed ad libitum.
The HEC, lasting 2 h, was conducted as described earlier
(21). Briefly, a Teflon cannula (VenflonViggo, Helsing-
borg, Sweden) was inserted into left antecubital vein for
infusion of all test substances. A second cannula was
inserted in a retrograde manner into a wrist vein of the
same hand for blood sampling, and a hand was placed
in a heated (65 8C) box to achieve venous blood
arterialization. A stepwise primed-continuous infusion
(1 mU/kg per min of Actrapid HM; NovoNordisk,
Copenhagen, Denmark) was administered to acutely
raise and maintain the plasma concentration of insulin
at 75 mU/ml. Plasma glucose concentrations during the
clamp were maintained at 5.0 mmol/l by continuous
infusion of 15% glucose. To prevent hypokalemia
during insulin infusion, potassium chloride was added
to 15% glucose infusion (30 mmol KCl/l of glucose).
Arterialized blood plasma glucose concentration was
determined every 5–10 min. Before the clamp, fasting
plasma glucose levels had been checked, and at
concentration lower than 6.0 mmol/l, the clamp
procedure was started. No glucose was infused until
plasma glucose had declined to the clamp-target level.
Needle biopsy of abdominal SAT Needle biopsy of
abdominal SAT was performed before (0 min) and
30 min into the clamp. Under local anaesthesia (1%
trimecain in a field block pattern), an incision (3–4 mm)
was made through the skin at the lower abdomen, and a
subcutaneous fat specimen (300 mg) was obtained by
needle aspiration. The samples were washed in 0.9%
natrium chloride solution, immediately frozen by liquid
nitrogen, and stored at K80 8C until used for RNA
extraction.
Indirect calorimetry Substrate utilization and EE were
assessed by indirect calorimetry (22). Gas exchange
measurements were performed during a 45 min basal
period before starting the insulin infusion and during





5 0-GGT TCA ATG GCT T
Leptin NM_000230 Hleptin-F:




5 0-CTA TCT GGG AGG G
Resistin AY207314 HRETN-F:
5 0-ATA AGC AGC ATT G
Cyclophilin XM_090070 HCLPNa-F:
5 0-CAA ATG CTG GAC Cplastic ventilated hood was placed over the subject’s
head and made airtight around the neck. A slight
negative pressure was maintained in the hood to avoid
loss of expired air. A constant fraction of air flowing out
of the hood was automatically collected for analysis.
Airflow and O2 and CO2 concentrations in expired and
inspired air were measured by a continuous open-
circuit system (metabolic monitor VMAX; Sensor
Medics, Anaheim, CA, USA). Blood samples were
taken at 0 and 120 min of the clamp study to assess
plasma levels of selected adipokines and blood urea
nitrogen. Urine was collected i) during the night before
the study (basal) and ii) during the clamp study
(0–120 min) to measure the urinary nitrogen excretion
to be able to calculate protein oxidation.
Measurements of blood pressure were performed as
three time readings at the beginning of the clamp, after
30 min resting position and during the clamp.Analytical methods
Plasma concentrations of glucose were measured
using the Beckman analyzer (Beckman Instruments
Inc., Fullerton, CA, USA) by glucose oxidase method.
Immunoreactive insulin (IRI) was determined by RIA
method using an IMMUNOTECH Insulin IRMA kit
(IMMUNOTECH a.s, Prague, Czech Republic) with
analytical sensitivity of 0.5 mIU/ml; intra- and inter-
assay coefficients of variation (CV) were below or equal
to 4.3 and 3.4% respectively. HbAlc was measured by
HPLC method (Tosoh HLC-723 G7; Tosoh Corporation,
Tokyo, Japan). This analyzer uses a non-porous ion
exchanger that separates HbAlc from other fractions. The
method was calibrated to IFCC reference procedure (23).
Plasma concentrations of TNFa were measured by
immunoassay (Human TNFa UltraSensitive RIA kit;
BioSource International, Camarillo, CA, USA; the
detection limit was !0.09 pg/ml, and intra- and
inter-assay CV were 5.3–6.7 and 8.2–9.7% respect-
ively); plasma concentrations of resistin were measured
by Human Resistin ELISA kit (BioVendor Laboratory
Medicine Inc., Brno, Czech Republic; the detection limite samples.
Reverse primer
GT TTG C-3 0
HACRP30-R:
5 0-TCA TCC CAA GCT GAT TCT G-3 0
TT TGC T-3 0
Hleptin-R:
5 0-GCT AAG AGG GGA CAA GAC A-3 0
GT CTT C-3 0
HTNFa-R:
5 0-TTG GGA AGG TTG GAT GTT C-30
GC CTG G-3 0
HRETN-R:
5 0-TGG CAG TGA CAT GTG GTC T-3 0
CA ACA CA-30
HCLPNa-R:
































































Figure 1 Effect of telmisartan treatment on fasting immunoreactive
insulin and plasma glucose. The circles with error bars symbolize
the group means with their 95% confidence intervals: telmisartan
(T; full circles) and placebo (P; open circles). For the fasting
immunoreactive insulin (A), the significance of the factors was as
follows: telmisartan: FZ7.6, PZ0.0224; subject (inter-individual
variability): FZ7.6, PZ0.0029. For the fasting plasma glucose (B),
the significance of the factors was as follows: telmisartan: FZ8.8,
PZ0.0129; subject (inter-individual variability): FZ3, PZ0.0392.
Statistical significance: *P!0.05.
576 P Wohl and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163was 0.033 ng/ml, and intra- and inter-assay CV were
2.8–3.4 and 5.1–6.9% respectively); plasma concen-
trations of leptin were measured by Human Leptin
ELISA kit (BioVendor Laboratory Medicine Inc.; the
detection limit was 0.5 ng/ml, and intra- and inter-
assay CV were 3–7.5 and 3.2–9.2% respectively);
plasma concentrations of adiponectin were measured
by Human Adiponectin ELISA kit (BioVendor Labora-
tory Medicine Inc.; the detection limit was 210 ng/ml,
and intra- and inter-assay CV were 6.4–7 and 7.3–8.2%
respectively), all according to the manufacturer’s
instructions.Table 3 Substrate utilization before (basal) and during hy
treatment with telmisartan or placebo.
Placebo
Basal In
REE (kcal/24 h) 1729G386 182
RQ 0.79G0.03* 0.8
Chox (mg/kg per min) 0.69G0.42* 1.3
Fox (mg/kg per min) 0.77G0.2* 0.4
Prox (mg/kg per min) 0.87G0.3* 0.4
REE, resting energy expenditure; RQ, respiratory quotient; Chox,
Differences between telmisartan and placebo were not statistical
www.eje-online.orgExpression of adipokines was analysed by the real-
time PCR method using the following protocol:
i) The RNA was isolated from the liquid nitrogen frozen
biopsy of the human fat tissue using the RNeasy Lipid
Tissue Mini kit and QIAzolLysis Reagent (Qiagen). The
starting amount of 100 mg tissue was excised from
the biopsy and homogenized in 1 ml of QIAzolLysis
Reagent (guanidine thiocyanate–phenol solution) for
2 min. From the homogenate, the RNA was isolated
by extraction on silica gel-based column, according
to the kit handbook. Possible contamination of
RNA with genomic DNA remains was taken out by
DNase digestion (RNase-free DNase Set; Qiagen).
This step is supposed to prevent any significant
DNA amplification, e.g. by gel electrophoresis.
ii) The cDNA was synthesized using a recombinant
Omniscript Reverse Transcriptase (Qiagen), ribonu-
clease inhibitor from human placenta (Sigma) and
(dT)16oligonucleotides.
iii) The real-time PCR procedure itself had been carried
out on the DNA Engine Opticon 2 System (MJ
Research, Waltham, MA, USA). HotStarTaq DNA
polymerase and SYBR Green fluorescent dye
(QuantiTec SYBR Green PCR kit; Qiagen) were used
for the RT-PCR. To eliminate the influence of primer
dimers, negative controls were used. As the reference
gene, human cyclophilin was used; there is no
evidence of insulin or ARB influence on cyclophilin.
Primers used for RT-PCR are given in Table 2.
iv) The data were processed by Q-gene 96 software
(Institute of Biochemistry and Genetics, University of
Basel, Basel, Switzerland).
Calculations
Insulin action was estimated as the glucose disposal (M)
and metabolic clearance rate (MCR) of glucose calcu-
lated during the last 20 min of the clamp after correction
for changes in glucose pool size (21). Calculations of
substrate oxidation were made using standard equations
(22). Urinary urea excretion during the clamp was
corrected for changes in urea pool size (24). Non-
oxidative glucose disposal (NEOX) was calculated by








glucose oxidation; Fox, lipid oxidation; Prox, protein oxidation.
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The data are expressed as meansGS.E.M. unless indicated
otherwise. Steady-state periods of both clamps were
compared using Wilcoxon’s paired test. The differences
between time courses of both clamps were evaluated
by a repeated-measures ANOVA model, including
the following factors and interactions: effect of telmi-
sartan treatment (placebo versus telmisartan) and effect
of hyperinsulinemia (clamp induced) as the within
factors, subject factor (represents the inter-individual
variability of subjects) and telmisartan!hyperinsuli-
nemia interaction. The last term indicated whether the
shapes of the time profiles for telmisartan and placebo
were different or not. The differences between subgroups
were evaluated using least significant difference (LSD)
multiple comparisons. The statistical significance
P!0.05 was chosen for both ANOVA testing and
multiple comparisons. Owing to a non-Gaussian data
distribution in all dependent variables, the data under-
went power transformations (directly in the ANOVA
model) to attain distributional symmetry and a constant
variance in the data as well as in residuals. The non-
homogeneities were detected using residual diagnostics.
The experimental points with absolute values
of studentized residual (after data transformation) O3
were excluded from the analysis. The fraction of such
points never exceeded 5% of the total number. Stat-
graphics Centurion v. XV statistical software (Stadtpoint
























































































Figure 2 Effects of telmisartan treatment and the clamp-induced
hyperinsulinemia on TNFa. The circles with error bars symbolize
the group means with their 95% confidence intervals: telmisartan
(T; full circles) and placebo (P; open circles). (A and D) The effect of
telmisartan is illustrated; (B and E) the effect of clamp-induced
hyperinsulinemia is demonstrated; (C and F) the interactions
between telmisartan and hyperinsulinemia are shown. For the
PTNFa (A–C), the significance of the factors and interactions was
as follows: telmisartan: FZ4.8, PZ0.0328; subject (inter-individual
variability): FZ2.7, PZ0.0085; hyperinsulinemia: FZ0.1,
PZ0.8698; telmisartan!hyperinsulinemia: FZ0.4, PZ0.6489.
For the ExTNFa (D–F), the significance of the factors and
interactions was as follows: telmisartan: FZ3.9, PZ0.0591; subject
(inter-individual variability): FZ1.8, PZ0.1122; hyperinsulinemia:
FZ92, P!0.0001; telmisartan!hyperinsulinemia: FZ0.2,
PZ0.6406. Statistical significance: *P!0.05, ***P!0.001.Results
Telmisartan compared to placebo treatment induced no
differences in body weight (89.8G19 vs 89.8G18 kg)
but resulted in lower blood pressure, both systolic
(126G10 vs 135G12 mmHg; P!0.03) and diastolic
(81G10 vs 90G10 mmHg; P!0.01), lower fasting
plasma glucose (P!0.05) and higher fasting IRI
(P!0.05). Fasting plasma glucose and IRI are shown
in Fig. 1. Insulin action was estimated by HEC combined
with indirect calorimetry. The clamps performed after
treatment with telmisartan versus placebo were com-
parable in terms of the mean plasma glucose concen-
trations (5.29G1.9 vs 5.34G0.3 mmol/l), CV of
glucose (2.89G1.9 vs 2.56G1.2%) and mean IRI
levels. Insulin action was comparable after telmisartan
and placebo. MCR (4.15G1.0 vs 4.08G1.9 ml/kg per
min), M (4.4G1.8 vs 3.9G1.7 mg/kg per min) and
NEOX (4.1G1.9 vs 3.0G2.3 mg/kg per min) did not
differ between telmisartan and placebo. Similarly, EE,
glucose and fat oxidations have not been statistically
different comparing telmisartan and placebo (Table 3).
No significant effect of telmisartan on basal plasma
concentrations of selected adipokines has been detected,
except of basal plasma leptin that has significantly
increased after telmisartan treatment (Fig. 2C–5C ).Plasma concentrations of TNFa during HEC are shown
in Fig. 2A–C. The ANOVA model indicated (Fig. 2A) a
significant decrease in plasma TNFa in telmisartan as
compared to placebo (telmisartan; P!0.05), whereas no
significant hyperinsulinemia effect (Fig. 2B) or interaction
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Figure 3 Effects of telmisartan treatment and the clamp-induced
hyperinsulinemia on adiponectin. The circles with error bars
symbolize the group means with their 95% confidence intervals:
telmisartan (T; full circles) and placebo (P; open circles). (A and D)
The effect of telmisartan is illustrated; (B and E) the effect of clamp-
induced hyperinsulinemia is demonstrated; (C and F) the
interactions between telmisartan and hyperinsulinemia are shown.
For the plasma adiponectin (A–C), the significance of the factors
and interactions was as follows: telmisartan: FZ0.9, PZ0.3618;
subject (inter-individual variability): FZ14.9, P!0.0001; hyperin-
sulinemia: FZ0.5, PZ0.6317; telmisartan!hyperinsulinemia:
FZ3.3, PZ0.0429. For the adiponectin expression (D–F), the
significance of the factors and interactions was as follows:
telmisartan: FZ1.3, PZ0.2709; subject (inter-individual variability):
FZ6.4, P!0.0001; hyperinsulinemia: FZ3.2, PZ0.0846; telmi-
sartan!hyperinsulinemia: FZ0.2, PZ0.6756. Statistical signi-
ficance: CP!0.05 for differences between telmisartan and placebo
in individual stages of HEC.
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expression of TNFa in subcutaneous adipose abdominal
tissue. In this study, the effect of clamp-induced hyper-
insulinemia (Fig. 2E) has been found to be significant
(P!0.001) and no telmisartan effect was detectedwww.eje-online.org(Fig. 2D), implicating the suppression of TNFa expression
by insulin, which is not influenced by telmisartan.
Plasma adiponectin concentrations are shown in
Fig. 3A–C. Plasma adiponectin concentrations have
shown a different time course during insulin-stimulated
conditions in telmisartan and placebo (Fig. 3C), docu-
mented by the significant telmisartan!hyperinsuline-
mia interaction (P!0.05). A significant increase in
plasma adiponectin was detected by LSD multiple
comparisons in 120 min of HEC (0 vs 120 min;
P!0.05) after telmisartan treatment, whereas no
changes were seen after placebo treatment. Relative
expressions of adiponectin were comparable during
both treatment periods and clamps, and both telmi-
sartan and hyperinsulinemia factors were not signi-
ficant (Fig. 3D–F).
Figure 4A–C shows plasma leptin concentrations.
Both basal and insulin-stimulated plasma leptin concen-
trations were significantly increased after telmisartan
treatment compared to placebo treatment (telmisartan
effect; P!0.001), while telmisartan did not alter the
relative expressions of leptin in SAT. There was a signi-
ficant decrease in leptin expressions during insulin-
stimulated conditions (HEC), as documented by the
significant hyperinsulinemia factor (P!0.001; Fig. 4E).
Plasma concentrations and tissue expressions of
resistin are shown in Fig. 5. The telmisartan treatment
resulted in an increase in plasma resistin concentrations,
as documented by a significant telmisartan factor
(P!0.01; Fig. 5A). The multiple comparisons tests
were in accordance with ANOVA testing. Figure 5B
shows the increasing plasma concentrations of resistin
during insulin-stimulated conditions (HEC), as indicated
by significant hyperinsulinemia factor (P!0.001),
whereas the effect of insulin on resistin expression was
opposite (Fig. 5E). There is a significant decrease in
resistin expressions during HEC in both telmisartan and
placebo (hyperinsulinemia factorP!0.01; Fig. 5E and F)
without differences between telmisartan and placebo.Discussion
This short-term placebo-controlled crossover study
demonstrate, in accordance with other studies (25),
that telmisartan decreases the fasting plasma glucose
and blood pressure, whereas the insulin sensitivity
assessed by hyperinsulinemic clamp technique did not
change after telmisartan treatment in our study
population. Thus, the decrease in blood glucose
cannot be explained by the improvement in insulin
sensitivity. However, we have found an increase in
basal plasma IRI and this finding could partly account
for the decrease in plasma glucose concentrations.
Additionally, we have not found any significant effect
of telmisartan on the substrate utilization.
There are still controversial results dealing with the
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Figure 4 Effects of telmisartan treatment and the clamp-induced
hyperinsulinemia on leptin. The circles with error bars symbolize the
group means with their 95% confidence intervals: telmisartan (T; full
circles) and placebo (P; open circles). (A and D) The effect of
telmisartan is illustrated; (B and E) the effect of clamp-induced
hyperinsulinemia is demonstrated; (C and F) the interactions
between telmisartan and hyperinsulinemia are shown. For the
plasma leptin (A–C), the significance of the factors and interactions
was as follows: telmisartan: FZ7.6, PZ0.0079; subject (inter-
individual variability): FZ35.4, P!0.0001; hyperinsulinemia:
FZ0.1, PZ0.9256; telmisartan!hyperinsulinemia: FZ0.6,
PZ0.5664. For the leptin expressions (D–F), the significance
of the factors and interactions was as follows: telmisartan: FZ2.4,
PZ0.133; subject (inter-individual variability): FZ4.2, PZ0.0012;
hyperinsulinemia: FZ56.8, P!0.0001; telmisartan!hyperinsuli-
nemia: FZ1, PZ0.3357. Statistical significance: **P!0.01 for
differences between initial and current state; ***P!0.001 for
differences between 0 and 30 min. CP!0.05 for differences
between telmisartan and placebo in individual stages of HEC.
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study, we did not find any significant changes in insulin
sensitivity after acute administration of losartan in
healthy subjects (28). Clinical trials with long-term
administration of ARBs (other than telmisartan) usingthe HEC technique for estimation of insulin sensitivity
reported both an increase (29, 30) and no effect (5, 15,
16, 31, 32) of ARBs on glucose disposal in insulin-
resistant subjects. Telmisartan is considered to be a
partial PPARG agonist, and there is experimental
evidence that it has specific metabolic advantages
(18). Although telmisartan has gained much attention
as one of the most metabolically potent ARB
compounds, there are virtually no clinical studies
evaluating the effect of telmisartan on insulin sensitivity
and substrate utilization using the clamp technique
combined with indirect calorimetry. However, a recent
study evaluating the long-term effect of telmisartan on
insulin sensitivity suggests that the magnitude of
PPARG stimulation by telmisartan may be modest
compared with thiazolidindiones (26). On the other
hand, some metabolic effects of telmisartan could be
mediated independently of PPARG (33). In addition, in a
rat model of metabolic syndrome, it increases EE and
protects against dietary-induced obesity (19).
In our study, we have failed to show a statistically
significant effect of telmisartan on insulin sensitivity
and substrate utilization, but our results might be
influenced by the short period of the study and the small
number of patients included. To the best of our
knowledge, no previous study has carefully evaluated
the effect of telmisartan on insulin sensitivity and
substrate utilization using the clamp technique com-
bined with indirect calorimetry in human subjects.
The homeostasis model assessment (HOMA) index
has been used in most of them (25, 34) and, thus, our
study may be the first of its kind.
Insulin secretion has not been carefully evaluated in
our study, but the improvement in blood glucose level
after telmisartan treatment could be related to the
improvement of b-cell function. It has been shown in
experimental animals that treatment with telmisartan
reduces oxidative stress and protects against islet b-cell
damage and dysfunction (35).
The main finding of the present study is the
significant short-term effect of telmisartan on adipokine
production during insulin-stimulated conditions. Adi-
ponectin, leptin and resistin plasma concentrations
increased, whereas a decrease in TNFa had been found
after telmisartan treatment. We also found an increase
in basal leptin concentrations. The changes in plasma
adipokines could not be directly explained by changes in
their expressions in SAT. The short-term effect of
telmisartan on adipokines during clamp-induced hyper-
insulinemia has not been investigated up to this time;
only the fasting plasma concentrations or adipose tissue
expressions have been reported in the literature so far.Tumour necrosis factor a
In the present study, the telmisartan treatment
was followed by a decrease in plasma TNFa concen-
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Figure 5 Effects of telmisartan treatment and the clamp-induced
hyperinsulinemia on resistin. The circles with error bars symbolize
the group means with their 95% confidence intervals: telmisartan
(T; full circles) and placebo (P; open circles). (A and D) The effect of
telmisartan is illustrated; (B and E) the effect of clamp-induced
hyperinsulinemia is demonstrated; (C and F) the interactions
between telmisartan and hyperinsulinemia are shown. For the
p-resistin (A–C), the significance of the factors and interactions was
as follows: telmisartan: FZ9, PZ0.0043; subject (inter-individual
variability): FZ40.9, P!0.0001; hyperinsulinemia: FZ18.1,
P!0.0001; telmisartan!hyperinsulinemia: FZ1.6, PZ0.2033. For
the Ex-resistin (D–F), the significance of the factors and interactions
was as follows: telmisartan: FZ1.9, PZ0.1753; subject (inter-
individual variability): FZ2.3, PZ0.0382; hyperinsulinemia:
FZ10.5, PZ0.0029; telmisartan!hyperinsulinemia: FZ0.3,
PZ0.6116. Statistical significances: **P!0.01, ***P!0.001 for
differencesbetween initial andcurrent state;CCP!0.01 fordifferences
between telmisartan and placebo in individual stages of HEC.
580 P Wohl and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163The expressions of TNFa in subcutaneous fat declined
during hyperinsulinemia but were not affected by
telmisartan treatment. The results are in agreement
with the decrease in fasting TNFa in plasma reportedwww.eje-online.orgafter 8-month telmisartan treatment in hypertensive
patients after stent implantation (36) and after 6- and
12-month administration of telmisartan in patients
with metabolic syndrome (34). In addition, pro-
inflammatory properties of TNFa could be attenuated
by telmisartan. Inhibition of TNFa-induced IL6
expression in vascular smooth muscle cells has been
reported after telmisartan treatment (37).Adiponectin
In our study, telmisartan increased the plasma adipo-
nectin concentrations during insulin-stimulated con-
ditions, whereas the expressions of adiponectin in
subcutaneous fat were not changed. In contrast to
some (13, 27, 36, 38–40), but not all (25), previous
studies, we failed to observe any stimulatory effect of
telmisartan on basal plasma adiponectin concentrations.
Only the trend of an increase has been found in our
insulin-resistant subjects. The results could implicate the
stronger metabolic effect of telmisartan during hyper-
insulinemia compared to basal (pre-prandial) conditions.
ARBs-induced activation of PPARG is advocated (9).
However, recently, it has been showed in 3T3-L1
adipocytes that telmisartan may stimulate adiponectin
gene transcription independent of PPARG (33).Leptin
An overall increase in circulating leptin after the
telmisartan treatment was documented in the present
study. Telmisartan had no significant effect on leptin
expressions in SAT, but the expression declined during
hyperinsulinemia. The decline was independent of
telmisartan treatment. In the literature, both increase
(25) and decrease (34) in fasting leptin concentrations
have been reported after long-term administration of
telmisartan in hypertensive and type 2 diabetic patients.
Moreover, the lack of effect of telmisartan on circulating
leptin has been found as well (26). Telmisartan-induced
increase in plasma concentrations of leptin might
attenuate body weight gain by reduced food intake
with HOMA-IR improvement (25). The effect of
telmisartan on leptin increase could not be clarified
within the context of metabolic processes in this short
time study (25). However, in accordance with some
authors, we have found a telmisartan-induced increase
in leptin and this finding remains to be explained.Resistin
To our surprise, in this study, an unexpected increase in
plasma resistin concentration was found during hyper-
insulinemia after telmisartan administration, which is a
novel observation in vivo. In contrast, Derosa et al. (40)
demonstrated a decrease in plasma resistin after the
telmisartan treatment in type 2 diabetic patients.
Telmisartan and selected adipokines 581EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163However, only fasting concentrations were assessed, the
treatment period was much longer (6 and 12 months),
and the subjects were treated also by rosiglitazone (40). In
our study, resistin expression decreased during the
hyperinsulinemia independent of telmisartan treatment.
The changes in the plasma concentrations and tissue
expressions of adiponectin, TNFa, leptin and resistin
during hyperinsulinemia are discordant, and the
expressions in SAT cannot explain the changes in
circulating adipokines. This finding implicates the role
of other sources of circulating adipokines – other fat
depots or non-adipose sources (e.g. stromal vascular
fraction of adipose tissue, macrophages or endo-
thelium), which have not been addressed in the present
study. However, the differences in the timing of blood
sampling and biopsies should be considered as well.
In addition, the reduction in adipose tissue mass
through weight loss in association with exercise can
increase adiponectin concentrations and lower TNFa
and IL6 levels in plasma, whereas drugs such as
thiazolinediones increase endogenous adiponectin pro-
duction (34, 41). Body weight and exercise had been
kept stable throughout our study, and the patients were
not treated with oral hypoglycemic agents. Thus, we
can exclude the interference of these confounding
factors with effect of telmisartan.
The present study also allowed us to roughly examine
the in vivo effect of insulin on adipokines and their
expressions comparing the fasting values with insulin-
stimulated conditions during clamp (hyperinsulinemia
factor). Only a few studies have investigated the effect of
insulin in vivo in human subjects. It has been shown by
Westerbacka et al. (42) that insulin per se could increase
the expression of a number of cytokines involved in insulin
sensitivity in adipose tissue, including adiponectin and
TNFa. We did not find any significant effect of acute in vivo
hyperinsulinemia induced by clamp on plasma adiponec-
tin, leptin or TNFa (the hyperinsulinemia factor was not
significant). On the other hand, the increase in plasma
resistin concentrations has been confirmed. An increase
in plasma resistin during clamp-induced hyperinsuline-
mia was reported in our previous study in healthy subjects
(28). Similarly, Heilbronn et al. (43) found an increase in
serum resistin concentrations in response to supraphy-
siological doses of insulin (164G5 mIU/l) in obese
subjects with and without diabetes. Contrary to the result
of Westerbacka et al. (42), the expressions of adiponectin
did not change, and expressions of TNFa, leptin and
resistin were even suppressed by acute hyperinsulinemia.
However, the present crossover study was not designed to
assess the acute effect of insulin on adipokines. The control
infusion to match the volume expansion during clamp
was not included. Furthermore, the biopsies were taken at
30 min of clamp – very early after starting the insulin
infusion, which is also an important limitation factor
of our study.
The major limitations of our study are small number
of subjects and/or short study duration. We did notmeasure peripheral blood flow. We could not exclude
that the effect of telmisartan has been mediated through
the blood flow improvement as well as blood pressure
improvement both directly and indirectly. Moreover, we
were not able to measure tissue protein levels of
adipokines, and thus we could not exclude that
telmisartan controls post-transcriptional rather than
transcriptional regulation. However, we found the effect
of telmisartan on the parameters mentioned earlier in
spite of the short treatment period. The timing of biopsy
at 30 min before equilibrium status had been achieved
might have an impact on the results while assessing
the acute effect of insulin when euglycemia had not
been reached. The biopsy should have been more
appropriately performed during the last part of the
clamp after 90 min.
We can conclude that, in patients with metabolic
syndrome with impaired fasting glucose, a short-term
treatment with telmisartan surprisingly increases
plasma adiponectin, leptin and resistin concentrations,
and decreases plasma TNFa levels. These results also
implicate that the effect of telmisartan could be
important during hyperinsulinemia, and this is the first
study dealing with positive effect of telmisartan on
plasma adipokines during hyperinsulinemia in patients
with impaired fasting glucose. The changes in plasma
concentrations of adipokines cannot be explained by
their expressions in SAT. The results support the
hypothesis that the changes in selected plasma adipo-
kines might be involved in the beneficial metabolic effects
of telmisartan in patients with metabolic syndrome.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This work was supported by the Health Ministry of the Czech Republic
(NR 9359-3, NS/10528-3 and MZO 00023001).Acknowledgements
The authors acknowledge the skilful technical assistance of Ms Dana
Lapesova and Ms Dagmar Sisakova.References
1 Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U,
Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O,
Lindholm LH, Nieminen MS, Omvik P, Oparil S & Wedel H.
Cardiovascular morbidity and mortality in the losartan interven-
tion for endpoint reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet 2002 359 995–1003.
(doi:10.1016/S0140-6736(02)08089-3)
2 Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L,
Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B
& Zanchetti A. Outcomes in hypertensive patients at highwww.eje-online.org
582 P Wohl and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163cardiovascular risk treated with regimens based on valsartan
or amlodipine: the VALUE randomised trial. Lancet 2004 363
2022–2031. (doi:10.1016/S0140-6736(04)16451-9)
3 Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI & Cooper ME.
Why blockade of the renin–angiotensin system reduces the
incidence of new-onset diabetes. Journal of Hypertension 2005 23
463–473. (doi:10.1097/01.hjh.0000160198.05416.72)
4 Schupp M, Janke J, Clasen R, Unger T & Kintscher U. Angiotensin
type 1 receptor blockers induce peroxisome proliferator-activated
receptor-gamma activity. Circulation 2004 109 2054–2057.
(doi:10.1161/01.CIR.0000127955.36250.65)
5 Scheen AJ. Prevention of type 2 diabetes mellitus through
inhibition of the renin–angiotensin system. Drugs 2004 64
2537–2565. (doi:10.2165/00003495-200464220-00004)
6 Staels B & Fruchart JC. Therapeutic roles of peroxisome proliferator-
activated receptor agonists. Diabetes 2005 54 2460–2470. (doi:10.
2337/diabetes.54.8.2460)
7 Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N,
Murakami H, Higashiura K & Shimamoto K. Blockade of
the renin–angiotensin system decreases adipocyte size with
improvement in insulin sensitivity. Journal of Hypertension 2004
22 1977–1982. (doi:10.1097/00004872-200410000-00021)
8 Sharma AM, Janke J, Gorzelniak K, Engeli S & Luft FC. Angiotensin
blockade prevents type 2 diabetes by formation of fat cells.Hypertension
2002 40 609–611. (doi:10.1161/01.HYP.0000036448.44066.53)
9 Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M,
Krikov M, Thone-Reineke C, Unger T & Kintscher U. PPARgamma-
activating angiotensin type-1 receptor blockers induce adiponec-
tin. Hypertension 2005 46 137–143. (doi:10.1161/01.HYP.
0000168046.19884.6a)
10 Komiya N, Hirose H, Kawabe H, Itoh H & Saito I. Effects of
telmisartan therapy on metabolic profiles and serum high
molecular weight (HMW)-adiponectin level in Japanese male
hypertensive subjects with abdominal obesity. Journal of Athero-
sclerosis and Thrombosis 2009 16 137–142.
11 Makita S, Abiko A, Naganuma Y, Moriai Y & Nakamura M. Effects
of telmisartan on adiponectin levels and body weight in
hypertensive patients with glucose intolerance. Metabolism 2008
57 1473–1478. (doi:10.1016/j.metabol.2008.05.019)
12 Levy BI. How to explain the differences between renin–angiotensin
system modulators. American Journal of Hypertension 2005 9S
134S–141S. (doi:10.1016/j.amjhyper.2005.05.005)
13 Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R,
Schulze F, Silberhorn E & Boger RH. Telmisartan improves insulin
sensitivity in nondiabetic patients with essential hypertension.
Metabolism 2006 55 1159–1164. (doi:10.1016/j.metabol.2006.
04.013)
14 Dyck DJ, Heigenhauser GJ & Bruce CR. The role of adipokines as
regulators of skeletal muscle fatty acid metabolism and insulin
sensitivity. Acta Physiologica 2006 186 5–16. (doi:10.1111/j.
1748-1716.2005.01502.x)
15 Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L,
Svensson MK, Ahlstrom H, Strom C, Lonn L, Ojbrandt K,
Johansson L & Lind L. Hydrochlorothiazide, but not Candesartan,
aggravates insulin resistance and causes visceral and hepatic fat
accumulation: the mechanisms for the diabetes preventing
effect of Candesartan (MEDICA) Study. Hypertension 2008 52
1030–1037. (doi:10.1161/HYPERTENSIONAHA.108.119404)
16 Fogari R, Derosa G, Zoppi A, Lazzari P, Corradi L, Preti P &
Mugellini A. Effect of delapril/manidipine vs olmesartan/
hydrochlorothiazide combination on insulin sensitivity and
fibrinogen in obese hypertensive patients. Internal Medicine 2008
47 361–366. (doi:10.2169/internalmedicine.47.0449)
17 Kurtz TW. New treatment strategies for patients with hypertension
and insulin resistance. American Journal of Medicine 2006 119
S24–S30. (doi:10.1016/j.amjmed.2006.01.011)
18 Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P,
Pravenec M, Qi N, Wang J, Avery MA & Kurtz TW. Identification of
telmisartan as a unique angiotensin II receptor antagonist with
selective PPARgamma-modulating activity. Hypertension 2004 43
993–1002. (doi:10.1161/01.HYP.0000123072.34629.57)www.eje-online.org19 Sugimoto K, Kazdova L, Qi NR, Hyakukoku M, Kren V,
Simakova M, Zidek V, Kurtz TW & Pravenec M. Telmisartan
increases fatty acid oxidation in skeletal muscle through a
peroxisome proliferator-activated receptor-gamma dependent
pathway. Journal of Hypertension 2008 26 1209–1215. (doi:10.
1097/HJH.0b013e3282f9b58a)
20 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH,
Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr,
Spertus JA & Costa F. Diagnosis and management of the metabolic
syndrome: an American Heart Association/National Heart, Lung,
and Blood Institute Scientific Statement. Circulation 2005 112
2735–2752. (doi:10.1161/CIRCULATIONAHA.105.169404)
21 DeFronzo RA, Tobin JD & Andres R. Glucose clamp technique: a
method for quantifying insulin secretion and resistance. American
Journal of Physiology 1979 237 E214–E223.
22 Ferrannini E. The theoretical bases of indirect calorimetry: a
review. Metabolism 1988 37 287–301. (doi:10.1016/0026-
0495(88)90110-2)
23 Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR,
Miedema K, Myers GL, Reinauer H, Sacks DB & Weykamp CW.
Global standardization of glycated hemoglobin measurement: the
position of the IFCC Working Group. Clinical Chemistry and
Laboratory Medicine 2007 45 1077–1080. (doi:10.1515/CCLM.
2007.246)
24 Tappy L, Owen OE & Boden G. Effect of hyperinsulinemia on
urea pool size and substrate oxidation rates. Diabetes 1988 37
1212–1216. (doi:10.2337/diabetes.37.9.1212)
25 Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S,
Yamazaki Y, Urakaze M, Hachiya H, Takata M, Senda S,
Iwata M, Satoh A, Sasaoka T, Ak ND, Temaru R & Kobayashi M.
Telmisartan reduced blood pressure and HOMA-IR with increasing
plasma leptin level in hypertensive and type 2 diabetic patients.
Diabetes Research and Clinical Practice 2007 77 210–214. (doi:10.
1016/j.diabres.2006.11.014)
26 Nakamura T, Kawachi K, Saito Y, Saito T, Morishita K, Hoshino J,
Hosoi T, Iwasaki T, Ohyama Y & Kurabayashi M. Effects of ARB or
ACE-inhibitor administration on plasma levels of aldosterone and
adiponectin in hypertension. International Heart Journal 2009 50
501–512. (doi:10.1536/ihj.50.501)
27 Negro R & Hassan H. The effects of telmisartan and amlodipine on
metabolic parameters and blood pressure in type 2 diabetic,
hypertensive patients. Journal of the Renin-Angiotensin-Aldosterone
System 2006 7 243–246. (doi:10.3317/jraas.2006.045)
28 Krusinova E, Klementova M, Kopecky J, Wohl P, Kazdova L,
Mlejnek P, Pravenec M, Hill M & Pelikanova T. Effect of acute
hyperinsulinaemia with and without angiotensin II type 1
receptor blockade on resistin and adiponectin concentrations
and expressions in healthy subjects. European Journal of
Endocrinology 2007 157 443–449. (doi:10.1530/EJE-07-0034)
29 Paolisso G, Tagliamonte MR, Gambardella A, Manzella D,
Gualdiero P, Varricchio G, Verza M & Varricchio M. Losartan
mediated improvement in insulin action is mainly due to an
increase in non-oxidative glucose metabolism and blood flow
in insulin-resistant hypertensive patients. Journal of Human
Hypertension 1997 11 307–312. (doi:10.1038/sj.jhh.1000434)
30 Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M,
Moniwa N, Yoshida D & Shimamoto K. Blockade of the renin–
angiotensin system increases adiponectin concentrations in
patients with essential hypertension. Hypertension 2003 42
76–81. (doi:10.1161/01.HYP.0000078490.59735.6E)
31 Fogari R, Zoppi A, Preti P, Fogari E, Malamani G & Mugellini A.
Differential effects of ACE-inhibition and angiotensin II antagon-
ism on fibrinolysis and insulin sensitivity in hypertensive
postmenopausal women. American Journal of Hypertension 2001
14 921–926. (doi:10.1016/S0895-7061(01)02140-9)
32 Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, Deyneli O,
Haklar G & Akalin S. Effects of ACE inhibition and AT1-
receptor antagonism on endothelial function and insulin
sensitivity in essential hypertensive patients. Journal of the Renin-
Angiotensin-Aldosterone System 2003 4 197–203. (doi:10.3317/
jraas.2003.032)
Telmisartan and selected adipokines 583EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 16333 Moriuchi A, Yamasaki H, Shimamura M, Kita A, Kuwahara H,
Fujishima K, Satoh T, Fukushima K, Fukushima T, Hayakawa T,
Mizuguchi H, Nagayama Y, Abiru N, Kawasaki E & Eguchi K.
Induction of human adiponectin gene transcription by telmisar-
tan, angiotensin receptor blocker, independently on PPAR-gamma
activation. Biochemical and Biophysical Research Communications
2007 356 1024–1030. (doi:10.1016/j.bbrc.2007.03.084)
34 Derosa G, Cicero AF, D’Angelo A, Ragonesi PD, Ciccarelli L,
Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A &
Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic
patients treated with rosiglitazone: effects on insulin-resistance,
leptin and tumor necrosis factor-alpha. Hypertension Research
2006 29 849–856. (doi:10.1291/hypres.29.849)
35 Hasegawa G, Fukui M, Hosoda H, Asano M, Harusato I, Tanaka M,
Shiraishi E, Senmaru T, Sakabe K, Yamasaki M, Kitawaki J,
Fujinami A, Ohta M, Obayashi H & Nakamura N. Telmisartan, an
angiotensin II type 1 receptor blocker, prevents the development of
diabetes in male Spontaneously Diabetic Torii rats. European
Journal of Pharmacology 2009 605 164–169. (doi:10.1016/
j.ejphar.2009.01.001)
36 Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY &
Lim DS. Comparison of effects of telmisartan and valsartan on
late lumen loss and inflammatory markers after sirolimus-eluting
stent implantation in hypertensive patients. American Journal of
Cardiology 2007 100 1625–1629. (doi:10.1016/j.amjcard.2007.
06.068)
37 Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H,
Yano K, Takeda K & Sunagawa K. Inhibition of tumor necrosis factor-
alpha-induced interleukin-6 expression by telmisartan through
cross-talk of peroxisome proliferator-activated receptor-gamma with
nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Hypertension 2009 53 798–804. (doi:10.1161/HYPERTENSIO-
NAHA.108.126656)38 Nagel JM, Tietz AB, Goke B & Parhofer KG. The effect of telmisartan
on glucose and lipid metabolism in nondiabetic, insulin-resistant
subjects. Metabolism 2006 55 1149–1154. (doi:10.1016/
j.metabol.2006.04.011)
39 Mori Y, Itoh Y & Tajima N. Telmisartan improves lipid metabolism
and adiponectin production but does not affect glycemic control in
hypertensive patients with type 2 diabetes. Advances in Therapy
2007 24 146–153. (doi:10.1007/BF02850002)
40 Derosa G, Fogari E, D’Angelo A, Cicero AF, Salvadeo SA,
Ragonesi PD, Ferrari I, Gravina A, Fassi R & Fogari R. Metabolic
effects of telmisartan and irbesartan in type 2 diabetic patients
with metabolic syndrome treated with rosiglitazone. Journal of
Clinical Pharmacy and Therapeutics 2007 32 261–268. (doi:10.
1111/j.1365-2710.2007.00820.x)
41 Ronti T, Lupattelli G & Mannarino E. The endocrine function
of adipose tissue: an update. Clinical Endocrinology 2006 64
355–365. (doi:10.1111/j.1365-2265.2006.02474.x)
42 Westerbacka J, Corner A, Kannisto K, Kolak M, Makkonen J,
Korsheninnikova E, Nyman T, Hamsten A, Fisher RM &
Yki-Jarvinen H. Acute in vivo effects of insulin on gene expression
in adipose tissue in insulin-resistant and insulin-sensitive subjects.
Diabetologia 2006 49 132–140. (doi:10.1007/s00125-005-
0075-5)
43 Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E
& Smith SR. Relationship between serum resistin concentrations
and insulin resistance in nonobese, obese, and obese diabetic
subjects. Journal of Clinical Endocrinology and Metabolism 2004 89
1844–1848. (doi:10.1210/jc.2003-031410)
Received 14 June 2010






Selected	  adipokines	  -­‐	  plasma	  concentrations	  and	  adipose	  tissue	  expressions	  























Diabetes	  Center	  of	  Institute	  for	  Clinical	  and	  Experimental	  Medicine,	  Prague,	  Czech	  Republic	  	  
2
Institute	  of	  Physiology,	  Academy	  of	  Sciences	  of	  the	  Czech	  Republic,	  Prague,	  Czech	  Republic	  	  
3




Physiological	  Research	  –	  IF	  1.505	  
Physiol	  Res.	  2010;	  59(1):89-­‐96	  
 
 
PHYSIOLOGICAL RESEARCH • ISSN 0862-8408 (print) • ISSN 1802-9973 (online)                              
© 2010 Institute of Physiology v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic 
Fax +420 241 062 164, e-mail: physres@biomed.cas.cz, www.biomed.cas.cz/physiolres 
 
Physiol. Res. 59: 89-96, 2010 
 
 
Selected Adipokines - Plasma Concentrations and Adipose Tissue 
Expressions during 24-Hour Lipid Infusion in Healthy Men 
 
 
J. KOPECKÝ, Jr1, E. KRUŠINOVÁ1, M. KLEMENTOVÁ1, L. KAZDOVÁ1,  
P. MLEJNEK2, M. PRAVENEC2, M. HILL3, T. PELIKÁNOVÁ1 
 
1Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 
2Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic, 
3Institute of Endocrinology, Prague, Czech Republic 
 
Received December 4, 2007 
Accepted February 12, 2009 




Our aim was to assess the reaction of TNFα, resistin, leptin and 
adiponectin to lipid infusion. Eight healthy subjects underwent a 
24-hour lasting infusion of lipid emulsion. Plasma concentrations 
and expressions of selected cytokines in subcutaneous fat were 
measured. TNFα plasma concentration did not change during the 
first 4 hours of hypertriglyceridemia, but a significant increase 
after 24 hours was detected (p<0.001 for 0; 30; 240 min vs. 
24 h). Plasma concentration of resistin significantly increased at 
30 min of infusion and remained elevated (p<0.01 for 0 min vs. 
30; 240 min; p<0.001 for 0 min vs. 24 h). Plasma concentrations 
of leptin and adiponectin did not show any significant changes. 
Although the expression of resistin in the subcutaneous adipose 
tissue tended to increase, the change was not significant. 
Expressions of TNFα, leptin and adiponectin were unaffected. In 
conclusions, our results indicate that acutely induced 
hyperlipidemia could influence the secretion of TNFα and resistin. 
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 Hyperlipidemia of either dietary origin or caused 
by lipid infusion promotes insulin resistance (IR) in 
rodents and humans (Boden and Chen 1995, Griffin et al. 
1999, Leung et al. 2004). Pathophysiological 
mechanisms underlying the association between the 
elevation of plasma non-esterified fatty acids (NEFA) and 
IR have not been fully determined – for the evidence of 
interplay between glucose and NEFA see review by 
Cahová et al. (2007). Some of the pathways that lead to 
IR might include following cytokines produced by 
adipose tissue: TNFα, resistin, leptin and adiponectin.  
 TNFα is a promising candidate for mediating IR, 
although most of it comes from other sources than 
adipose tissue (Fain et al. 2003, Gabriely et al. 2002). 
Plasma concentrations of TNFα are related to obesity and 
IR (Hotamisligil et al. 1993). TNFα knock-out mice are 
more insulin sensitive than controls and there is the 
evidence that TNFα may directly interfere with insulin 
signaling by inhibiting phosphorylation of the insulin 
receptor (Hotamisligil et al. 1994). It impairs human 
preadipocyte differentiation, in mature adipocytes it 
decreases the activity of markers of differentiation, 
(Petruschke and Hauner 1993) and increases their 
apoptosis (Prins et al. 1997). TNFα has been shown to 
mediate NEFA-induced IR in 3T3-L1 adipocytes in vitro 
(Nguyen et al. 2005)  
 Resistin was named for its putative role in 
mediating IR in obesity. In mice, it is a product of an 
adipocyte-specific gene whose expression is down-
regulated by rosiglitazone (Arner 2005). Serum levels of 
resistin were found to be elevated in rodent models of 
obesity and diabetes implicating a dysregulation of 
resistin in these disease states (Arner 2005). In humans, 
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however, the role of resistin is unclear. The human 
homologue of resistin is only expressed at very low levels 
in adipose tissue and in circulating monocytes, and the 
reports on its function are controversial (Janke et al. 
2002, Savage et al. 2001). 
 Leptin is a cytokine secreted mainly by adipose 
tissue, its circulating levels are in direct proportion to 
adipose tissue mass and nutritional status (Maffei et al. 
1995). Therefore, it is a likely candidate for mediating 
insulin sensitivity. It influences the human energy 
balance by altering energy intake and expenditure 
(Hukshorn and Saris 2004). It was shown in experimental 
animals that leptin infusion could prevent IR induced by 
acute lipid infusion (Dube et al. 2007).  
 Consistent inverse association between 
adiponectin and IR as well as the pro-inflammatory state 
has been established (Nedvídková et al. 2005). Several 
mechanisms of its metabolic effects have been described 
(Kadowaki et al. 2006, Whitehead et al. 2006): induction 
of glucose uptake and NEFA oxidation in muscle, 
increased insulin sensitivity and NEFA oxidation and 
reduced glucose output and NEFA influx in liver.  
 Our aim was to assess the reaction of TNFα, 
resistin, leptin and adiponectin to lipid infusion. We have 
evaulated both the plasma concentrations and expression 
of their genes in the abdominal subcutaneous adipose 
tissue in healthy humans. 
 
Subjects and methods 
 
Subjects 
 We examined eight young healthy males. All of 
them were euthyroid and none had a concomitant disease. 
They were not taking any drugs, and none had a family 
history of diabetes. Clinical characteristics are in Table 1. 
The study was conducted after approval by local ethics 
committee. Informed consent was obtained from all the 
individuals after the purpose, nature, and potential risks 
of the study had been explained. 
 
Experimental protocol 
 The subjects were instructed to adhere to their 
ordinary lifestyle, to avoid changes in food intake, 
alcohol consumption, and vigorous exercise on the day 
before examination. They were examined after overnight 
fasting with only tap water allowed ad libitum. The study 
always started between 7:45-8:00 AM. Subjects were 
excluded from the study if the weight change was more 
than 3 kg in 6 months. 
 
Table 1. Characteristics of the study group.  
 
n 8 
Age (years) 25.8±3.7 
Weight (kg) 83.4±4.7 
Body mass index (kg.m-2)  25±1.7 
Waist circumference (cm) 88.5±5.0 
Fasting blood glucose (mmol.l-1) 4.35±0.7 
Blood glucose at 120 min of OGTT (mmol.l-1) 4.55±0.7 
Fasting IRI (mIU.l-1) 4.50±2.85
HbA1c (%) - according to IFCC 2.58±0.61
Albuminuria (μg.min-1) 2.52±2.6 
Serum creatinine (μmol.l-1) 87±10.5 





Data are expressed as mean ± SD (IFCC, International 
Federation of Clinical Chemistry and Laboratory Medicine). 
 
 
 A 24-h infusion of lipid emulsion (Intralipid 
20 %; Fresenius Kabi AB, Uppsala, Sweden) was 
administered through teflon cannula in the antecubital 
vein. Intralipid 20 % contained soya oil 200 g, egg 
lecithin 12 g and glycerol 22 g per 1 liter. The speed was 
set to 125 ml.h-1 for the first 4 h, and then until the 24th 
hour to a constant rate that was calculated to achieve a 
total dose of 3 g of fat.kg body weight-1.d-1 This two-step 
setting of infusion was used to achieve both maximum 
effect and to stay within the clinically allowed 
boundaries. Thirty minutes before blood sampling a 
second cannula was inserted retrogradely into a wrist vein 
for blood collection. To assess the plasma levels of 
selected adipokines, blood samples were taken at 0 min, 
30 min, 240 min and 24 h of the infusion. Thirty minutes 
before taking each sample the hand was placed in a 
heated (65 ºC) box in order to achieve venous blood 
arterialization. Needle biopsy of abdominal subcutaneous 
adipose tissue was performed before (0 min), and at the 
4th and 24th hour of the lipid infusion. Under local 
anesthesia (1 % trimecain in a field block pattern) an 
incision (3-4 mm) was made through the skin at the lower 
abdomen and a subcutaneous fat specimen (200 mg) was 
obtained by needle (Braunüle MT, no.4; B. Braun, 
Melsungen, Germany) aspiration. Different place and 
incision was used each time, but the same depth in the 
adipose tissue mass when performing the needle 
aspiration was attempted. The samples were washed in 
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NaCl 0.9 % solution, immediately frozen by liquid 






Plasma glucose concentrations were measured on 
a Beckman analyzer (Beckman Instruments Inc, Fullerton, 
CA, USA) using the glucose oxidase method. Hemoglobin 
A1c was measured by fully automated analyzer Tosoh 
HLC-723 G7 (Tosoh Corporation, Tokyo, Japan). Method 
was calibrated to IFCC reference procedure (Mosca et al. 
2007). Immunoreactive insulin (IRI) was determined by 
radioimmunoassay (Insulin IRMA kit, IMMUNOTECH 
as, Prague, Czech Republic). Plasma concentrations of 
NEFA were estimated by Free fatty acids, Half-micro test 
(Roche Diagnostics GmbH, Penzberg, Germany), whereas 
plasma concentrations of triglycerides (TG) by enzymatic 
assay (BIO-LA-TEST, PLIVA-Lachema, Brno, Czech 
Republic). 
 
Adipokine assessment in plasma  
Plasma concentrations of TNFα were measured 
by immunoassay (Human TNF-α UltraSensitive; 
BioSource Int., Camarillo, CA, USA) and the detection 
limit was <0.09 pg/ml, intra-assay and inter-assay 
coefficients of variation (CV) of 5.3 to 6.7 % and 8.2 to 
9.7 %, respectively). Plasma concentrations of resistin 
were determined using a Human Resistin ELISA kit 
(BioVendor Lab. Med. Inc., Brno, Czech Republic) the 
detection limit was 0.033 ng/ml, intra-assay and inter-assay 
CV of 2.8 to 3.4 % and 5.1 to 6.9 %, respectively. Pplasma 
concentrations of leptin were measured by a Human Leptin 
ELISA kit (BioVendor Lab. Med. Inc., Brno, Czech 
Republic), the detection limit was 0.5 ng/ml, intra-assay 
and inter-assay CV of 3 to 7.5 % and 3.2 to 9.2 %, 
respectively. Plasma concentrations of adiponectin were 
determined using a Human Adiponectin ELISA kit 
(BioVendor Lab. Med. Inc., Brno, Czech Republic) the 
detection limit was 210 ng/ml, intra-assay and inter-assay 
CV of 6.4 to 7 % and 7.3 to 8.2 %, respectively (all 
according to manufacturers instructions). 
 
Assessment of expressions in adipose tissue  
Expression of each adipokine was analyzed by the 
real-time PCR method. Subcutaneous adipose tissue 
(100 mg) was excised from the biopsy, and homogenized 
in 1 ml of a QIAzol Lysis Reagent (Guanidin Thiocyanate 
– Phenol solution) for 2 min. The RNA was isolated from 
the liquid nitrogen frozen biopsy using the RNeasy Lipid 
Tissue Mini Kit (QIAGEN, Valencia, CA, USA) and 
QIAzol Lysis Reagent (QIAGEN, Valencia, CA, USA). 
Possible contamination of RNA with genomic DNA 
remains was taken off by DNase digestion (RNase-free 
DNase Set; QIAGEN, Valencia, CA, USA). The cDNA 
was synthesized using a recombinant Omniscript Reverse 
Transcriptase (QIAGEN, Valencia, CA, USA), 
Ribonuclease Inhibitor from human placenta (SIGMA, St. 
Louis, MO, USA), and (dT)16 oligonucleotides. 
 The real-time PCR procedure itself has been 
carried out on the DNA Engine Opticon 2 System (MJ 
Research, Waltham, MA, USA). HotStar Taq DNA 
polymerase and SYBR Green fluorescent dye (QuantiTec 
SYBR Green PCR Kit, QIAGEN, Valencia, CA, USA) 
were used for the RT-PCR reaction. To eliminate the 
influence of primer dimmers, negative controls were used. 
The human gene cyclophilin was used as a reference. 
Primers used are shown in Table 2. The data were 
processed by Q-gene 96 software.  
 
Statistical analysis 
 The time profile was evaluated using a repeated 
measures ANOVA model consisting of the time and 
subject factors. To evaluate the differences between basal 
values and individual stages of the time profile, the 
ANOVA testing was followed by least significant 
difference multiple comparisons. A probability level of 
p<0.05 was considered as statistically significant in all 
statistical tests. Due to non-Gaussian data distribution in 
most of the dependent variables, these data underwent a 
power transformation to attain distributional symmetry and 
constant variance. Non-homogeneities were detected using 
residual diagnostics. The experimental points showing 
absolute values of studentized residuals greater than 3 were 
excluded from the analysis. With the exception of serum 
leptin levels (6.3 %), the proportions of such data never 
exceed 5 % of the total number. Statistical software 
Statgraphics Plus v. 5.1 from Manugistics (Rockville, MD, 




 Our primary goal was to assess the reaction of 
selected adipokines to acute lipid infusion and the 
following results were obtained. TNFα plasma 
concentration did not change during the first 4 h of 
hypertriglyceridaemia, but a significant increase after 24 h 
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was detected (p<0.001 for 0; 30; 240 min vs. 24 h; Fig. 1a). 
The expression of TNFα in subcutaneous adipose tissue 
did not change (Fig. 2a). Plasma concentration of resistin 
significantly increased at 30 min of infusion and remained 
elevated throughout the 24 h (p<0.01 for 0 min vs. 30; 240 
min; p<0.001 for 0 min vs. 24 h; Fig. 1b). The expression 
of resistin in the subcutaneous adipose tissue tended to 
increase, but the change was not significant (Fig. 2b). 
Plasma concentrations of leptin and adiponectin (Fig. 1c-d) 
did not show any significant changes and their expressions 
were not significantly altered.  
 To validate the effectiveness of lipid infusion, 




forward primer reverse primer 
Adiponectin XM_290602 HACRP30-F:  
5´-GGT TCA ATG GCT TGT TTG C -3´ 
HACRP30-R:  
5´-TCA TCC CAA GCT GAT TCT G-3´ 
Leptin NM_000230 Hleptin-F:  
5´-CCC TAA GCC TCC TTT TGC T-3´ 
Hleptin-R:  




5´-CTA TCT GGG AGG GGT CTT C-3´ 
HTNFa-R:  
5´-TTG GGA AGG TTG GAT GTT C -3´ 
Resistin AY207314 HRETN-F:  
5´-ATA AGC AGC ATT GGC CTG G-3´ 
HRETN-R:  
5´-TGG CAG TGA CAT GTG GTC T-3´ 
Cyclophilin XM_090070 HCLPNa-F: 
5´-CAA ATG CTG GAC CCA ACA CA -3´
HCLPNa-R: 






Fig. 1a-d. Plasma levels of selected adipokines during 24-hour lipid infusion. The bars with error bars represent re-transformed means 
with their 95 % confidence intervals. F in the embedded tables represents Fisher’s statistics for individual factors. R2 (squared 
correlation coefficient of the linear model) symbolize the proportion of the total variability in the dependent variable, which is explained 
by the ANOVA model. Asterisks symbolize significant differences between individual stages of the time profiles and basal values (** for 
p<0.01, *** for p<0.001) as detected by least significant difference multiple comparisons. 
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plasma levels of TG, NEFA, glucose and IRI were 
monitored. TG increased almost 8-fold and NEFA about 
3.5-fold in the 4th hour and they remained elevated until 
the end of infusion at more than 3-fold and 2-fold, 
respectively (Figs 3a and 3b). Blood glucose was stable 
throughout the 24 h (Fig. 3c). After initial modest rise, 
IRI concentrations were also stable (Fig. 3d). Cytokine 
plasma concentrations did not correlate with IRI 




 We have characterized the plasma levels of 
adipose tissue cytokines and their expression in adipose 
tissue during pharmacologically-induced hyperlipidemia. 
This was achieved by an intravenous lipid infusion, in 
which the effectiveness in rise of plasma TG and NEFA 
was verified. We have decided not to use heparin infusion 
alongside because heparin as a co-factor of a lipoprotein 
lipase would decrease plasma TG concentrations and 
 
 
Fig. 2a,b. Expressions of selected adipokines in subcutaneous abdominal adipose tissue during 24-hour lipid infusion. The bars with 
error bars represent re-transformed means with their 95 % confidence intervals (expression of selected cytokine related to expression 





Fig. 3a-d. Concentrations of serum triglycerides (●), non-esterified free fatty acids (NEFA, □), blood glucose (◊) and immunoreactive 
insulin (IRI,▲) during the 24-hour lipid infusion. Data are shown as means with their 95 % confidence intervals. 
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increase plasma NEFA concentrations, which was not our 
aim. It could also add further bias through possible 
unknown effects. Since heparin was used in some further 
cited experiments (Garcia-Lorda et al. 2003, Nisoli et al. 
2000, Yang et al. 2005), this sole fact could be the reason 
for differences in results obtained. 
 Our finding of an increase in TNFα plasma 
concentration during lipid infusion is novel. It is partly in 
accordance with the report of Nisoli et al. (2000) who 
found the increase in TNFα gene expression in 
subcutaneous gluteal fat tissue after a 5-h intralipid/ 
heparin infusion. In our results, the expressions in 
adipose tissue showed only a tendency to increase but not 
a significant rise. This can be explained by the 
differences in expressions in different fat depots. Both in 
human (Fain et al. 2003) and rodent (Gabriely et al. 
2002) studies, it has been reported that production of both 
of resistin and TNFα is much higher in visceral than in 
subcutaneous fat. Moreover, most of the free circulating 
TNFα comes from circulating monocytes and significant 
amounts of resistin, although originally reported as 
adipocyte-specific (Kim et al. 2001), might be of the 
same source (Savage et al. 2001).  
 During lipid infusion, plasma concentrations of 
resistin have increased significantly. This is in 
accordance with the reports from animal models (Yang et 
al. 2005) where intralipid/heparin infusion induced 
hepatic and peripheral IR and was associated with 
elevated plasma resistin levels. In human, it is a novel 
observation. Since the increase in expression of resistin 
mRNA in subcutaneous adipose tissue was not 
significant, we can conclude that this adipocyte depot is 
not responsible for its increased plasma concentration. 
 Plasma concentration of leptin did not show any 
significant changes and its expression was not 
significantly altered. Although most studies have not 
shown direct effect of lipid infusion on leptin, as when 
consistent release from adipose tissue during lipid 
without heparin infusion was reported (Samra et al. 
1998), some other results were also obtained: no change 
in plasma levels together with increase in leptin RNA 
expression in adipocytes in gluteal region during lipid 
and heparin infusion (Nisoli et al. 2000) and modest 
decline of its plasma levels during lipid and heparin 
infusion (Garcia-Lorda et al. 2003). 
 Response of adiponectin to acute lipid load was 
also not statistically significant. The same result of 
unchanged plasma concentrations was observed during 
intralipid/heparin infusion (Krzyzanowska et al. 2007).  
 Lipid infusion resulting in a subsequent increase 
in NEFA plasma concentrations is a well-known method 
used for inducing IR (Boden and Chen 1995, Griffin et 
al. 1999, Leung et al. 2004). Therefore, although we have 
not measured insulin sensitivity, we suggest that the 
changes we have observed might be implicated in the 
pathogenesis of lipid-induced IR. Our results are in 
agreement with a theory that TNFα is implicated in 
NEFA-induced IR as shown in vitro (Nguyen et al. 
2005). For resistin it is an unclear result because it is 
often found not to be associated with IR (Utzschneider et 
al. 2005), although the studies are usually limited to 
correlations between resistin and various measures of 
metabolic syndrome. Rather exception is a report of 
Sheng et al. (2008) where overexpression of resistin in 
human hepatocytes induced IR most likely by blocking 
insulin signal transduction pathways of PI-3K/Akt and of 
CAP/c-cbl. 
 We are aware that there are limits to our study. 
Increase in plasma lipid concentrations by intravenous 
infusion certainly differs from dietary and lifestyle 
induced hyperlipidemia observed in real life. Small 
number of subjects examined might have prevented us 
from seeing some other possibly significant results and 
therefore the value of “negative” results is limited. In 
addition, the lack of placebo control, which was not done 
due to the potential troublesome interpretation of a 24-h 
long fasting, to some extent limits the reliability of 
“positive” results. Circadian variations were partly 
assessed by 24-h duration. Glycerol (a component of 
intralipid emulsion) fortunately does not affect insulin 
secretion (Boden and Chen 1999, Pelkonen et al. 1968), 
glucose effectiveness (Hawkins et al. 2003) or insulin 
sensitivity (Ferrannini et al. 1983). However, the effect of 
glycerol on resistin and TNFα can not be excluded. 
Resistin could also be affected by hyperinsulinemia, 
although this observation was made at several-fold higher 
insulin concentrations (Krušinová et al. 2007) than 
observed during our lipid infusion. We have also found 
significant inter-individual and intra-individual 
differences of the mRNA content in adipose tissue 
samples for each adipokine. We must, however, note that 
this could partly be due to different adipocytes/stroma-
vascular cells ratio in each sample. In future studies, this 
can be assessed by separation of these fractions by 
collagenase tissue digestion (Rodbell 1963). 
 In conclusion, our results indicate that acutely 
induced hyperlipidemia could increase the secretion of 
TNFα and resistin. This finding supports the hypothesis 
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that these adipokines could be involved in the 
pathogenesis of lipid-induced IR. 
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Fatty acid binding proteins in adipose tissue: A promising
link between metabolic syndrome and atherosclerosis?
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1. Introduction
Insulin resistance, hypertension, dyslipidaemia and impair-
ment of glucose homeostasis are closely linked to obesity,
forming a cluster of abnormalities well known as metabolic
syndrome [1] that is associated with accelerated atherosclero-
sis and cardiovascular disease.
Recently, molecular pathways linking obesity with meta-
bolic and atherosclerotic defects are being intensively
explored. Obesity is being considered as a chronic inflamma-
tory state, in which the excess accumulation of adipose tissue
plays a central role [2,3]. Increasing evidence shows that
adipose tissue is not only an inert energy depot, but also exerts
important endocrine functions, secreting multiple cytokines,
adipokines, hormones and free fatty acids (FFA) and thus
participates in regulation of energy metabolism, insulin
sensitivity and inflammation and contributes to the develop-
ment of metabolic syndrome [4].
Dysregulation of lipid metabolism with increased FFA
plasma concentrations is consistently associated with insulin
resistance and type 2 diabetes [5]. Elevated FFA not only
modify glucose and lipid metabolism, but also influence cell
signaling cascades and gene expression [6]. These hydro-
phobic compounds are transported in the circulation bound to
albumin, their cellular uptake occurs by passive diffusion or by
protein-mediated binding and translocation mechanisms,
while intra-cellularly, fatty acid binding proteins (FABPs)
represent the important carriers for FFA.
Specifically, adipocyte-specific FABPs have gained much
attention in recent years, since their role in insulin resistance,
type 2 diabetes and atherosclerosis has been suggested based
on studies in FABP-deficient mice models [7]. Although
comprehensive research in knock-out mice models has
brought evidence of the specific impact and mechanisms of
action of FABPs in metabolism and inflammation, the
definitive biology and function of FABPs in human physiology
and disease remain not fully clarified.
2. FABP family
FABPs are small (14–15 kDa) cytoplasmic proteins that bind
reversibly with high affinity to hydrophobic ligands, such as
saturated and unsaturated long chain fatty acids, eicosa-
noids and other lipids. FABPs can be found across all
species, demonstrating strong evolutionary conservation
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a b s t r a c t
Adipocyte/macrophage fatty acid binding protein (A-FABP) has been shown to be closely
associated with metabolic syndrome, obesity and development of atherosclerosis. More-
over, A-FABP has been recently suggested as a potential therapeutic target of these
abnormalities in animal models. The present review aims to summarize current knowledge
on A-FABP functions and regulations both in animal models and humans, since the role of A-
FABP in human physiology and disease has not been presently clarified.
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[8]. At least 9 tissue-specific cytoplasmic FABPs have been
identified at present (Table 1). The overall gene structure
conserved between all family members, consists of 4 exons
separated by 3 introns and contains canonical TATA box
upstream of the transcription site [9]. Chromosomal map-
ping of the FABP genes shows that they are dispersed in the
genome, but some loci create a synteny group (A-FABP, E-
FABP, and M-FABP). Within different species the genes are
located on different but comparable chromosomes [8]. The
three-dimensional protein structure also shows similar
features in all FABP types despite the differences in amino
acid sequence (22–73% similarity of the protein structure).
They are composed of ten antiparallel b strands that form a
b barrel. The single bound ligand can be found within the
barrel in internal water filled cavity [8,10].
The functions of cytoplasmic FABPs include enhancement
of FFA solubility and transport of FFA to specific enzymes and
cellular compartments (to the mitochondria and peroxisomes
for oxidation, to the endoplasmic reticulum for reesterifica-
tion, to the lipid droplet for storage, or to the nucleus for
regulation of gene expression) [8,10,11]. Over-expression and
anti-sense studies have proposed roles of FABP in FFA import,
storage and export as well as cholesterol and phospholipid
metabolism [12].
By modulation of FFA availability, FABPs have an indirect
regulatory effect on various cellular processes in which FFA
are involved, such as signal transduction. FFAs transmit a
stress response through activation of protein kinase C u,
inhibitor of kappa kinase (IKK) or c-jun NH2-terminal kinase
(JNK) that have been linked to insulin resistance and metabolic
syndrome [7]. Additionally, the role of FFAs in regulation of
gene transcription has been well characterized, especially for
those genes involved in lipid metabolism, e.g. acyl-CoA
synthase, acyl-CoA oxidase, stearoyl-CoA desaturase, carini-
tine–palmitoyl transferase or A-FABP itself [8]. Several
mechanisms of FFA-mediated regulation of gene transcription
have been proposed [13]: binding to and activation of a
transcription factor, modification of the mRNA stability or
regulation of the transcription factor expression. It has been
proven that FABPs cooperate with transcription factors of
PPAR family (peroxisome proliferator-activated receptor) by
means of induction of ligand-dependent transactivation of
PPARs [11].
Following detailed review of recent knowledge on the




Two types of FABPs are expressed in adipocytes: A-FABP
(mouse homologue aP2) – a predominant cytosolic protein of
mature adipocytes, accounting for6% of total cellular protein
[14], and E-FABP (mouse homologue mal1) – a minor isoform
found in fat cells.
3.1.1. Knock-out models
Their functions have been demonstrated in the following
knock-out mice models: aP2/ mice, mal1/ mice and aP2-
mal1/ mice. The phenotype of aP2/ mice is unremarkable
at baseline with normal growth, reproduction and no defects
in adipose tissue [15]. This is explained by compensatory up-
regulation of mal1 protein. However, in the context of dietary
or genetic obesity [15,16] the aP2 deficient mice are protected
from development of insulin resistance and type 2 diabetes in
spite of slightly higher body weight and elevated FFA plasma
concentrations. aP2/ mice also failed to express tumor
necrosis factor alpha in adipose tissue. Adipocytes from aP2/
mice exhibited 40% decrease in basal lipolysis in vivo and in
vitro [14,17] and 2- to 3-fold decrease in FA release [18] and
thus higher cellular as well as plasma FFA levels, suggesting
that aP2 mediates FA efflux in normal physiology. The reduced
lipolysis in aP2/mice was initially attributed to the ability of
A-FABP to bind and activate the hormone-sensitive lipase
(HSL) [14,19] forming 1:1 complexes with the lipase. However
the activation of HSL by A-FABP is rather dependent upon FA
binding properties of FABP, because in absence of FA no FABP-
HSL association could be demonstrated [20]. E-FABP has been
also shown to interact with HSL.
Additionally in the absence of aP2, the acute insulin
secretory response to b-adrenergic stimulation was markedly
suppressed [16,17]. Furthermore an increase in muscle glucose
oxidation and de novo lipogenesis in adipocytes, reduced
expression of HSL in adipose tissue, together with increased
serum and tissue adiponectin, but unaltered adiponectin
expression, were detected in aP2 knock-out model maintained
on a high-fat diet [21].
The following mice model – mal1/ mice – also exhibits a
small increase in insulin sensitivity, slightly decreased body
weight without changes of total fat mass on the background of
dietary induced and genetic obesity [22]. Transgenic mice
overexpressing mal1 did not show any changes in body
Table 1 – FABP types, their tissue occurrence.
FABP type Gene name Alternative names Tissue
Liver FABP FABP1 L-FABP Liver, intestine, stomach
Intestinal FABP FABP2 I-FABP Intestine, stomach
Heart FABP FABP3 H-FABP Heart, kidney, skeletal muscle, aorta, adrenals, placenta, brain, testes,
ovary, lung, mammary gland
Adipocyte FABP FABP4 A-FABP; aP2; ALBP Adipose tissue, macrophages
Epidermal FABP FABP5 E-FABP; mal1; KLBP Skin, brain, lens, retina, endothelium, adipose tissue, kidney, liver
Ileal FABP FABP6 Il-FABP Ileum, ovary
Brain FABP FABP7 B-FABP Brain
Myelin FABP FABP8 MP2 Peripheral nervous system
Testis FABP FABP9 T-FABP Testis
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weight, FFA and lipid concentrations during dietary induced
obesity but a decrease in glucose clearance was observed [22].
Additionally, increased lipolysis and increased expression but
lower serum levels of resistin were detected in this transgenic
model [21].
To overcome the compensatory increase of mal1 produc-
tion in aP2/ mice and to examine the impact of both FABPs
on adipocyte function and systemic metabolic homeostasis,
mice lacking both aP2 and mal1 were developed [23]. They
exhibit a striking phenotype: in contrast to individual aP2 or
mal1 deficiency, they do not gain weight on high fat diet, show
increased O2 consumption and CO2 production. The observed
increase in insulin sensitivity and improvement of lipid profile
in aP2-mal1/mice exceed those observed in individual FABP
deficiency and the combined knock-out model is also
protected from hepatosteatosis. At the cellular level, mole-
cular mechanisms have been identified that underlie the
observed phenotypic changes: enhanced insulin receptor
signaling and AMP-activated kinase activity in skeletal
muscle, and reduced stearoyl-CoA desaturase-1 activity and
decreased SREBP1c expression in liver [23].
3.1.2. Regulation of A-FABP expression in adipocytes
A-FABP expression is enhanced during adipocyte differentia-
tion [24] and is mostly regulated at the transcriptional level
[10]. In vitro studies in adipocytes showed that A-FABP
expression is positively regulated by fatty acids, PPARg [25]
and insulin [26,27], as well as by PPARg agonists such as
thiazolidinediones (TZD) [28–30]. The latter was also proven in
obese Zucker rats [31]. Recently, Cabré and co-workers have
demonstrated that TZD induced human adipocyte differentia-
tion in vitro is associated with increase in A-FABP mRNA and
cellular protein levels as well as with increase of A-FABP
secreted to culture media [30]
PPARg regulates the expression of A-FABP through PPRE
(peroxisome proliferator responsive element) present in the A-
FABP gene promoter [32]. On the other hand, an interaction of
FFA with FABP is essential for relocation of the lipid ligand to
the nucleus, where the entire FABP/FFA complex activates
PPARg in a ligand dependent fashion. The interaction between
FABP and PPAR proceeds in receptor and ligand selective
manner: A-FABP activates PPARg, E-FABP interacts with PPARb
[11].
In obesity, both A-FABP [33,34] and E-FABP [35] expression
is increased in animal models.
3.1.3. A-FABP in human adipose tissue
The evidence in humans is not that uniform as in the animal
models.
In obesity, A-FABP expression in subcutaneous adipose
tissue (SAT) was comparable to lean subjects [36,37], neither
correlated with measures of adiposity [36], insulin resistance
or FFA composition [38]. On the contrary, E-FABP was shown
to be more expressed in SAT of lean subjects [37], whereas
other studies demonstrated correlation of E-FABP expression
in SAT with intra-abdominal fat volume, triglycerides [36] or
glucose [38].
Fisher and coworkers [37] suggested the A-FABP/E-FABP
ratio to be a summarizing measure of FABP changes. They
have shown a lower ratio in lean subjects compared to obese
(comparable A-FABP expression, higher E-FABP expression in
lean versus obese), as well as in obese patients after
substantial weight loss following the gastric banding surgery.
However, the individual values of both FABP expressions
significantly increased after weight loss.
On the other hand, short-term overfeeding in healthy
women [39] was associated with increased expression and
activation of PPRAg, as shown by increased expression of A-
FABP and its correlation with PPARg expression. The fat mass
gain was positively related to PPARg and A-FABP mRNA
changes.
There are regional differences in adipose tissue FABP
expression that might be influenced by obesity [40,41]: in obese
individuals A-FABP mRNA and protein were higher in SAT
compared to visceral adipose tissue (VAT), which was in
accordance with higher rates of basal lipolysis detected in
SAT adipocytes [41]. E-FABP expression was comparable
between the depots in obese individuals. Lean subjects
displayed higher E-FABP expression in VAT, A-FABP protein
and mRNA were similar in both depots. The authors concluded
that the A-FABP/E-FABP ratio might be an important measure
being higher in SAT in both lean and obese subjects. In this
study, expressions of both FABPs were suggested to be higher in
lean subjects; however, the groups were not directly compared.
Inanothergroupof leanandoverweightsubjects,higherA-FABP
expression inSATcomparedtoVATwasalsodemonstrated [42].
Gender difference in FABP expression was suggested by
Fisher et al. [37], who described higher A-FABP/E-FABP ratio in
men compared to women in both lean and obese subgroups.
Taking into account the separate FABP expression the effect of
gender was not significant.
Other regulatory mechanisms (insulin, FFA, thiazolidine-
diones) have not been tested in vivo with concern to human
adipose tissue.
3.2. Macrophages
Both A-FABP and E-FABP are also present and expressed in
macrophages [24,43] that show striking similarities to adipo-
cytes in their biology and functions—both are able to
accumulate lipids, secrete cytokines and express number of
the same genes involved in lipid metabolism and inflamma-
tion [6].
First evidence on FABP functions and regulations in
macrophages is derived from cell cultures—primary isolated
human monocytes or monocyte THP-1 cell lines. A-FABP
expression was not detected in the resting cells but became
evident following differentiation stimulation with phorbol
myristate acetate [43], oxidized LDL [44], PPARg activators [45]
or lipopolysacharide/Toll like receptor activation [46]. On the
contrary, the oxidized LDL-induced A-FABP expression was
attenuated following treatment with atorvastatin [47].
E-FABP is regulated in an identical manner as A-FABP in cell
cultures [24]. However, unlike adipocytes, macrophages do not
exhibit the compensatory increase in E-FABP expression in A-
FABP deficient mice [43]. Although being a minor isoform in
adipocytes, E-FABP protein levels are comparable to A-FABP in
macrophages.
Studies dealing with molecular mechanisms of FABP action
in macrophages have shown that A-FABP deficiency reduced
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 8 2 s ( 2 0 0 8 ) s 1 2 7 – s 1 3 4 S129
Author's personal copy
cholesterol-ester accumulation as well as production of
inflammatory cytokines both in the resting state and during
differentiation, but it increased the cellular FFA [43]. In the
absence of A-FABP, the macrophage PPARg activity is
enhanced, leading to elevated CD36 expression and stimula-
tion of cellular lipoprotein uptake [48]. The proteins of
cholesterol efflux pathway are also up-regulated in A-FABP
deficiency and thus cholesterol release is preferred to
accumulation. In parallel, A-FABP deficient macrophages
display reduced IkB kinase and NF-kB activity resulting in
suppression of inflammatory functions [48]. In accordance
with these findings, an overexpression of A-FABP in human
macrophages drives cholesterol ester accumulation and
triggers foam cell formation [7,37].
In a rodent model of accelerated atherosclerosis – apo-
lipoprotein E-deficient (apoE/) mice, the ablation of aP2 gene
has led to substantial reduction of vascular atherosclerotic
lesions in the absence of differences in serum lipids or insulin
sensitivity [43]. This effect can be attributed to macrophage-
specific action of aP2 in formation of atherosclerotic lesions, as
it was confirmed by bone marrow transplantation studies
[24,43].
Combined aP2 and mal1 deficiency in apoE/mice has led
to further dramatic reduction of atherosclerosis development
compared to aP2/ mice and wild type mice with the same
background [49]. Moreover, the aP2 and mal1 null mice also
have significantly improved survival (by 67%) in apoE/
background even when challenged with the Western hyperch-
olesterolaemic diet for 1 year, probably due to increased
stability of atherosclerotic plaques [49].
3.3. Skeletal muscle
Recently it has been shown that A-FABP is also present and
expressed within skeletal muscle fibers [50], although in
markedly lesser amount than H-FABP, which is generally
accepted as dominating FABP in skeletal muscle (the mRNA H-
FABP: A-FABP ratio was 10:1). Interestingly A-FABP mRNA and
protein were more abundant in the endurance trained
subjects, suggesting a physiological role of A-FABP in meta-
bolic adaptation.
3.4. Plasma
Although A-FABP has been traditionally thought to be a
cytoplasmic protein, Xu and coworkers have demonstrated
using tandem mass spectrometry-based proteomic analysis
that A-FABP is released from 3T3-L1 adipocytes into extra-
cellular medium in the absence of any obvious cell damage
[51]. The presence of A-FABP in human plasma was confirmed,
showing comparable or higher concentrations than those of
several major adipokines (10–60 ng/ml) [51]. Adipose tissue is
considered as a source of circulating A-FABP; however, the
relative contribution of adipocytes versus macrophages
(resident in adipose tissue or circulating) to plasma concen-
trations of A-FABP has not been elucidated so far. The only
study in vivo, showing adipose tissue expressions and plasma
concentration of A-FABP in parallel in animal model, revealed
a positive correlation between serum A-FABP and its expres-
sion levels in visceral, subcutaneous and epididymal fat
depots [52]. The human data on relation between A-FABP
expression in adipose tissue and its serum concentration are
lacking.
Mechanism of A-FABP secretion from cells remains also
unclear, since the protein has no ordinary secretory signal
peptide and its molecular weight is relatively low [53].
Similarly, the physiological functions of circulating A-FABP
remain to be determined. There is increasing evidence on the
predictive role of increased serum A-FABP in metabolic
syndrome and cardiometabolic risk, which is based on
population studies discussed bellow. However, at the mole-
cular level no data explaining a causal relationship are
available at present. It is speculated that circulating A-FABP
might function as a lipid hormone transporter or in hormone-
like fashion to modulate systemic insulin sensitivity and
energy metabolism [51,52]. Further intriguing questions have
been raised: what are factors influencing the balance between
serum and tissue A-FABP? How can an increase in circulating
A-FABP lead to progression of cardiometabolic risk? [52].
3.4.1. Regulations of circulating A-FABP
Serum A-FABP concentrations were reported to be positively
and independently associated with parameters of adiposity,
hyperglycaemia, insulin resistance (assessed as HOMA index)
and metabolic syndrome abnormalities in an Asian population
in cross-sectional [51] and longitudinal [52,54] studies, as well
as in a cohort of Caucasian population [53]. Plasma A-FABP
increased significantly with the increasing number of pre-
valent components of metabolic syndrome [30,51,55]. Higher
circulating A-FABP levels in comparison with lean subjects
were detected in overweight/obese patients [51,56] and
children [57], in patients with metabolic syndrome [53] and/
or type 2 diabetes [30,58]. In subjects with impaired glucose
homeostasis both increase [52] and no difference [58] in
plasma A-FABP have been reported.
Another specific example of metabolic syndrome and/or
lipodystrophy is represented by HIV-infected patients. In this
cohort, plasma A-FABP is also strongly correlated with
metabolic syndrome abnormalities, including insulin levels
[55]. Patients in the highest quartile of A-FABP presented 6-fold
increased odds ratio for metabolic syndrome and 3-fold
increased odd for lipodystrophy.
The longitudinal studies even showed predictive values of
high A-FABP levels for development of metabolic syndrome
over the course of 5 years [54] and for prevalence of type 2
diabetes over the course of 10 years [52], which were
independent on obesity, insulin resistance or glycaemic
indexes. However, the latter study had a relatively high rate
of loss to follow-up (136 of 544 subjects were lost at 10 years).
Those patients did not differ in baseline characteristics from
the subjects who returned to follow-up except for older age,
but they were assumed to be free from type 2 diabetes for the
analysis at 10 years. This might have introduced a substantial
bias in the analysis.
The inverse association between plasma A-FABP and
adiponectin [51,52,54] and the positive correlation with high
sensitivity CRP [30,52,54] (adjustment for adiposity taken into
account) suggested a contribution of A-FABP to systemic
inflammation. On the contrary, another study shows a
positive correlation between A-FABP and adiponectin con-
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centrations [30]. Leptin was found to be positively correlated to
A-FABP levels in a cohort of obese children [57].
Sexual dimorphism of plasma A-FABP is consistently
reported [30,51,53,54,58,59] with higher levels in women
compared to men, except for one study in obese children
[57]. Possible explanations for the gender difference include
higher body fat percentage in women or sex differences in
regional fat distribution, as women generally have more SAT
than men, whereas men have more VAT. Several lines of
evidence have shown the increased A-FABP expression in SAT
compared to VAT [40–42]. Another potential underlying
mechanism might represent the A-FABP regulation by sex
hormones [58]. The persistence of the gender difference in
postmenopausal women suggested that estrogen might not be
an important regulator. The potential suppressive role of
testerone (as it is in the case of adiponectin secretion) is being
investigated [58].
Weight loss induced by bariatric surgery in obese adults [56]
or lifestyle intervention in obese children [57] led to significant
reduction of plasma A-FABP. A-FABP plasma concentrations
and their changes were only related to parameters of adiposity
but not to insulin resistance in both studies.
Pharmacological interventions have been also shown to
influence circulating A-FABP in humans in vivo. Three months
treatment with atorvastatin in hyperlidaemic non-diabetic
subjects substantially decreased plasma A-FABP indepen-
dently on changes in total cholesterol levels [59]. Another
cross-sectional study in subjects with type 2 diabetes [30]
found no difference in A-FABP concentrations in statin-
treated subjects but reported increased A-FABP levels in
TZD-treated subgroup. In the prospective study with 12 weeks
pioglitazone treatment in type 2 diabetes [30], the authors also
reported significant increase in plasma A-FABP that was
paralleled by increased PPARg activity in peripheral blood
mononuclear cells. This finding is in accordance with in vitro
data [29,45] and could be explained by the fact, that TZD
through PPARg activation induce adipocyte differentiation and
intra-cellular fat accumulation [30].
3.4.2. E-FABP in plasma
Much fewer evidence is available for circulating E-FABP.
Increased plasma concentrations are reported in morbidly
obese subjects [56]. After gastric banding-induced weight loss
plasma E-FABP decreased bellow the concentration found in
lean subjects.
4. Human genetic studies
In humans a functionally significant genetic variant of A-FABP
locus has been identified [60]. The T-87C allele in the promoter
region of A-FABP gene disturbs the CAAT box/enhancer-
binding protein binding and thus reduces the transcriptional
activity of the A-FABP promoter, resulting in decrease in A-
FABP expression in adipose tissue. This ‘‘loss-of-function’’
allele was confirmed in vivo—its presence results in signifi-
cantly reduced A-FABP expression in SAT of carrier subjects.
The prevalence of this allele is rather low in general
population (4%). In population genetic studies with 7899
participants, the carriers of this T-87C polymorphism had
lower triglyceride levels, reduced risk for coronary heart
disease and in obese subpopulation the risk for type 2 diabetes
was also reduced. No other association between the studied
single nucleotide polymorphism and inflammatory or meta-
bolic syndrome markers has been found.
5. A-FABP as a target for treatment of insulin
resistance and atherosclerosis
Recently, a potent selective inhibitor of A-FABP – the
compound BMS309403 – has been developed that competi-
tively inhibits binding of endogenous FA within the internal
cavity of FABP [61]. In vitro the A-FABP inhibitor reduced
macrophage transformation into foam cells, as shown by 40%
lower cholesterol ester accumulation, which was attributed to
substantial increase in cholesterol efflux. Similarly to knock-
out models, treatment with BMS309403 led to reduced
expression of inflammatory cytokines in macrophages. In
vitro treatment of adipocytes resulted in decrease in FA
uptake. Mice models of genetic and dietary obesity treated
with A-FABP inhibitor presented lower glucose, insulin and
triglycerides levels, increased adiponectin, but also increased
FFA concentrations. The improvement in insulin sensitivity
and glucose tolerance indicated by these results was proven
also in hyperinsulinaemic–euglycaemic clamp studies
(decrease in hepatic glucose production and increased glucose
uptake in skeletal muscle and adipose tissue). Treated mice
exhibited attenuated macrophage infiltration as well as
cytokine expression in adipose tissue, diminished triglyceride
accumulation in liver and reduced activity of cellular
inflammatory pathways in both tissues. In apoE knock-out
mice, A-FABP inhibition substantially reduced atherosclerotic
lesions, regardless of no changes in body weight, glucose and
lipid metabolism.
6. Role of adipocyte/macrophage FABP in
metabolic syndrome in humans
Although experimental data on A-FABP in knock-out mice
provide an exciting insight into its central regulatory role in
metabolic syndrome, even with the option of treatment by
selective inhibition of A-FABP, several discrepancies and
questions based on available human studies arise.
6.1. What is the relation between plasma and tissue levels
and expressions of A-FABP? What are the sources of
circulating A-FABP and how it is released from cells?
In humans, plasma concentrations and adipose tissue
expression of A-FABP have never been shown in parallel.
The evidence on plasma A-FABP is in accordance with
experimental data, showing the association of high A-FABP
levels with metabolic syndrome abnormalities, body mass and
insulin resistance [51,53,54] or a decrease in A-FABP after
weight loss [56,57]; on the other hand, the studies focused on
adipose tissue expression are contradictory. They report no
difference in A-FABP expression or even a decrease in E-FABP
expression in obese subjects [36,37], as well as increased
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expression of both FABPs after weight loss [37]. Furthermore,
no consistent association between A-FABP expression and
measures of adiposity or insulin resistance was found [36,38].
These findings implicate involvement of other source of
circulating A-FABP – macrophages. Their contribution to
whole-body A-FABP balance has not been elucidated so far.
Another related question would be the mechanism of
cellular secretion of A-FABP, since it might be involved in
maintaining of balance between serum and tissue levels.
Therefore, the clarification of regulations of FABP expression
in human adipose tissue and macrophages together with its
plasma concentrations awaits further studies.
6.2. What are the physiological functions of circulating A-
FABP and how do they differ in metabolic diseases and
atherosclerosis?
A-FABP might participate in transport of FFA and lipid
hormones and thus modulate systemic insulin sensitivity
and energy metabolism [54]. Whether the causative mechan-
isms of these functions at the molecular level are similar to
those proposed in mice, it remains to be elucidated.
6.3. What are the possible consequences of long-term
A-FABP inhibition that is suggested as a potent treatment of
metabolic syndrome and atherosclerosis in mice?
The high evolutionary conservation of FABPs indicates that
they belong to thrifty genes that were important for survival.
Thus A-FABP possibly ensures sufficient lipid storage in
adipocytes and potent inflammatory response in macro-
phages [62], which may have impact on the long-term body
weight regulation or in conditions requiring strong inflam-
matory response.
6.4. What is the physiological role of E-FABP – the minor
isoform derived from adipose tissue and macrophages?
Few data on E-FABP in humans are available. The interesting
finding showing that E-FABP expression might account for the
differences between fat depots and changes with adiposity
[37,40] needs to be confirmed by further studies.
6.5. What is the relation of A-FABP to the individual
components of metabolic syndrome?
In different human studies, this relation was not expressed
to the same extent. This might partially lie in difference in
ethnicity or in the size of population studied. The associa-
tion with measures of obesity and dyslipidaemia is
consistent for all studies mentioned above. However, no
association with parameters of insulin resistance was
observed in Caucasian cohort of type 2 diabetes [30] or in
a specific cohort of insulin resistance—in polycystic ovary
syndrome [63]. Considering that insulin resistance was
mostly assessed as HOMA index, for more precise dis-
crimination the insulin clamp technique should be used.
Similarly, the association between A-FABP and impairment
of glucose homeostasis is not definite with studies reporting
both A-FABP increase [52] and no difference [58].
6.6. Finally, is the regulation of A-FABP by currently
available therapies relevant for treatment of metabolic
syndrome?
A study with TZD treatment has brought a confusing element
about our knowledge of A-FABP. The TZD-treated patients
showed higher A-FABP plasma concentrations, probably due
to PPARg stimulated adipocyte differentiation and intra-
cellular fat accumulation [30]. While this mechanism appears
to be logical, supported also by experimental data [29,45], the
clinical relevance of such ‘‘negative’’ effect of a potent insulin-
sensitizing drug awaits further clarification.
7. Role of adipocyte/macrophage FABP in
atherosclerosis in humans
The proof of A-FABP expression in macrophages together
with clarification of A-FABP’s role in macrophage metabo-
lism [43,64] provided a very clear concept of the role of
FABP in inflammation and development of atherosclerosis,
which is supported by the data in apoE deficient mice
[24,43,49].
The current evidence in vivo in humans is not extensive.
In a cohort of Chinese women but not in men, serum A-FABP
was shown to be an independent determinant of carotid
intima-media thickness as a measure of atherosclerosis
[58]. In women but not in men, higher A-FABP levels
were associated with the presence of plaques. On the
contrary, another study in Caucasian population with type 2
diabetes showed that circulating A-FABP was not associated
with clinical or subclinical atherosclerosis in both genders
[30].
Moreover, atorvastatin treatment has been show to reduce
A-FABP plasma concentrations [59] suggesting that this might
be one of the pleiotropic effects of statin drugs in athero-
sclerosis.
The involvement of A-FABP in atherosclerosis is also
supported by the genotype–phenotype study [60], demonstrat-
ing that the carriers of T-87C polymorphism have reduced risk
for coronary heart disease.
Further studies in large cohorts, in different ethnicities,
different levels of glucose intolerance, clinical and subclinical
atherosclerosis as well as longitudinal studies are needed to
confirm the role of A-FABP in atherosclerosis in vivo in
humans.
8. Conclusions
Adipocyte/macrophage FABP clearly links several mechan-
isms and pathways that are involved in the development of
obesity, metabolic syndrome and atherosclerosis. To translate
these important data from mice models to humans will
require further comprehensive investigations. Whether cir-
culating adipocyte/macrophage FABP represents a biomarker
of obesity, metabolic syndrome and atherosclerosis or
whether it is a causative factor of metabolic and inflammatory
dysregulation, which can be effectively and safely inhibited,
remains to be elucidated.
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